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CHAPTER 1 
 
Migraine overview 
  
   
 
 
 
1. Migraine overview 
1.1. Definition, classification and diagnostic criteria 
The term migraine stems from hemicrania, describing a periodic disorder consisting of 
paroxysmal unilateral headache, accompanied by nausea, vomiting, photophobia and/or 
phonophobia.  Hemicrania was later changed to Latin words - hemigranea and migranea; 
eventually the French cognate, migraine, gained acceptance in the eighteenth century and has 
prevailed ever since.  A working definition of migraine is benign recurring headache and/or 
neurological dysfunction usually attended by pain-free interludes and often provoked by 
stereotyped stimuli (1).  Migraine may be triggered by certain factors (red wine, menses, hunger, 
lack of sleep, glare, perfumes, periods of let down) and relieved by others (sleep, pregnancy).  
Premonitory symptoms occur hours to a day or two before a migraine attack with or without 
aura.  Migraine is more common in females, with a hereditary predisposition towards attacks and 
the cranial circulatory phenomenon appears to be secondary to a primary central nervous system 
(CNS) disorder. 
The Headache Classification Committee of the International Headache Society (IHS) 
published the classification and diagnostic criteria for headache disorders in 1988 (Table 1.1) (2).  
The terms “common migraine” and  “classical migraine” have been replaced by “migraine 
without aura” and “migraine with aura”, respectively.  These operational criteria have been 
validated by different approaches and have enabled us to distinguish different headache entities 
in a reliable manner (3-6).  In recent years, the IHS criteria have been used world-wide in several 
multicentre double-blind drug trials, which have shown a reasonably consistent response rate to 
triptans (7), reflecting a consensus in the defined migraine group. In a recent MAZE survey, the 
Migraine Disability Assessment Scale (MIDAS) questionnaire has been used to assess the impact 
of migraine on work, home and social lives. MIDAS scores confirmed the debilitating effect of 
migraine; >50% of respondents had a MIDAS grade of III or IV, indicating moderate or severe 
disability.  Less than one-third of patients reported that their current medication was consistently 
effective and only 36% were 'very satisfied' with their current therapy (8).  These results show 
that migraine patients world-wide are still not receiving adequate treatment and a significant 
unmet need in migraine care still remains. 
1.2. Pathophysiology of migraine 
Although the pathophysiology of migraine is still far from clear, three phases mark the 
characteristic clinical features of migraine: initiating trigger phase, aura and finally the headache 
phase.  Little is known about the initial triggering phase, but, certainly over the years, there is a 
better understanding regarding its pathogenesis of migraine headache (9-12).  Theories, which 
have been propounded, are briefly described below: 
1.2.1. Vasodilator theory of migraine 
It was Heyck in 1969 (9), who proposed that opening of the cranial arteriovenous anastomoses, 
which is reflected with abrupt reduction in the difference between arterial and jugular venous 
blood oxygen saturation, heralds the onset of a migraine attack.  In addition, it was found that the 
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Table 1.1.  Classification and diagnostic criteria for migraine according to the Headache 
Classification Committee of The International Headache Society. 
Migraine without aura 
A. At least 5 attacks fulfilling B-D. 
B. Headache attacks, lasting 4-72 hours (untreated or unsuccessfully treated). 
C. Headache has at least two of the following characteristics: 
1. Unilateral localisation 
2. Pulsating quality 
3. Moderate or severe intensity 
4. Aggravation by walking  stairs or similar routine physical activity 
D. During headache at least one of the following: 
1. Nausea and/or vomiting 
2. Photophobia and Phonophobia 
E. At least one of the following: 
1. History, physical- and neurological examinations do not suggest association with 
head trauma, vascular or non-vascular disorders, use of or withdrawal from 
noxious substances, non-cephalic infections, metabolic disorders or disorder of 
cranial or facial structures. 
2. History and/or physical- and/or neurological examinations do suggest such 
disorder, but it is ruled out by appropriate investigations. 
3. Such disorder is present, but migraine attacks do not occur for the first time in 
close temporal relation with the disorder. 
Migraine with aura 
A. At least 2 attacks fulfilling B 
B. At least 3 of the following 4 characteristics 
1. One or more fully reversible aura symptoms indicating focal cerebral cortical- 
and/or brain stem dysfunction. 
2. At least one aura symptom develops gradually over more than 4 minutes or, 2 or 
more symptoms occur in succession 
3. No aura symptom lasts more than 60 minutes.  If more than one aura symptom is 
present, accepted duration is proportionally increased. 
4. Headache follows aura with a free interval of less than 60 minutes.  (It may also 
begin before or simultaneously with the aura). 
C. At least one of the following: See above under E.  for migraine without aura 
 
diameter of temporal arteries is increased in patients suffering from migraine; treatment with 
ergotamine normalised the vessel diameter (13).  Mechanical distension of the cerebral arteries 
does cause pain (14).  Further, intravenous administration of serotonin, a known vasoconstrictor, 
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alleviates pain (15).  This theory has been put to question by studies, which demonstrate the lack 
of correlation between pain and vasodilatation in migraineurs (16-18). 
1.2.2. Neurological theory of migraine 
This theory explains the premonitory symptoms associated with migraine, which is difficult to 
explain by a vascular hypothesis.  Thus, it suggests that there is abnormal firing and 
neurotransmitter release at certain brain neurones (19).  This expanding cortical spreading 
depression (CSD) manifests as aura symptoms associated with the initiation of the migraine 
attack.  CSD probably starts with a cellular efflux of K+, leading to depolarisation and a period of 
relative electrical silence (20). Evidence is accumulating that CSD might be associated with 
migraine and other neurological disorders. New imaging techniques will provide a greater 
understanding of these phenomena and could lead to newer methods of treatment (20).  Several 
observations, like the absence of pain sensing fibres in the brain or the prevalence of headache, 
after rather than during a stressful insult, point to some inconsistencies in this theory. 
1.2.3. Neurogenic dural inflammation theory 
Neurogenic inflammation within cephalic tissues, involving vasodilatation and plasma protein 
extravasation, has been proposed as a mechanism in migraine pathogenesis.  There is a release of 
pro-inflammatory vasoactive peptides, including substance P, neurokinin A and calcitonin 
gene-related peptide (CGRP) (21, 22).  While substance P and neurokinin A increase blood 
vessel permeability (with transient vasodilatation), CGRP causes a profound and a long lasting 
vasodilatation without increasing blood vessel permeability (23).  During electrical stimulation 
of the trigeminal ganglion or the intravenous administration of capsaicin, neurogenic plasma 
protein extravasation develops within the dura mater (24). Studies have shown that neurogenic 
plasma protein extravasation from blood vessels in the dura mater can be reduced by 
sumatriptan, 5-carboxytryptamine, dihydroergotamine, ergotamine as well as methysergide (25).  
The therapeutic efficacy of triptans is believed to be due to their ability to block the stimulated 
secretion of vasoactive neuropeptides from trigeminal nerves to break the vicious nociceptive 
cycle in migraine (26).  A component of this nociceptive cycle involves activation of mitogen-
activated protein kinase signalling pathways.  Indeed, activation of mitogen-activated protein 
kinase pathways can increase CGRP synthesis and secretion (27).  More recently, another 
neurotransmitter and vasodilator, nitric oxide (NO) has been proposed to play a role in the 
development of migraine headache and inhibition of its synthesis by nitric oxide synthase 
inhibitors results in reduced frequency and intensity of migraine attacks (28).  The initial 
headache is now believed to be via a direct action of the NO-cGMP pathway that causes 
vasodilatation by vascular smooth muscle relaxation, while the delayed headache is likely to be a 
result of triggering trigeminovascular activation.  In fact, delayed headache response triggered by 
NO donors in humans may be, in part, due to increased nNOS (neuronal nitric oxide synthase) 
activity in the trigeminal system that causes CGRP release and dural vessel dilation.  Further, 
eNOS (endothelial nitric oxide synthase) activity in the endothelium causes NO production and 
smooth muscle relaxation by direct activation of the NO-cGMP pathway, and may be involved in 
the initial headache response (21). 
To summarise (Figure 1.1), an unknown triggering event results in cranial vasodilatation 
leading to enhanced blood volume in each cardiac cycle.  This increases pulsations within 
affected blood vessels.  The increased pulsations are sensed by ‘stretch’ receptors in the vessel 
wall. The resultant enhancement in the perivascular (trigeminal) sensory nerve activity provokes 
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headache and other associated symptoms.  This stimulation of the trigeminal nerve may release 
other neuropeptides, thus reinforcing vasodilatation and perivascular nerve activity (29). 
1.3. Experimental models for acutely acting antimigraine drugs 
The choice of the models used to investigate pharmacological actions of newly synthesised 
compounds largely determines whether or not useful medications will be discovered.  Detection 
of compounds with a pharmacological profile similar to a drug with known clinical activity may 
lead to compounds superior to existing drugs.  The novelty of the compound may however be 
minor.  On the other hand, compounds acting as antagonists at the newly discovered receptors or 
against the newly described naturally occurring mediators, or the agonists mediating their action, 
may lead to potentially useful compounds, which are likely to be novel. 
1.3.1. Animal models 
The migraine models described are based on the view that intracranial extracerebral 
vasodilatation is an integral part of pathophysiology of migraine and that ergot alkaloids and 
sumatriptan, which do not readily cross the blood-brain barrier owe their therapeutic efficacy 
primarily to the vasoconstriction of the dilated blood vessels (11, 30, 31). 
1.3.1.1. Constriction of dilated carotid arteriovenous anastomoses 
The involvement of arteriovenous anastomoses (Figure 1.2) is based on the findings that (i) 
during migraine, the oxygen saturation difference between arterial and jugular venous blood 
Figure 1.1.  Schematic diagram illustrating the putative pathogenesis of migraine and 
the possible sites of action of antimigraine compounds. 
Migraine generator cerebral blood 
flow
No aura
Aura
vasodilatation
Peptide release
TGN
TNC
Thalamus
CortexPain
Hypothalamus
Photophobia
Phonophobia
CT ZoneNausea , Vomiting
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decreases and this is normalised after treatment or spontaneous alleviation of the attack (9, 32) 
and (ii) antimigraine agents decrease carotid blood flow by a vasoconstrictor action exclusively 
on the arteriovenous anastomoses (33, 34). 
Using selective serotonin (5-hydroxytryptamine; 
5-HT) 5-HT1B (SB224289) and 5-HT1D (BRL15572) 
receptor antagonists, it was demonstrated that the 
constriction of porcine carotid arteriovenous anastomoses 
as well as canine external carotid vasculature by 
sumatriptan is mediated via 5-HT1B receptors and not 
5-HT1D or 5-HT1F receptors (35, 36).  Over the years, this 
vascular model, which focuses on the measurement of 
arteriovenous anastomotic blood flow, has proven its 
worth for screening of compounds with therapeutic 
activity in migraine. 
1.3.1.2. Suppression of ‘neurogenic’ inflammation 
Activation of the trigeminal nerves during a migraine 
attack has been suggested to produce headache by 
provoking a painful, sustained neurogenic inflammation (vasodilatation and plasma protein 
extravasation) within the meningeal vasculature (17).  Trigeminal sensory afferent fibres are 
known to contain pro-inflammatory neuropeptides, like CGRP, substance P and neurokinin A.  
Electrical or chemical stimulation of the trigeminal ganglion in animals induces plasma 
extravasation in the dura mater (37-40).  Increases in the cerebral and meningeal blood flow are 
mainly attributed to the actions of CGRP (41), whereas extravasation seems to be mediated 
predominantly by substance P release and NK1 receptor activation (42).  It is important to 
mention that activity of a compound in this model does not necessarily mean effectiveness in 
migraine, as has been observed with compounds like CP122288 (43), ETA/B receptor antagonist 
bosentan (44) and tachykinin NK1 receptor antagonists, lanepitant (45) and RPR100893-20 (46). 
1.3.1.3. Inhibition of cranial vasodilatation 
Electrical stimulation of the trigeminal ganglion causes dilatation in the dural vessels, as 
observed in anaesthetised rat (37) and decreases carotid vascular resistance in cat (47), monkey 
(48) and guinea pig (49).  Recent evidence suggests a role for neuropeptides, like CGRP, 
released from the trigeminal sensory nerve endings in the development of migraine.  On 
stimulation of trigeminal ganglion in cats, there is an increase in the cerebral blood flow, which 
can be blocked by CGRP antagonist CGRP8-37 and by sumatriptan (18, 41).  In a recent study on 
marmosets, stimulation of the trigeminal ganglion resulted in an ipsilateral increase in the facial 
blood flow due to the release of CGRP.  Administration of BIBN4096BS significantly and 
dose-dependently inhibited this response evoked by trigeminal ganglion stimulation (50). These 
newly developed compounds are small molecules with high selectivity for human CGRP 
receptors.  Hypothetically, these agents should be efficacious in the relief of migraine headaches 
via blockade of the effects of CGRP (51). 
1.3.1.4. Central trigeminal neuronal inhibition 
Noxious electrical, mechanical, or chemical stimulation of cerebral blood vessels in 
anaesthetised cats elicits nociceptive firing in trigeminal nerves, which can be detected 
electrophysiologically in central nuclei, such as the trigeminal nucleus caudalis (the first central 
synapse of the trigeminal fibres) or in higher centres, e.g. thalamus (52).  Known antimigraine 
Figure 1.2. Schematic depiction of 
arteriovenous anastomoses. 
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drugs, like zolmitriptan and naratriptan, have shown their ability to inhibit the action potentials 
generated in trigeminal nucleus caudalis after superior sagittal sinus stimulation in the cat (53, 
54).  Similarly, the efficacy of sumatriptan in inhibiting evoked potentials and c-fos expression in 
the nucleus caudalis was observed, but only after disruption of the blood brain barrier.  
CP-99,994, a NK1-receptor antagonist, readily gains access into the CNS and blocks c-fos 
expression suggesting a central action on the trigeminal nerves, in addition to blockade of the 
NK1 receptors located on cranial vasculature. 
1.3.2. Human models for migraine 
1.3.2.1. Contraction of isolated cranial vessels (for therapeutic efficacy) 
Triptans have the ability to potently contract isolated human cranial vessels, including the middle 
meningeal, temporal, middle cerebral and basilar arteries (55-58).  This model has been useful 
for screening acutely acting antimigraine drug, like sumatriptan and other triptans, due to the fact 
that cranial vasculature is rich in 5-HT1B/1D receptors as compared to 5-HT2 receptors in 
peripheral vessels (59).  Concentration response curves to agonists are made and, subsequently, 
the Emax (maximal contractile responses) and pEC50 (agonist potency) and pA2 (antagonist 
potency) used in the study are calculated (60). 
1.3.2.2. Contraction of isolated coronary artery and saphenous vein (for potential side effects) 
All current acutely acting antimigraine drugs have a potential to contract the human coronary 
arteries (61).  Although 5-HT2 receptors predominate over 5-HT1 receptors, the contraction of 
human coronary arteries by triptans is a class effect and is mediated mainly by activation of 
5-HT1 receptors (61-63).  In vitro studies have demonstrated that the coronary vasoconstrictor 
effect of ergot alkaloids but not of the triptans, lasts longer and is resistant to repeated wash (29, 
61).  Therefore, one can predict the possible side effects associated with known acutely acting 
antimigraine compounds and their structural analogues or novel compounds with potential 
antimigraine activity using this model. 
1.3.2.3. Headache induced by glyceryl trinitrate or histamine 
Human models, using glyceryl trinitrate (64) and histamine provocation, have been validated as 
potential diagnostic tests for migraine (65, 66).  Intravenous infusion of glyceryl trinitrate or 
histamine is given in healthy subjects, followed by scoring of the intensity of the headache on a 
0-10 point rating scale.  With histamine, the development of the headache is rapid, reaching peak 
levels and then declines (67).  Potential antimigraine drugs may be evaluated in these models. 
1.4. Drug discovery in migraine 
Target and lead discoveries remain the main component of today’s early pharmaceutical research 
for the management of human diseases.  The aim of target discovery is the identification and 
validation of suitable drug targets or receptors for therapeutic intervention, whereas lead 
discovery identifies novel chemical molecules that act on those receptors.  When lead molecules 
have been identified, they have to be optimised in terms of potency, selectivity, 
pharmacokinetics and toxicology.  For compounds that are targeted to the central nervous 
system, another important aspect is blood-brain barrier penetration. 
Over the years, the drug discovery in migraine is aimed to abolish acute attacks of 
headache and for prophylactic use, with minimal side effects.  Both groups have drugs that are 
specific for migraine (ergot alkaloids and triptans to abort attacks) and those that are used on 
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account of other properties (non-specific action) (68).  Analgesics, anxiolytics or sedatives and 
antidepressants are mainly used in the amelioration of symptoms, like pain, nausea, vomiting, 
anxiety, fear and occasionally depression.  During a migraine attack there is gastric stasis, which 
lead to failure of some patients to respond to treatment.  This prompted the development of 
compounds having antiemetic and prokinetic activity, like metoclopramide (69). 
It was in 1926 that ergotamine was introduced for the treatment of migraine on the 
assumption that heightened sympathetic activity is the main cause for this disease, but the 
vasoconstrictor effect of ergotamine on extracranial vasculature was soon apparent (13).  
Recently, it is thought that the therapeutic efficacy of the ergots could be related to inhibition of 
the neurogenic inflammation (70) or central inhibition of the trigeminal neurones by binding to 
the receptors in the trigeminal nucleus caudalis (71).  In 1945, dihydroergotamine was 
introduced in migraine therapy as a more potent sympatholytic agent than ergotamine (72).  This 
therapeutic action of ergotamine and dihydroergotamine is believed to be through the activation 
of α-adrenoceptors (particularly α2) and 5-HT (particularly 5-HT1B/1D) receptors and, perhaps, D2 
receptor blockade (36, 73).  In addition, activation of certain novel receptors may also be 
involved (36).  Perhaps due to the involvement of multiple receptors, the ergot alkaloids are 
associated with a number of side effects, including nausea and vomiting, gangrene and 
myocardial infarction (74, 75).  Thus, the selectivity of 5-HT1B/1D receptors associated with 
sumatriptan and the second-generation triptans represented an important step forward in 
migraine therapy, by providing better-tolerated relief. 
1.4.1. The triptans 
1.4.1.1. Sumatriptan 
The development and clinical use of sumatriptan, the first serotonin 5-HT1B/1D receptor agonist, 
ushered a new era for the clinicians treating patients for migraine.  The fact that compounds 
mimicking 5-HT at the craniovascular receptors should abort migraine attacks stems from the 
observations that (i) urinary excretion of 5-hydroxyindoleacetic acid increases, while platelet 
5-HT decreases during migraine; (ii) migraine-like symptoms can be precipitated by reserpine 
and alleviated by 5-HT, which causes carotid vasoconstriction; and (iii) ergotamine and 
methysergide elicit selective vasoconstriction, partly via 5-HT receptors located on cephalic 
arteriovenous anastomoses (76).  This resulted in the synthesis of the tryptamine derivatives 
having selectivity for the craniovascular 5-HT1 receptors and the subsequent identification and 
introduction of sumatriptan by Humphrey and colleagues (77).  Although triptans have some 
variable 5-HT1A, 5-HT1E or 5-HT1F agonist actions, it seems that the commonality of their action 
is at the 5-HT1B/1D receptor sites (78).  The distribution of 5-HT1B and 5-HT1D receptors and their 
potential involvement in the antimigraine activity, has been demonstrated by pharmacological, 
immunocytochemical and molecular techniques (59, 79-81).  In the spinal trigeminal tract of 
human brain stem, a greater proportion of fibres (>1 µm diameter) expressed CGRP 
immunoreactivity, compared with substance P or 5-HT1D receptor immunoreactivity.  The 
5-HT1D receptor immunoreactivity was localised on some CGRP and substance P 
immunoreactive fibres.  This suggests that 5-HT1D receptors can regulate the release of CGRP 
and substance P and may be relevant to the clinical effectiveness of 5-HT1B/1D receptor agonists 
in the treatment of migraine and other cranial pain syndromes (82). 
The effects of sumatriptan and other triptans include carotid vasoconstriction, inhibition of 
trigeminal nerves innervating intracranial blood vessels and dura mater and inhibition of 
trigeminal neurones in trigeminocervical complex in the brain stem and the upper cervical spinal 
20 Chapter 1: Migraine overview 
 
cord.  It appears that the antimigraine activity of triptans is the combined result of cranial 
vasoconstriction by activation of 5-HT1B receptors and inhibition of neuropeptide release.  
Although it is a significant achievement in migraine treatment, sumatriptan is not without some 
limitations, for e.g. low oral bioavailability, short half-life, metabolism via monoamine oxidase 
in the liver and its inability to cross the blood brain barrier (83-85).  Moreover, approximately 
30% of patients report inadequate relief or do not respond to oral sumatriptan or are prone to 
headache recurrence ranging from 33 to 38% (86, 87).  The mechanism of headache recurrence 
is unclear, but it reflects that the migraine attack outlasts the duration of treatment effect (88).  
The subcutaneous route of administration of sumatriptan is most efficacious and fast acting as 
compared to the oral route, but the adverse effect profile is also more when compared to other 
delivery methods (88).  The adverse effects associated with the use of sumatriptan use are 
observed in about 40% of the patients and they include most notably tightness or pressure in the 
chest, neck and/or throat, shortness of breath, palpitations and anxiety (89).  Although the risk of 
coronary ischaemia with sumatriptan treatment is commonly stated, in a recent study on the 
Japanese population, chest symptoms following sumatriptan injection are not strongly associated 
with coronary ischaemia (90). Therefore, the mechanism of chest symptoms following 
sumatriptan administration should be further elucidated. 
Alternative formulations of sumatriptan appear promising in improving the tolerability and 
efficacy profile of sumatriptan.  In addition, investigators have turned to the development of new 
drugs, the so called “second-generation triptans”: zolmitriptan (AstraZeneca), naratriptan 
(GlaxoSmithKline), rizatriptan (Merck Sharp & Dohme), eletriptan (Pfizer), almotriptan 
(Almirall Prodesfarma); frovatriptan (Vernalis/Elan), donitriptan (Pierre Fabre).  In general, the 
second-generation triptans exhibit a superior pharmacokinetic profile, like higher bioavailability, 
increased plasma half-life and shorter tmax compared to sumatriptan (Table 1.2) (76).  In addition, 
their higher lipophilicity can facilitate penetration into the brain. 
1.4.1.2. Zolmitriptan 
Zolmitriptan was the first of the second-generation triptans that was approved after sumatriptan.  
Apart from its better oral bioavailability and brain penetration as compared to sumatriptan, it also 
yields active metabolites, one of which (N-desmethyl metabolite 183C91) retains 5-HT1B/1D 
receptor agonist activity (at least twice as potent as the parent molecule) (91).  Patients with 
hepatic impairment also seem to tolerate zolmitriptan well, requiring no dosage adjustment. 
1.4.1.3. Naratriptan 
Naratriptan has the highest oral bioavailability amongst the triptans.  The affinity at the 5-HT 
receptor subtypes (5-HT1B, 5-HT1D and 5-HT1F) is also high and is more lipophilic (92) with easy 
brain penetrability.  Because of the fact that the recommended dose has been set low, the clinical 
adverse effect profile of naratriptan is more favourable, but the clinical efficacy is inferior, as 
compared to other triptans.  Thus, naratriptan may be the drug of choice in patients who have a 
mild migraine attack and are sensitive to the adverse effect profile of other triptans.  The 
incidence of headache recurrence seems lower after treatment with naratriptan 2.5 mg (17 to 28 
%) than that observed with other triptans.  However, this may be partly related to its lower 
clinical efficacy. 
1.4.1.4. Rizatriptan 
Rizatriptan has a high affinity for 5-HT1B/1D receptors, but has limited interaction with other 
5-HT receptors, including 5-HT1A, 5-HT1E and 5-HT1F (93).  It undergoes a moderate first-pass 
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metabolism, which limits its oral bioavailability (94).  Of special note is the fact that rizatriptan 
has been observed to accumulate in the breast milk of rats at concentrations 5-fold higher than 
the plasma concentration.  Consequently, caution should be exercised for its use in nursing 
women.  Nonetheless, rizatriptan is quite effective in treating acute migraine, with a dose-related 
increase in efficacy (95). 
1.4.1.5. Eletriptan 
Eletriptan is a conformationally restricted analogue of sumatriptan and it displays increased 
affinity for 5-HT1B/1D receptors (96).  Drugs inhibiting Cyp3A4 isoenzyme may affect the 
metabolism of eletriptan.  Eletriptan 20 mg, 40 mg, and 80 mg are effective for the treatment of 
an acute migraine attack.  This effectiveness is dose-related, with statistically significant 
differences between doses for pain-free response and 24-hour outcomes.  Eletriptan also 
compares well with other triptans available for outcomes measured up to 2 hours and provides 
meaningful relief for 24 hours.  Taken as a single dose, it is well tolerated.  The incidence of 
minor adverse effects is dose-dependent, with 80 mg giving significantly more adverse effects 
than 40 mg (97). 
1.4.1.6. Almotriptan  
Almotriptan binds equally well to both 5-HT1B and 5-HT1D receptors (98).  It displays superior 
vasoconstrictor profile in human meningeal artery as compared to sumatriptan and has also been 
demonstrated to inhibit plasma protein extravasation in guinea pigs (99).  It has a favourable 
adverse effect profile and is not associated with any increase in the heart rate or blood pressure 
and does not cross blood brain barrier (100).  Importantly, however, it is as efficacious in 
migraine as sumatriptan (101, 102). 
Table 1.2.  Pharmacokinetic profile of triptans. 
Tmax (h) Compound Formu-
lation 
Dose 
(mg) Outside  
attack 
During 
attack
Protein 
binding 
(%) 
Vd 
(L/kg) 
T1/2β 
(h) 
Bioavai-
lability 
(%) 
Sumatriptan Oral 
sc 
in 
100 
6 
20 
2.5 
0.25 
 14-21 2.4 2-2.5 
2 
2 
14 
96 
Zolmitriptan Oral 2.5 2  25 7 3 40 
Naratriptan Oral 2.5 1.5-2  28-31 170 5-6 63-74 
Rizatriptan Oral 10 1 1 14 110-140 2-2.5 47 
Eletriptan Oral 80 1.5 2.8   4-5 50 
Almotriptan Oral 12.5 2.5    3.6 70 
Frovatriptan Oral 2.5 2-4 2-4   25 24-30 
sc, subcutaneous; in, intranasal; Tmax, time to reach peak plasma concentration; T1/2β, terminal 
elimination half-life; Vd, volume of distribution. 
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1.4.1.7. Frovatriptan  
Frovatriptan has recently been marketed.  Like other triptans, frovatriptan demonstrates 
functional cerebrovascular selectivity compared with coronary circulation (103, 104).  The 
drawback associated with frovatriptan is that it does not have a fast onset of action (105).  A 
comparative efficacy and pharmacokinetic profile of triptans is given in Table 1.2. 
1.4.1.8. Donitriptan 
Donitriptan (F11356; hydrochloride salt or F12640; mesylate salt, Pierre Fabre, Castres, France) 
has been selected from a series of compounds because of its exceptional high efficacy at 
5-HT1B/1D receptors in vitro and in pharmacological models of migraine in vivo (106, 107). In 
isolated guinea pig trigeminal ganglion neurons, F11356 was more potent (pD2: 7.3 versus 6.7) 
than sumatriptan in inducing outward hyperpolarizing Ca2+-dependent K+ current.  In 
anaesthetised pigs, it elicited a cranioselective and potent carotid vasoconstriction (108).  In vitro 
studies have confirmed its cranioselectivity, with similar coronary side-effect profile as 
sumatriptan (109).   Therefore, due to its long duration of action and excellent tolerability in 
animals, donitriptan may provide an attractive alternative to currently available treatments.  The 
drug is currently undergoing clinical evaluation. 
1.4.2. Role of α-adrenoceptors in migraine 
As described above, carotid arteriovenous anastomoses are dilated and play an important role in 
the pathogenesis of migraine.  Therefore, it is reasonable to believe that α-adrenoceptors could 
be involved in maintaining the vascular tone of the carotid circulation, which may provide a 
potential avenue for the development of newer antimigraine drugs (110).  It has been shown that 
several acutely acting antimigraine agents, including the ergots and triptans, produce potent 
vasoconstriction in the canine and porcine carotid vasculature mediated by 5-HT1B/1D receptors 
(33, 73, 111).  Interestingly, the canine carotid vasoconstrictor responses of the ergot alkaloids 
are mediated by 5-HT1B/1D receptors and α2-adrenoceptors (73) as well as an unidentified 
receptors/mechanism (36).  On the other hand, the vasoconstriction of porcine carotid 
arteriovenous anastomoses by sumatriptan is mediated exclusively by 5-HT1B receptors (111).  
The above lines of evidence, combined with the high affinity of ergotamine and 
dihydroergotamine at α-adrenoceptors (112), suggest their therapeutic efficacy (113) may be 
partly explained by an action mediated via α-adrenoceptors.  However, the possible involvement 
of α-adrenoceptors in the porcine carotid vasculature has been hampered, mainly on the basis 
that porcine carotid arteriovenous anastomoses were described to be insensitive to sympathetic 
nerve stimulation or intracarotid infusions of noradrenaline (114).  This discrepancy is striking 
since in conscious pigs arteriovenous anastomoses are under a vasoconstrictor sympathetic tone, 
which involves α1-adrenoceptors (115).  In fact, sympathetic nerve stimulation as well as 
exogenous noradrenaline causes α-adrenoceptor-mediated vasoconstriction of arteriovenous 
anastomoses in the hind limb of several species (116-120).  Finally, in vitro experiments have 
shown that stimulation of α-adrenoceptors results in contraction of the isolated carotid artery of 
several species, including the dog (121, 122), rabbit (123) and pig (124). 
A series of compounds have been described with α-adrenoceptor agonistic activity (125).  
One such compound, S19014 (spiro[(1,3-diazacyclopent-1-ene)-5:2’-(4’,5’-dimethylindane)]), 
shows a high affinity at both α1- and α2-adrenoceptor subtypes.  Interestingly, S19014 shows a 
wide variation in its efficacy (maximum effect, Emax) and potency (EC50, concentration needed to 
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elicit 50% of Emax) in contracting rabbit, dog and human saphenous vein (EC50: 18, 79 and 
8500 nM, respectively; Emax: 92, 49 and 36% of K+-induced contraction, respectively), rabbit 
aorta (EC50: 816 nM; Emax: 36% of K+-induced contraction) and dog femoral artery (practically 
inactive) (126). 
1.4.3. Role of CGRP in migraine 
CGRP exists in two forms, 
designated α-CGRP and β-CGRP or 
CGRP-I and CGRP-II (127).  The 
main feature of this peptide is a 
disulphide linkage between Cys2 and 
Cys7, a probable region of α-helix 
between residues 12 and 19 and a 
C-terminal amide; Figure 1.3 (23, 128).  CGRP-α was cloned in the early 1980s from the 
alternative splicing of the calcitonin gene (129, 130).  Subsequently, characterisation of CGRP-β 
bearing high sequence homologies with the α-form was done (131).  Other members of this 
family include calcitonin, amylin and adrenomedullin. Due to their structural similarities, the 
peptides share some biological activities, suggesting a possible interaction with similar G-protein 
coupled receptors.  The receptors have been characterised on the basis of pharmacological 
responses and radioligand binding studies (132).  These peptides are widely distributed in the 
peripheral tissues as well as the central nervous system and induce multiple biological effects, 
including potent vasodilatation (CGRP and adrenomedullin), reduction in nutrient intake 
(amylin) and decreased bone resorption (calcitonin).  CGRP inhibitors have therapeutic potential 
in conditions where excessive CGRP-mediated vasodilatation is present, i.e. neurogenic 
inflammation, migraine and other headaches, thermal injury, circulatory shock and flushing in 
menopause (133).  Exciting progress has been made in this field with the development of a 
selective dipeptide CGRP receptor antagonist (BIBN4096BS) (50) and cloning of Receptor 
Associated Membrane Proteins (RAMPs) and Receptor Component Proteins (RCPs), both of 
which are key chaperones required for functional activation of G-protein-coupled receptors. 
1.4.3.1. CGRP receptor subtypes 
CGRP acts via two types of CGRP receptors: CGRP1 and CGRP2.  CGRP1 receptor subtype is 
particularly sensitive to the antagonistic properties of the fragment human CGRP8-37, but mostly 
insensitive to the weak agonist effects of the linear analogue [Cys(ACM)2,7]hCGRPα (134).  By 
contrast, the CGRP2 receptor subtype is less sensitive to CGRP8-37, while the linear analogue 
demonstrated agonist potency in the 10-8-10-7 M range for this receptor (134).  However, the 
final demonstration of the existence of these receptor subtypes must come from their respective 
cloning and the development of fully selective agonists and antagonists, preferably of 
non-peptide nature.  Progress on these fronts has been slow and difficult.  This is probably 
because of the unique molecular features of the CGRP1 receptor.  However, potent small 
molecule peptides as well as non-peptide antagonists of these receptors are finally becoming 
available (50, 135).  The proposed classification of CGRP receptors is described in Table 1.3 
(23, 128, 132, 135). 
Figure 1.3.  Aminoacid sequences of human and rat 
CGRP showing high degree of homology. 
Human CGRPα
Human CGRPβ
Rat CGRPα
Rat CGRPβ
--N-----------------M—S-------------NH2
S-N------------------—D----------E--NH2
S-N------------------—D-------------NH2
ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2
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Figure 1.4.  Schematic representation of CGRP1 receptor 
showing interactions of RAMP1 protein with CRLR and a 
receptor component protein (RCP).  This complex is tightly 
coupled to Gs to promote cAMP production. 
α β γ AC
cAMP
Gs
RCP
CRLR
CGRP
RAMP
1.4.3.2. Molecular features of CGRP receptors 
A G-protein coupled receptor (GPCR) clone was isolated from rat pulmonary blood vessels and 
termed calcitonin receptor like receptor (CRLR) (136).  The relevance of CRLR as a CGRP 
receptor remained elusive till the discovery of the RAMPs.  RAMPs are a novel family of 
transmembrane proteins (137).  These proteins facilitate intracellular translocation of the 
CRLR-maturing protein and its insertion into the plasma membrane.  Moreover, the various 
RAMPs (RAMP1, RAMP2, RAMP3) dramatically alter the pharmacological profile of CRLR 
(137).  RAMP1 (148 amino acid protein) is a single domain and its co-transfection with CRLR in 
a variety of cells, like HEK293, COS-7 and oocytes, confers a CGRP1 receptor like profile to 
CRLR with CGRPα and CGRP8-37 exhibiting high affinities for this receptor complex.  CGRP8-37 
inhibited the effects of CGRP on cAMP production in these co-transfected cells.  On the other 
hand, CRLR-RAMP2 receptor complex behaves as an adrenomedullin receptor with 
adrenomedullin-like peptides having much greater affinity than CGRP derivatives (137).  
Recently, the respective 
expression of CRLR, RAMP1 
and RAMP2 was investigated 
in rat osteoblast-like UMR106 
cells.  A dominant functional 
interaction of CRLR with 
RAMP1 was observed (138).  
Although the simultaneous 
expression of RAMP2 did not 
effect CRLR-RAMP1 
association of the functional 
CGRP receptor, RAMP1 
inhibited the association of 
RAMP2 with CRLR, hence 
reducing the likelihood of 
generating an adrenomedullin-
like receptor.  Thus, RAMPs 
Table 1.3.  Pharmacological characteristics of CGRP receptor subtypes. 
Receptor subtype Parameter 
CGRP1 CGRP2 
Potency CGRPα, CGRPβ>ADM>amylin CGRPα, CGRPβ>ADM>amylin 
Selective agonist None [Cys(ACM)2,7]hCGRPα 
Selective antagonist hCGRP8-37 (pA2: 7-8) 
BIBN4096BS (pA2: 8 and up to 11 
in human SK-N-MC cells) 
SB-273779 (Ki: 250±15 nM) for 
cloned hCGRP1  
BIBN4096BS (pA2: 6.5-7) 
CGRP8-37 (pA2: 5.5-6.5) 
Second messenger Gs (cAMP production) Gs 
Prototypical bioassays Atrium, pulmonary artery, spleen, 
SK-N-MC cells. 
Vas deferens, urinary bladder, liver, 
HCA-7 cells 
ADM, adrenomedullin 
 Chapter 1: Migraine overview 25 
might also have a role in receptor desensitisation.  The respective expression of various RAMPs 
is differentially regulated.  In human endothelial and vascular smooth muscle cells, mRNAs for 
CRLR and RAMP2 are more abundant than those of RAMP1 and RAMP3, while the expression 
of RAMP1, but not RAMP2, is dependent on the plasma concentration of corticosterone (139).  
Thus, the physiological response of a given tissue to CGRP and related peptides can be markedly 
changed depending on the level of expression of RAMPs.  It is thus of interest to establish the 
regulation of CRLR and the various RAMPs precisely in a given tissue or organ because such 
regulation could have a major impact in a variety of pathological conditions.  In addition to the 
RAMPs, the CGRP-receptor complex might require another protein known as RCP to function 
optimally.  RCPs (146 amino acid long) do not belong to any specific class of proteins; 
Figure 1.4 (140). 
1.4.3.3. Development of non-peptide CGRP receptor antagonists 
Various structure-activity studies have been conducted to develop smaller molecules that behave 
as antagonists.  Among these peptides, [Asp31, Pro34, Phe35]CGRP27-37 and [Pro34, 
Phe35]CGRP27-37 were recently reported as potent antagonists at the CGRP1 receptor expressed 
in SK-N-MC cells (141).  A major breakthrough in the field was reported recently following the 
development of a potent dipeptide CGRP antagonist, BIBN4096BS (50, 142) (Figure 1.5). 
BIBN4096BS demonstrates a very high 
affinity for the human CGRP receptor expressed 
in SK-N-MC cells (Ki: 14.4±6.3 pM; pA2: 11; 
compared to pA2: 7.5 for CGRP8-37), to block 
CGRPα-induced cAMP production in these cells 
(50).  Interestingly, BIBN4096BS demonstrates 
species specificity with a 100-fold lower affinity 
for the rat (3.4±0.5 nM) versus the human 
(32±1.7 pM) CGRP1 receptor (50).  Interestingly, 
BIBN4096BS was shown to competitively 
antagonise the effects of hCGRPα with pA2 
values in the nanomolar range in the rat atria, such 
a potency being 10-fold higher than that of CGRP8-37 (Table 1.3).  However, in the rat vas 
deferens, a CGRP2 receptor bioassay showed BIBN4096BS less potent at inhibiting the effects of 
these various CGRP homologues.  This selectivity profile discriminates between the CGRP1 and 
CGRP2 receptors.  Thus, BIBN4096BS should prove useful to provide new information on 
CGRP receptor subtypes.  Comparative pA2 values of hCGRP8-37 and BIBN4096BS against 
CGRP in various prototypical assays are shown in Table 1.3. 
Another compound SB-273779 [N-methyl-N-(2-methylphenyl)-3-nitro-4-(2-thiazolyl 
sulfinyl)nitrobenzanilimide], a selective non-peptide antagonist at the CGRP1 receptor has been 
described.  SB-273779 inhibits [125I]CGRP binding to SK-N-MC (human neuroblastoma cells) 
and human cloned CGRP1 receptor with Ki values of 310 and 250 nM, respectively (135).  
SB-273779 also inhibits CGRP-activated adenyl cyclase in these systems with IC50 values of 
390 nM and 210 nM.  In addition, SB-273779 antagonised CGRP-mediated stimulation of 
intracellular Ca2+ in recombinant CGRP receptors, inhibition of insulin-stimulated 
[14C]deoxyglucose uptake, vasodilation in rat pulmonary artery, and decrease in blood pressure 
in anaesthetised rats (135).  These results suggest that SB-273779 is a valuable tool for studying 
CGRP-mediated functional responses in complex biological systems. 
Figure 1.5.  Chemical structure of 
BIBN4096BS. 
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1.4.3.4. Neuroanatomical localisation and physiological aspects of CGRP in relation to 
migraine 
Most sensory fibres to cranial structures are derived from the trigeminal ganglion.  CGRP, 
substance P and neurokinin A are the dominant neuropeptides found in the sensory nerves among 
which CGRP seems to be the major 
constituent (143).  The role of 
CGRP in the pathogenesis of 
migraine appears to be due to its 
potent vasodilator action (18, 22, 
144).  Electrical stimulation of 
trigeminal ganglion induces release 
of CGRP and substance P (40, 
145).  In the trigeminal ganglion, 
CGRP-immunoreactive neurones 
occur in high numbers (40% of all 
neuronal cells), whereas substance 
P-immunoreactive neurones are 
fewer (18%), as has also been 
observed in cats, with CGRP: 
substance P ratio being 3:1 (143).  
Both CGRP and substance P are 
described as potent vasodilators of 
cranial vessels, with the former 
being around 10-1000 times more 
potent (143).  Interestingly, neurokinin receptor antagonists do not have any beneficial effects in 
aborting acute migraine attack (45).  In addition, there are indications that CGRP is released 
during migraine headache and not substance P (22).  A model has been proposed to explain the 
role of mitogen-activated protein kinase (MAPK) activity and 5-HT1 receptor activation on 
CGRP gene expression in neuronal cells (Figure 1.6) (27).  Activation of MAPK pathways, 
following depolarisation or by inflammatory mediators, initiates a cascade involving 
extracellular signal regulated kinases (ERK), Jun amino terminal kinases (JNK) and P38 proteins 
that ultimately lead to an increase in CGRP gene expression and release (27).  5-HT1 receptor 
agonists, such as sumatriptan, elicit a prolonged elevation of intracellular Ca2+ that mediates 
repression of stimulated CGRP transcription and secretion via induction of specific phosphatases 
(27).  The regulation of CGRP gene expression by MAPK signal transduction cascades may be 
particularly relevant to migraine pathology, since many inflammatory mediators implicated in 
migraine pathophysiology are known activators of MAPK pathways. 
Experiments on guinea pig basilar artery have demonstrated that the CGRP-mediated 
relaxation is due to CGRP1 receptors and are not dependent on intact endothelium (146).  This is 
supported with pharmacological studies on human intracranial arteries, which have shown that 
they have mainly CGRP1 receptors that mediate relaxation (147, 148).  Additionally, 
CGRP-induced vasodilatation has been observed in human lenticulostriate arteries of various 
diameters and this is mediated via CGRP1 receptors (149, 150). 
Figure 1.6.  Model of CGRP regulation in migraine and 
effect of serotonergic antimigraine drugs. 
Depolarisation
CGRP
5-HT1
Cerebral blood vessel
Neurogenic inflammation
Trigeminal 
Ganglia neuron
sumatriptan
Ca++
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1.5. Aims of the thesis 
Taking an account of the present chapter, the aims of the present thesis were: 
• To investigate the possible role of α-adrenoceptors as well as CGRP and 5-HT receptors with 
respect to antimigraine activity. 
• To evaluate therapeutic potential of certain novel compounds (donitriptan, S19014, A61604 
and BIBN4096BS) in porcine model of migraine and their possible mechanism of action 
using selective agonists and antagonists. 
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2. Effects of BIBN4096BS on regional cardiac 
output distribution and on CGRP-induced 
carotid haemodynamic responses in the pig 
 
2.1. Introduction 
Calcitonin gene related peptide (CGRP), a 37 amino acid neuropeptide generated by 
alternative splicing of the calcitonin gene (1), is widely distributed in the body, including in 
trigeminal sensory nerve fibres innervating central and peripheral blood vessels, where it is 
co-localised with other vasoactive neuropeptides, such as substance P and neurokinin A (2, 
3).  CGRP is a potent vasodilator agent in a wide variety of tissues (4-7) and, although 
exogenous α-CGRP has potent systemic and regional haemodynamic effects (8), the 
physiological role of endogenous CGRP is not clear (9).  This is mainly due to the 
unavailability of potent and selective CGRP receptor antagonists; the most widely used 
CGRP receptor antagonist thus far, CGRP8-37, is not very potent and displays partial agonist 
properties (10, 11).  Clearly, the advent of ‘silent’, selective and potent non-peptide CGRP 
receptor antagonists would be valuable in this regard. 
Interestingly, CGRP has been implicated in the pathogenesis of migraine (12-15), and it 
can mediate neurogenic dilatation of cranial blood vessels as well as sensory nerve 
transmission between the first and second order afferent input from these vessels during 
migraine headache (3, 16-18).  Significantly, plasma levels of CGRP, but not of other 
neurotransmitter (e.g. neuropeptide Y, vasoactive intestinal peptide or substance P), are 
elevated during migraine and, after sumatriptan, these levels are normalised paralleling the 
resolution of headache (12, 19).  Therefore, inhibition of α-CGRP release or blockade of 
α-CGRP-induced vasodilatation may be a novel approach in the management of acute 
migraine headache. 
Doods and colleagues (20) have recently described a small molecule CGRP receptor 
antagonist, BIBN4096BS (1-piperidinecarboxamide, N-[2-[[5-amino-1-[[4-(4-pyridinyl)-1-
piperazinyl] carbonyl]pentyl] amino]- 1-[(3,5-dibromo-4-hydroxyphenyl) methyl]- 2-
oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, [R-(R*,S*)]-), which possesses over 
200 fold higher affinity for human (SK-N-MC cells; Ki: 14 pM) than for rat (spleen; Ki: 
3.4 nM) CGRP receptors.  BIBN4096BS as well as the endogenous ligand CGRP and its 
analogues concentration-dependently displace [3H]BIBN4096BS from SK-N-MC cell 
membranes with the rank order of affinity: BIBN4096BS > human α-CGRP = 
human β-CGRP > [Cys(Et)2,7] human α-CGRP > adrenomedullin (high affinity site) = 
human α-CGRP8-37 = human β-CGRP8-37 >> calcitonin = amylin (21).   The compound 
inhibits vasodilatation evoked by trigeminal ganglion stimulation in marmosets (20) and by 
CGRP in several human isolated blood vessels (22-24).  The purpose of the present study in 
anaesthetised pigs was to investigate the effects of BIBN4096BS on: (i) the complete 
distribution of cardiac output to assess the potential role of endogenous CGRP in regulating 
basal vascular tone and thereby the cardiovascular safety of BIBN4096BS, and 
(ii) the haemodynamic responses produced by intracarotid arterial (i.c.) infusion of α-CGRP 
in a model predictive of antimigraine activity (25, 26). 
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2.2. Methods 
2.2.1. General 
After an overnight fast, 25 domestic pigs (Yorkshire x Landrace, females, 10-14 kg) were 
sedated with intramuscular injections of azaperone (120 mg) and midazolam hydrochloride 
(10 mg) and then anaesthetised with sodium pentobarbital (600 mg, i.v.).  After tracheal 
intubation, the animals were connected to a respirator (BEAR 2E, BeMeds AG, Baar, 
Switzerland) for intermittent positive pressure ventilation with a mixture of room air and 
oxygen.  Respiratory rate, tidal volume and oxygen supply were adjusted to keep arterial 
blood gas values within physiological limits (pH: 7.35-7.48; pCO2: 35-48 mmHg; 
pO2: 100-120 mmHg).  Anaesthesia was maintained with a continuous i.v. infusion of sodium 
pentobarbital (12-20 mg.kg-1.h-1).  Heart rate was measured with a tachograph (CRW, 
Erasmus University, Rotterdam, The Netherlands) triggered by electrocardiogram signals.  A 
catheter was placed in the inferior vena cava via the right femoral vein for the administration 
of vehicle and BIBN4096BS.  Another catheter was placed in the aortic arch via the left 
femoral artery for the measurement of arterial blood pressure (Combitrans disposable 
pressure transducer; Braun, Melsungen, Germany) and arterial blood withdrawal for the 
measurement of blood gases (ABL-510; Radiometer, Copenhagen, Denmark).  During the 
experiment, body temperature was kept around 37°C and the animal was continuously 
infused with physiological saline to compensate for fluid losses. 
Heart rate and systolic, diastolic and mean arterial blood pressure as well as the 
pulsatile and mean carotid artery blood flows (see later) were continuously monitored on a 
polygraph (CRW, Erasmus University, Rotterdam, The Netherlands). 
2.2.2. Cardiac output and its distribution 
Cardiac output was measured by the thermodilution method using a 6F Swan-Ganz catheter 
(Braun Melsungen AG, Melsungen, Germany) introduced into the pulmonary artery via the 
left femoral vein. 
The distribution of cardiac output was determined with 15.5±0.1 (s.d.) µm diameter 
microspheres labelled with 141Ce, 113Sn, 103Ru, 95Nb or 46Sc (NEN Dupont, Boston, USA).  
For each measurement, a suspension of about 1,000,000 microspheres, labelled with one of 
the isotopes, was injected into the left ventricle via a catheter guided by way of the left 
carotid artery.  Starting 15 s before microsphere injection and lasting 70 s, a reference arterial 
blood sample was withdrawn (Withdrawal pump, Harvard Apparatus Company, Southnatick, 
Mass, USA; rate: 6 ml.min-1) via a catheter placed into the right femoral artery.  An infusion 
of the corresponding volume of Haemaccel compensated blood loss during this procedure. 
At the end of the experiment, the animal was killed using an overdose of pentobarbital.  
Subsequently, a number of tissues (lungs, kidneys, heart, stomach, small intestine, spleen, 
liver, adrenals, brain, skin and skeletal muscles) were dissected out, weighed and put into 
vials.  The radioactivity in these vials was counted for 5 min in a γ-scintillation counter 
(Packard, Minaxi autogamma 5000), using suitable windows for the discrimination of the 
different isotopes (141Ce: 120-167 KeV, 113Sn: 355-435 KeV, 103Ru: 450-548 KeV, 
95Nb: 706-829 KeV and 46Sc: 830-965 KeV).  All data were processed by a set of specially 
designed computer programs (27), using a personal computer.  Tissue blood flows were 
calculated by multiplying the ratio of tissue and reference blood sample radioactivities by the 
blood withdrawal rate (6 ml.min-1) and normalised to 100 g tissue weight.  Systemic and 
tissue vascular conductances were calculated by dividing cardiac output (ml.min-1) and tissue 
blood flows (ml.min-1/100 g tissue), respectively, by mean arterial blood pressure (mmHg).  
Radioactivity in the lungs mainly represents peripheral arteriovenous anastomotic blood flow 
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(the non-nutrient part of the cardiac output), although a small part (1-1.5% of cardiac output) 
is derived from the bronchial arteries (28). 
2.2.3. Carotid haemodynamic responses to CGRP 
Both common carotid arteries and the external jugular veins were dissected free and the 
accompanying vagosympathetic trunks were cut between two ligatures in order to prevent a 
possible influence of CGRP via baroreceptor reflexes.  Pulsatile and mean blood flows were 
measured in the right common carotid artery with a flow probe (internal diameter: 2.5 mm) 
connected to a sine-wave electromagnetic flow meter (Transflow 601-system, Skalar, Delft, 
The Netherlands).  The amplitude of carotid blood flow signals provided an index of carotid 
flow pulse.  Carotid vascular conductance was calculated by dividing carotid blood flow  
(ml.min-1) by mean arterial blood pressure (mmHg). 
The right external jugular vein was catheterised for obtaining jugular venous blood 
samples to determine blood gases.  Two hub-less needles, connected to polyethylene tubes, 
were inserted into the right common carotid artery and used for intracarotid (i.c.) infusions of 
phenylephrine (α1-adrenoceptor agonist) and α-CGRP, respectively.  It should be noted that 
under pentobarbital anaesthesia carotid arteriovenous anastomoses are dilated (29) and, 
therefore, to elicit vasodilator responses to CGRP, a continuous infusion of phenylephrine 
was used throughout the experiment.  We have previously reported that phenylephrine 
decreases total carotid blood flow and conductance exclusively due to constriction of carotid 
arteriovenous anastomoses (30), resulting in an increase in the difference between arterial and 
jugular venous oxygen saturations (A-V SO2 difference) (31). 
2.2.4. Experimental protocols 
In the case of cardiac output distribution experiments (n=12), baseline values of heart rate, 
mean arterial blood pressure, cardiac output and its distribution to the various tissues (see 
above) were determined after a stabilisation period of at least 90 min.  The animals were then 
divided into two groups (n=6 each) receiving three i.v. infusions (rate: 0.5 ml.min-1) of either 
BIBN4096BS (100, 300 and 1000 µg.kg-1) or its vehicle (5 ml of acidified distilled water); 
each dose was given over 10 min with an intervening period of 10 min before the next dose.  
At the end of each infusion, the above mentioned haemodynamic variables were collated 
again.  Lastly, the final measurements were made 40 min after the third dose of vehicle or 
BIBN4096BS (recovery). 
In the case of the carotid artery experiments (n=13), phenylephrine (10 µg.kg-1.min-1 
for 10 min, followed by 3-6 µg.kg-1.min-1 throughout the rest of the experiment) was infused 
into the right common carotid artery to maintain carotid blood flow at a constant low level.  
After a stabilisation period of at least 90 min, values of heart rate, arterial blood pressure, 
total carotid blood flow and A-V SO2 difference were collated.  The animal was then given 
three sequential i.c. infusions (rate: 0.083-1 ml.min-1, depending on the weight of the animal) 
of CGRP (10, 30 and 100 pmol.kg-1.min-1) for 3 min and the above variables (except the 
A-V SO2 difference, which was determined only after the highest dose) were collated again.  
After the highest dose of α-CGRP, a recovery period of 20 min was allowed to elapse when 
all haemodynamic parameters returned to baseline levels.  At this point, the animals were 
divided into two groups receiving three i.v. infusions (rate: 0.5 ml.min-1) of either 
BIBN4096BS (100, 300 and 1000 µg.kg-1; n=7) or its vehicle (5 ml of acidified distilled 
water; n=6); each dose was given over a period of 10 min with an intervening period of about 
10 min before the next dose.  Ten min after each treatment, the values of mean arterial blood 
pressure, heart rate, total carotid blood flow and A-V SO2 difference were collated.  CGRP 
was infused as above after each treatment and data were collated again. 
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It may be mentioned that the vehicle of α-CGRP (distilled water) was devoid of any 
systemic and carotid haemodynamic responses (data not shown). 
2.2.5. Data presentation and statistical analysis 
All data have been expressed as mean±s.e.mean, unless stated otherwise.  The significance of 
changes from baseline values within one group (vehicle or BIBN4096BS) was evaluated with 
Duncan's new multiple range test, once an analysis of variance (randomised block design) 
had revealed that the samples represented different populations (27, 32).  The differences in 
baseline haemodynamic values and percent change (from baseline values) in haemodynamic 
variables by corresponding doses of the vehicle and BIBN4096BS (between group 
comparisons) were evaluated by Student's unpaired t-test.  Student's unpaired t-test was also 
applied to compare the changes in the effects of CGRP observed after different corresponding 
doses of the vehicle and BIBN4096BS.  Statistical significance was accepted at P<0.05 
(two-tailed). 
2.2.6. Ethical approval 
The Ethics Committee of the Erasmus MC, Rotterdam, dealing with the use of animals in 
scientific experiments, approved investigation protocols, which adhere to EEC guidelines. 
2.2.7. Compounds 
The following compounds were used: azaperone (Stresnil®; Janssen Pharmaceuticals, Beerse, 
Belgium), BIBN4096BS and human α-CGRP (Boehringer Ingelheim Pharma KG, Biberach, 
Germany), heparin sodium (to prevent blood clotting in catheters; Leo Pharmaceutical 
Products, Weesp, The Netherlands), midazolam hydrochloride (Dormicum®; Hoffmann La 
Roche b.v., Mijdrecht, The Netherlands), phenylephrine hydrochloride (Sigma-Aldrich 
Chemie b.v., Zwijndrecht, The Netherlands) and sodium pentobarbital (Sanofi Sante b.v., 
Maasluis, The Netherlands). 
Phenylephrine and α-CGRP were dissolved in distilled water, while BIBN4096BS was 
initially dissolved in 0.5 ml of 1N HCl and subsequently diluted with 4 ml of distilled water, 
and then adjusted to pH 6.5 with 1N NaOH. 
2.3. Results 
2.3.1. Effect of BIBN4096BS on cardiac output and its distribution 
2.3.1.1. Baseline values 
Baseline values of heart rate, mean arterial blood pressure, cardiac output (expressed as 
cardiac index) and systemic vascular conductance in anaesthetised pigs (n=12) were: 108±3 
beats.min-1, 102±2 mmHg, 133±4 ml.min-1.kg-1 and 1491±54 ml.min-1.mmHg-1, respectively.  
Baseline values of regional vascular conductances (ml.min-1.mmHg-1/100 g tissue) were: 
brain, 31±3; heart, 104±10; liver, 34±8; stomach, 24±2; lungs (mainly systemic arteriovenous 
anastomoses), 229±37; adrenals, 138±10; kidneys, 263±14; spleen, 126±15; skeletal muscles, 
3.3±0.3; and skin, 11±2. 
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2.3.1.2. Systemic and regional haemodynamic changes 
Systemic haemodynamic values collated at baseline, after vehicle or BIBN4096BS (100, 300 
and 1000 µg.kg-1, i.v.) and after a 40-min recovery period are shown in Figure 2.1.  There 
were no statistically significant differences (P>0.05) in baseline values in the vehicle and 
BIBN4096BS groups.  Except for small decreases in heart rate by the vehicle (maximum 
change: 4±1%) and cardiac index by BIBN4096BS (maximum change: 19±8%), no other 
changes were observed.  The changes in cardiac index by BIBN4096BS did not differ 
significantly (P>0.05) from those in the vehicle-treated animals (maximum change: 7±3%). 
Figure 2.2 presents regional vascular conductances in a number of tissues in animals 
treated with either vehicle or BIBN4096BS (100, 300 and 1000 µg.kg-1, i.v.).  Baseline 
values in the two groups were not significantly different (P>0.05) in any of the tissues, 
including the liver, lungs and skin.  Apart from decreases in liver conductance, no other 
changes in regional vascular conductances were noticed in the vehicle-treated group.  
BIBN4096BS produced small decreases in vascular conductance to liver, and with the 
highest dose (1000 µg.kg-1) in lungs, adrenals, kidneys and spleen.  Only the latter changes 
were significant when compared with the corresponding changes in the vehicle-treated 
animals. 
Figure 2.1.  Heart rate (HR), mean arterial 
blood pressure (MAP), cardiac index (CI) 
and systemic vascular conductance (SVC) 
measured at baseline, after i.v. treatments 
with either vehicle (V, three times 5 ml; n=6) 
or BIBN4096BS (BIBN; 100, 300 and 
1000 µg.kg-1; n=7) and after 40 min 
recovery.  All values are presented as 
mean±s.e.mean.  *, P<0.05 vs. baseline.  The 
changes after BIBN4096BS are not 
significantly different from those in the 
corresponding vehicle group. 
Figure 2.2.  Regional vascular conductances at 
baseline (Bas), after i.v. treatments with either 
vehicle (V, three times 5 ml; n=6) or 
BIBN4096BS (100, 300, and 1000 µg.kg-1, i.v.; 
n=6) and after 40 min recovery (Rec).  All 
values are presented as mean±s.e.mean.  
*, P<0.05 vs. baseline.  #, P<0.05 vs. the 
corresponding change in animals treated with 
vehicle. 
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2.3.2. Effect of BIBN4096BS on the haemodynamic responses to i.c. infusions of 
α-CGRP 
2.3.2.1. Baseline values 
Baseline values in anaesthetised pigs (n=13) were: heart rate, 129±5 beats.min-1; mean 
arterial blood pressure, 122±4 mmHg; carotid flow pulse, 1.7±0.1 arbitrary units (a.u.); total 
carotid blood flow, 67±7 ml.min-1; total carotid vascular conductance, 56±5 
10-2 ml.min-1.mmHg-1 and A-V SO2 difference, 26±3%.  Baseline values in the two groups of 
animals (vehicle and BIBN4096BS) did not differ significantly. 
2.3.2.2. Systemic and carotid haemodynamic responses 
Figure 2.3 shows the original tracings illustrating the systemic (blood pressure and heart rate) 
and carotid (flow pulse and total carotid blood flow) haemodynamic responses in 
anaesthetised pigs obtained with α-CGRP (10, 30 and 100 pmol.kg-1.min-1, i.c.) before and 
after i.v. treatments with three doses of vehicle (5 ml each time; upper panel) or 
BIBN4096BS (100, 300 and 1000 µg.kg-1; lower panel).  The infusions of α-CGRP did not 
affect heart rate, but decreased arterial blood pressure and increased carotid flow pulse and 
blood flow.  These changes were accompanied by a redness of head skin and ears on the side 
of infusion (not shown in the figure).  The effects of α-CGRP were clearly attenuated in the 
animals receiving BIBN4096BS, but not in the ones treated with vehicle. 
The effects of α-CGRP (10, 30 and 100 pmol.kg-1.min-1, i.c.) in the animals treated 
with vehicle or BIBN4096BS (100, 300 and 1000 µg.kg-1, i.v.) were quantified as percent 
changes from baseline values (Figure 2.4).  In both groups, infusions of α-CGRP before 
treatments with vehicle or BIBN4096 (control infusions) produced dose-dependent decreases 
in mean arterial blood pressure and increases in total carotid blood flow (data not shown) and 
conductance; heart rate was not affected (data not shown).  These responses to α-CGRP 
remained unaffected after vehicle, but, in contrast, were dose-dependently antagonised by 
BIBN4096BS (Figure 2.4). 
Figure 2.3.  Original 
tracings from experiments in 
anaes-thetised pigs 
illustrating systemic and 
carotid haemo-dynamic 
responses to infusions of 
α-CGRP (•; 10, 30 or 100 
pmol.kg-1.min-1, i.c.) given 
before and after i.v. 
treatments with either 
vehicle (three times 5 ml; 
upper panel) or 
BIBN4096BS (BIBN, 100, 
300 and 1000 µg.kg-1; lower 
panel).  BP; systolic and 
diastolic arterial blood 
pressures; MAP, mean 
arterial blood pressure; HR, 
heart rate; FP, carotid blood 
flow pulse; TCBF, total 
carotid blood flow. 
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As shown in Figure 2.5, infusions of α-CGRP (100 pmol.kg-1.min-1, i.c.) clearly 
increased carotid blood flow (depicted as the maximum changes) and carotid blood flow 
pulsations (compare baseline and control values).  While there was little change in animals 
treated with vehicle, BIBN4096BS (100, 300 and 1000 µg.kg-1, i.v.) dose-dependently 
antagonised the responses to α-CGRP. 
2.3.2.3. Changes in the A-V SO2 difference 
α-CGRP (100 pmol.kg-1.min-1, i.c.) produced a significant reduction in the A-V SO2 
difference in both groups of animals (Figure 2.6; compare baseline and control values).  The 
response to CGRP remained largely unaffected after treatments with vehicle, but 
Figure 2.4.  Changes in mean arterial 
blood pressure and total carotid vascular 
conductance from baseline values by i.c. 
infusion of α-CGRP in anaesthetised pigs 
given before (Control) and after i.v. 
treatments with vehicle (three times 5 ml; 
n=6) or BIBN4096BS (100, 300 and 1000 
µg.kg-1, n=7).  All values are expressed as 
mean±s.e.mean.  The two highest doses of 
α-CGRP significantly decreased mean 
arterial blood pressure and increased total 
carotid conductance (significance not 
shown for the sake of clarity).  These 
effects of α-CGRP were dose-dependently 
antagonised by BIBN4096BS.  #, P<0.05 
vs. response after the corresponding 
volume of vehicle. 
Figure 2.5.  Maximum carotid 
blood flow changes and carotid 
blood flow pulsations measured 
at baseline and following infu-
sions of α-CGRP (100 pmol. 
kg-1.min-1, i.c.) given in anaes-
thetised pigs before (Control) 
and after i.v. treatments with 
vehicle (V, 5 ml three times; 
n=6) or BIBN4096BS (100, 300 
and 1000 µg.kg-1, n=7).  All 
values are expressed as mean± 
s.e.mean.  a.u., Arbitrary units. 
*, P < 0.05 vs. baseline values;  
#, P<0.05 vs. response after the 
corresponding volume of 
vehicle. 
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BIBN4096BS (100, 300 and 1000 µg.kg-1, i.v.) dose-dependently blocked the reduction in the 
A-V SO2 difference by α-CGRP.  In fact, the CGRP-induced decrease in the A-V SO2 
difference was enhanced after the highest dose of BIBN4096BS (Figure 2.6). 
 
2.4. Discussion 
2.4.1. General 
Undoubtedly, a remarkable progress has been achieved in acute antimigraine therapy (33).  
Notwithstanding, the exact pathophysiological mechanisms underlying migraine remain 
unclear.  There is, however, evidence supporting the involvement of the trigeminovascular 
system in migraine pathophysiology (17, 19, 34, 35).  Thus, activation of the 
trigeminovascular system leads to neuropeptide release, including that of CGRP, and 
neurogenic dural vasodilatation (17).  Of particular relevance is the finding that plasma 
concentration of CGRP is elevated during the headache phase of migraine, and this is 
normalised after treatment with sumatriptan (12, 19, 34).  Hence, it is reasonable to assume 
that a potent CGRP receptor antagonist, such as BIBN4096BS (20), might be useful in 
migraine therapy.  BIBN4096BS behaves as a ‘silent’ competitive antagonist at CGRP 
receptors mediating relaxation of human temporal, cranial and coronary arteries (22-24).  The 
present study in anaesthetised pigs was designed: (i) to analyse, using BIBN4096BS, the 
potential role of endogenous CGRP in regulating vascular tone in vivo; and (ii) to investigate 
the effects of BIBN4096BS on the systemic and carotid haemodynamic responses produced 
by α-CGRP.   
2.4.2. Systemic and regional haemodynamic effects of BIBN4096BS 
It is well known that CGRP-immunoreactive nerve fibres are widely distributed in the 
cardiovascular system, with a higher preponderance in arteries than in veins (36).  CGRP 
decreases blood pressure and has positive inotropic and chronotropic effects on the heart (37), 
which are mainly mediated via CGRP1 receptors (36, 38, 39).  Though CGRP has diverse 
biological actions within the cardiovascular system, our experiments showing few systemic 
Figure 2.6.  Differences 
between arterial and jugular 
venous oxygen saturations 
(A-V SO2 difference) measured 
at baseline and after infusions of 
α-CGRP (100 pmol.kg-1. min-1, 
i.c.) given in anaesthe-tised pigs 
before (Control) and after i.v. 
treatments with vehicle (Veh, 5 
ml three times; n=6) or 
BIBN4096BS (100, 300 and 
1000 µg.kg-1, n=7).  All values 
are expressed as mean±s.e. 
mean.  *, P < 0.05 vs. baseline 
values;  #, P<0.05 vs. response 
after the corresponding volume 
of vehicle. 
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haemodynamic changes with BIBN4096BS do not support a major role for CGRP in the 
regulation of cardiovascular function in the anaesthetised pig. 
As far as regional haemodynamics is concerned, a moderate decrease (compared to 
vehicle) in vascular conductances in the lungs, adrenals, kidneys and spleen was observed 
with the highest dose (1000 µg.kg-1) of BIBN4096BS (Figure 2.2).  Similarly, renal 
vasoconstriction was noticed in conscious rats with a high (300 nmol.kg-1.min-1), but not with 
a low (30 nmol.kg-1.min-1) dose of CGRP8-37 (8).  Since both BIBN4096BS and CGRP8-37 
caused renal changes only in doses that were considerably higher than those needed for 
CGRP antagonism, it does not appear that endogenous CGRP regulates renal vascular tone.  
Also, Shen et al. (9) recently reported that 30 µg.kg-1.min-1 (~10 nmol.kg-1.min-1) of CGRP8-
37, which antagonised CGRP-induced haemodynamic responses, caused little regional 
haemodynamic effects in conscious dogs as well as anaesthetised rats, thereby not supporting 
an important physiological role for endogenous CGRP in regulating vascular tone.  Although 
we cannot rule out the involvement of CGRP in certain other circumstances, for example, 
cardiac preconditioning or coronary artery disease (40-42), the present results imply 
cardiovascular safety of BIBN4096BS.  Nevertheless, one will have to explore the role of 
CGRP in cardiovascular pathophysiology before establishing whether or not CGRP receptor 
antagonists are completely safe in patients afflicted with cardiovascular disorders. 
2.4.3. CGRP-induced haemodynamic responses and antagonism by BIBN4096BS 
Activation of CGRP receptors elicits dilatation in different vascular beds in several species 
(8, 9, 43).  Consistent with these studies, our experiments show that i.c. infusions of α-CGRP 
produced a marked vasodilatation in the porcine carotid circulation, with accompanying fall 
in arterial blood pressure.  The fact that the animals were systematically 
vagosympathectomised may explain why the hypotension was not accompanied by a 
baroreflex-mediated tachycardia, as reported earlier (43).  Interestingly, the ipsilateral skin 
redness, together with the marked decrease in A-V SO2 difference by CGRP, indicates that 
porcine carotid arteriovenous anastomoses dilated in response to α-CGRP (31).  However, 
we previously reported that i.c. infusions of α-CGRP failed to increase porcine arteriovenous 
anastomotic blood flow, despite a marked increase in the total carotid and capillary blood 
flows (43).  Admittedly, arteriovenous anastomotic blood flow was not directly measured in 
these experiments, but we have recently observed that i.c. infusions capsaicin, which released 
CGRP, did increase carotid arteriovenous anastomotic blood flow with a concomitant 
decrease in the A-V SO2 difference (44).  Thus, it appears that the discrepancy between the 
two investigations may be due to different anaesthetic regimens employed (pentobarbital and 
fentanyl/thiopental, respectively) and, particularly, the use of phenylephrine in the present 
experiments.  Phenylephrine potently constricts arteriovenous anastomoses (30). 
In the present experimental study in anaesthetised pigs, BIBN4096BS proved to be an 
effective antagonist at the CGRP receptors mediating the systemic (hypotension) as well as 
the carotid (increased blood flow, pulsations and skin redness) haemodynamic responses to 
α-CGRP.  The fact that BIBN4096BS also abolished α-CGRP-induced decreases in the 
A-V SO2 difference suggests its action on carotid arteriovenous anastomoses; for further 
considerations, see Saxena (31). Interestingly, BIBN4096BS also antagonised the 
capsaicin-induced increases in carotid arteriovenous anastomotic blood flow as well as 
decreases in the A-V SO2 difference, but not the plasma CGRP concentrations (44). 
One cannot be certain about the nature of CGRP receptors that mediate porcine carotid 
vascular responses, but cardiac inotropic and vasodilator responses are mediated 
predominantly by CGRP1 receptors (39), where BIBN4096BS has a very high affinity (7, 20). 
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2.4.4. Potential therapeutic efficacy of BIBN4096BS in the treatment migraine 
Considering that plasma CGRP levels are elevated during the headache phase of migraine 
(34) and that BIBN4096BS dose-dependently blocked α-CGRP-induced carotid 
haemodynamic responses, it is likely that BIBN4096BS may be effective in migraine.  The 
compound is presently under clinical investigation for the acute treatment of migraine and the 
results are awaited with great interest. 
In conclusion, our study clearly demonstrates that BIBN4096BS is an effective antagonist at 
vascular CGRP receptors in anaesthetised pigs, but has little haemodynamic effects of its 
own, a finding that negates a major physiological role for CGRP in cardiovascular regulation.  
The potent blockade of the carotid haemodynamic effects of CGRP does suggest that 
BIBN4096BS may be effective in migraine treatment. 
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 3. Effects of the CGRP receptor antagonist 
BIBN4096BS on capsaicin-induced carotid 
haemodynamic changes in anaesthetised pigs 
 
3.1. Introduction 
Although a complete understanding of the pathogenesis of migraine remains elusive thus far, 
there seems little doubt that dilatation of cranial blood vessels, including carotid 
arteriovenous anastomoses, is involved in the headache phase (1).  Moreover, evidence is 
accumulating that a release of vasoactive neuropeptides from the trigeminal sensory nerves 
may be an important factor in the genesis of migraine (2).  In this respect, a high circulating 
plasma concentration of calcitonin gene related peptide (CGRP) has been demonstrated 
during migraine headache (3) and these concentrations can be normalised by triptans in 
parallel with alleviation of headache (3, 4).  Indeed, CGRP is widely distributed in the body, 
including the central and peripheral parts of the trigeminovascular system (5-8), where it is 
co-localised with substance P, neurokinin A and/or 5-HT1D receptors (9-11).  CGRP can 
mediate neurogenic dilatation of cranial blood vessels as well as sensory nerve transmission 
between the first and second order afferent input from these vessels during migraine 
headache (2, 10-12).  Thus, it follows that inhibition of CGRP-mediated cranial 
vasodilatation and sensory nerve transmission with a potent and selective CGRP receptor 
antagonist may prove a novel strategy in treating migraine. 
The recent discovery of a di-peptide CGRP receptor antagonist BIBN4096BS 
(1-piperidinecarboxamide, N-[2-[[5-amino-1-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl] 
pentyl] amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]- 4-(1,4-dihydro-2-
oxo-3(2H)-quinazolinyl)-, [R-(R*,S*)]-) (13, 14) represents a significant advance in 
exploring the pathophysiological role of CGRP in migraine.  BIBN4096BS displays a very 
high affinity for human CGRP receptors (13, 15-18).  This compound is undergoing clinical 
trials for aborting migraine headache and the clinical results are awaited with great interest. 
Using an animal model that seems to be predictive of antimigraine activity (1, 19-23), 
the present study in anaesthetised pigs was designed (i) to investigate the effects of capsaicin 
(pungent substance in red chilli pepper), which releases neuropeptides, including CGRP (24-
27), on systemic and carotid haemodynamics, and (ii) to establish if BIBN4096BS is able to 
attenuate the responses induced by capsaicin.  A preliminary account of this investigation was 
presented at the XIVth World Congress of Pharmacology (28). 
3.2. Materials and methods 
3.2.1. General 
After an overnight fast, a total of 22 pigs (Yorkshire x Landrace, females, 10-14 kg; n=11 
each for vehicle and BIBN4096BS) were sedated with azaperone (120 mg, i.m.) and 
midazolam hydrochloride (10 mg, i.m.) and then anaesthetised with sodium pentobarbital 
(600 mg, i.v.).  After tracheal intubation, the animals were connected to a respirator (BEAR 
2E, BeMeds AG, Baar, Switzerland) for intermittent positive pressure ventilation with a 
mixture of room air and oxygen.  Respiratory rate, tidal volume and oxygen supply were 
adjusted to keep arterial blood gas values within physiological limits (pH: 7.35-7.48; pCO2: 
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35-48 mmHg; pO2: 100-120 mmHg).  Anaesthesia was maintained with a continuous i.v. 
infusion of sodium pentobarbital (12-20 mg.kg-1 h-1).  This anaesthetic regimen, together with 
bilateral vagosympathectomy (see below), increases heart rate and markedly dilates carotid 
arterioles and arteriovenous anastomoses due to a loss of parasympathetic and sympathetic 
tone, respectively.  Consequently, carotid blood flow, particularly its arteriovenous 
anastomotic fraction, is considerably higher in these pigs than in conscious or thiopental-
anaesthetised pigs (29). 
Heart rate was measured with a tachograph (CRW, Erasmus University, Rotterdam, 
The Netherlands) triggered by electrocardiogram signals.  Both common carotid arteries were 
dissected free and the accompanying vagosympathetic trunks were cut between two ligatures 
to prevent any possible influence via baroreceptor reflexes on the carotid vascular responses 
produced by capsaicin.  Pulsatile and mean carotid blood flows were measured in the right 
common carotid artery with a flow probe (internal diameter: 2.5 mm) connected to a 
sine-wave electromagnetic flow meter (Transflow 601-system, Skalar, Delft, The 
Netherlands).  The amplitude of carotid blood flow signals provided an index of carotid flow 
pulse.  Subsequently, three hub-less needles, connected to a polyethylene tube, were inserted 
into the right common carotid artery for the administration of capsaicin, radioactive 
microspheres and the α1-adrenoceptor agonist phenylephrine.  The use of phenylephrine is 
necessitated by the fact that the carotid arterioles and arteriovenous anastomoses are already 
in a dilated state under the present anaesthetic regime (29) and, therefore, to study the effects 
of vasodilator agents (in the present case capsaicin) one has to constrict them first.  As 
described earlier (30), phenylephrine decreases total carotid conductance exclusively by 
constricting carotid arteriovenous anastomoses, which results in an increase in the difference 
between arterial and jugular venous oxygen saturations (A-V SO2 difference) (31). 
Lastly, catheters were placed in the right external jugular vein for the withdrawal of 
venous blood samples to measure blood gases (ABL-510; Radiometer, Copenhagen, 
Denmark) and plasma concentrations of CGRP (see below), inferior vena cava (via the left 
femoral vein) for the administration of the vehicle or BIBN4096BS and aortic arch (via the 
left femoral artery) for the measurement of arterial blood pressure (Combitrans disposable 
pressure transducer; Braun, Melsungen, Germany) as well as withdrawal of arterial blood 
samples to measure blood gases. 
Heart rate and systolic, diastolic and mean arterial blood pressures as well as mean and 
pulsatile carotid artery blood flows were continuously monitored on a polygraph (CRW, 
Erasmus University, Rotterdam, The Netherlands).  Vascular conductances were calculated 
by dividing respective blood flows (ml.min-1) by mean arterial blood pressure (mmHg), 
multiplied by one hundred and expressed as 10-2 ml.min-1.mmHg-1.  During the experiment, 
body temperature was maintained at 37±1°C by a heating pad and the animal was infused 
with physiological saline to compensate for fluid losses. 
3.2.2. Distribution of carotid blood flow 
The distribution of common carotid blood flow into tissue (capillary) and arteriovenous 
anastomotic fractions was determined in 13 pigs (later receiving vehicle, n=7 or 
BIBN4096BS, n=6) with radioactive microspheres (diameter: 15.5±0.1 µm; S.D.), labelled 
with 141Ce, 113Sn, 103Ru, 95Nb or 46Sc (NEN Dupont, Boston, USA).  For each measurement, a 
suspension of about 200,000 microspheres, labelled with one of the isotopes, was mixed and 
injected into the carotid artery.  At the end of the experiment, the animal was killed using an 
overdose of pentobarbital and the heart, kidneys, lungs and different cranial tissues were 
dissected out, weighed and put in vials.  The radioactivity in these vials was counted for 
5 min in a γ-scintillation counter (Packard, Minaxi autogamma 5000), using suitable windows 
for discriminating the different isotopes (141Ce: 120-167 KeV, 113Sn: 355-435 KeV, 
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103Ru: 450-548 KeV, 95Nb: 706-829 KeV and 46Sc: 830-965 KeV).  All data were processed 
by a set of specially designed computer programs (32). 
The distribution of total carotid blood flow to different tissues (Qtis) was calculated by 
the formula: Qtis = (Itis/Itotal) x Qcarotid, where Itis is tissue radioactivity, Itotal is the sum of 
radioactivity counted in tissues and Qcarotid is the total common carotid blood flow at the time 
of microsphere injection.  Since little or no radioactivity was detected in the heart or kidneys, 
it can be assumed that all microspheres trapped in lungs reach the lungs from the venous side 
after escaping via carotid arteriovenous anastomoses.  Therefore, the amount of radioactivity 
in the lungs can be used as an index of the arteriovenous anastomotic fraction of carotid blood 
flow (32, 33). 
3.2.3. Determination of plasma concentration of CGRP 
Jugular venous blood samples were obtained from 12 pigs, receiving vehicle or BIBN4096BS 
(n=6 each).  Four of these animals (2 each for vehicle and BIBN4096BS) had been used for 
carotid haemodynamic experiments, while the other 8 were separate experiments using the 
same protocol except that the radioactive microspheres were not used.  Blood was transferred 
immediately into a polypropylene tube containing ethylene dinitro-tetraacetic acid (1 mg ml-1 
of blood) and aprotinin (500 KIU ml-1 of blood).  Aprotinin was used to inhibit endogenous 
plasma proteases, since we observed that CGRP is not detectable in biological samples 
without aprotinin (unpublished).  After centrifugation at 1600 g for 15 min, plasma samples 
were coded and stored at -80°C until CGRP measurements were performed.  The person 
measuring CGRP concentrations remained blind to the treatments, until all data had been 
collated. 
CGRP was extracted from plasma using a C18 SEP-COLUMN, dried by lypholisation, 
and measured by radioimmunoassay (34), as per protocol of the Peninsula Laboratories, Inc 
(Belmont, CA, U.S.A.).  The recovery of CGRP from the extraction procedure was 
ascertained by assaying control samples paired with a duplicate sample spiked with known 
quantities of CGRP.  The column recovery values were 85, 79, 81, 89 and 92% (Mean=85.2; 
Standard deviation=5.4; Coefficient of variation=6.3%).  The CGRP concentrations measured 
in the actual samples were, however, not corrected for the loss in the extraction procedure. 
3.2.4. Experimental protocol 
Following surgery and after haemodynamic condition of the animals (n=22) had been stable 
for 15-20 min (heart rate: 107±4 beats.min-1, mean arterial blood pressure: 95±2 mmHg, 
mean carotid blood flow: 120±12 ml.min-1 and A-V SO2 difference: 7.6±1.1%), 
phenylephrine was infused into the right common carotid artery at a rate of 10 µg.kg-1.min-1 
for 10 min, followed by 3-6 µg.kg-1.min-1 throughout the rest of the experiment.  The latter 
dose of phenylephrine was chosen so that the external jugular venous oxygen saturation was 
between 60-70% and mean carotid blood flow was about 40% of the original value.  After a 
period during which haemodynamic variables remained constant for at least 60 min (heart 
rate: 130±4 beats.min-1, mean arterial blood pressure: 105±2 mmHg, mean carotid blood 
flow: 48±5 ml.min-1 and A-V SO2 difference: 31±2.3%; n=22), the animals received 
consecutive infusions (0.15, 0.45, 1.5 and 4.5 ml, i.c. during 3 min each) of capsaicin vehicle 
(see Compounds and kits section).  It is important to mention that the vehicle of capsaicin 
was devoid of any systemic and carotid haemodynamic responses (data not shown). 
Five to 10 min after the last infusion of capsaicin vehicle, blood samples were obtained 
for the measurements of blood gases and CGRP concentration and values of heart rate, 
arterial blood pressure and total carotid blood flow and conductance were collated (baseline 
values; 11 pigs each for vehicle and BIBN4096BS).  In 12 of the 22 pigs (6 each for vehicle 
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and BIBN4096BS) the first batch of radioactive microspheres was injected for determining 
the baseline distribution of carotid blood flow.   The animals then received consecutive 
infusions of capsaicin (0.3, 1, 3 and 10 µg.kg-1.min-1, i.c. for 3 min each) and heart rate, 
arterial blood pressure and total carotid blood flow were determined at the end of each 
infusion.  In addition, after the last infusion of capsaicin (10 µg.kg-1.min-1), blood gases, 
plasma CGRP concentration and carotid blood flow distribution were measured as described 
above (control values).  Subsequently, a recovery period of 20 min was allowed until all 
haemodynamic parameters had returned to baseline levels.  At this point, the animals were 
divided into two groups, which were treated with i.v. infusions (rate: 0.5 ml.min-1 for 10 min) 
of either vehicle (three times 5 ml of acidified distilled water) or BIBN4096BS (100, 300 and 
1000 µg.kg-1).  Ten min after each infusion, capsaicin was given and haemodynamic and 
biochemical variables were measured again, as described above. 
3.2.5. Data presentation and statistical analysis 
All data are presented as mean±s.e.mean, unless stated otherwise.  The statistical analysis 
was performed using the SPSS package for windows (version 10.0; SPSS Inc., Chicago, IL, 
USA).  The significance of changes within one group (vehicle or BIBN4096BS) was 
analysed with repeated-measures ANOVA, followed by Greenhouse-Geisser correction for 
serial autocorrelation (35) and Bonferroni correction for multiple comparisons (36).  The 
significance of the between-group changes (vehicle versus BIBN4096BS treatments) was 
first analysed with repeated-measures ANOVA, including baseline measurements as a 
covariate (37) and the Greenhouse-Geisser correction.   If the two groups differed 
significantly, pairwise comparisons of corresponding values in the vehicle- and 
BIBN4096BS-treated groups were performed using univariate analysis (38), followed by 
Bonferroni correction.  Statistical significance was accepted at P<0.05 (two-tailed). 
3.2.6. Ethical approval 
The Ethics Committee of the Erasmus MC, Rotterdam, dealing with the use of animals in 
scientific experiments, approved the protocols for this investigation. 
3.2.7. Compounds and kits 
The following compounds were used: aprotinin (5850 KIU mg-1; Roth, Karlsruhe, Germany), 
azaperone (Stresnil®; Janssen Pharmaceuticals, Beerse, Belgium), BIBN4096BS (gift from 
Boehringer Ingelheim Pharma KG, Biberach, Germany), capsaicin, tween 80, ethanol and 
phenylephrine hydrochloride (all from Sigma-Aldrich Chemie b.v., Zwijndrecht, 
The Netherlands), ethylene dinitro-tetraacetic acid (Merck, Darmstadt, Germany), heparin 
sodium (to prevent blood clotting in catheters; Leo Pharmaceutical Products, Weesp, 
The Netherlands), midazolam hydrochloride (Dormicum®; Hoffmann La Roche b.v., 
Mijdrecht, The Netherlands), phenylephrine hydrochloride (Sigma-Aldrich Chemie b.v., 
Zwijndrecht, The Netherlands) and sodium pentobarbital (Sanofi Sante b.v., Maasluis, 
The Netherlands).  The radioimmunoassay kit for CGRP was purchased from Peninsula 
Laboratories, Inc. (Belmont, CA, U.S.A.). 
Capsaicin was initially dissolved in tween 80, ethanol and physiological saline in the 
ratio of 0.5:1:8.5 ml, respectively.  Phenylephrine was dissolved in distilled water, while 
BIBN4096BS was initially dissolved in 0.5 ml of 1N HCl, then diluted with 4 ml of distilled 
water and adjusted to pH 6.5 by 1N NaOH. 
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3.3. Results 
3.3.1. Baseline values 
Baseline values in the 22 pigs used were: heart rate, 126±3 beats.min-1; mean arterial blood 
pressure, 105±3 mmHg; total carotid blood flow, 40±5 ml.min-1; total carotid vascular 
conductance, 39±5 10-2 ml.min-1.mmHg-1 and A-V SO2 difference, 38±2%.  No significant 
differences in baseline values were found between the two groups of animals (n=11 each) that 
later received vehicle or BIBN4096BS. 
3.3.2. Effect of different doses of capsaicin on heart rate, blood pressure and carotid 
blood flow 
Figure 3.1 depicts heart rate, mean arterial blood pressure and total carotid blood flow and 
conductance changes produced by the infusions of capsaicin (0.3, 1, 3 and 10 µg.kg-1.min-1, 
i.c.) before (control response) and after treatments with BIBN4096BS (100, 300 and 
1000 µg.kg-1.min-1, i.v.) or the corresponding volumes of vehicle.  In both groups of animals, 
capsaicin elicited dose-dependent increases in mean arterial blood pressure as well as total 
carotid blood flow and conductance, without significantly affecting heart rate.  These effects 
of capsaicin remained essentially unchanged after the administration of vehicle (0.5 ml), 
except that a slight attenuation was noticed in the increases in carotid blood flow and 
conductance after the third dose of vehicle.  In contrast, BIBN4096BS produced a 
dose-dependent attenuation of capsaicin-induced increases in total carotid blood flow and 
conductance, but not in blood pressure. 
Figure 3.1.  Heart rate (HR), mean arterial 
blood pressure (MAP) and total carotid blood 
flow (TCBF) and vascular conducta-nce 
(TCC) values at baseline (B) and following 
infusions of capsaicin (0.3, 1, 3, 10 
µg.kg-1.min-1, i.c.) in anaesthetised pigs 
before (Control) and after i.v. administra-
tions of vehicle (V, 5 ml three times; n=11) 
or BIBN4096BS (100, 300 and 1000 µg.kg-1, 
n=11).  All values are expressed as 
mean±s.e.mean. While the heart rate was not 
affected, capsaicin increased the mean 
arterial blood pressure as well as total carotid 
blood flow and conductance  (significance 
not shown for the sake of clarity).  
BIBN4096BS dose-dependently antagonised 
capsaicin-induced carotid haemodynamic 
changes, but not the increase in arterial blood 
pressure.  #, P<0.05 vs. response after the 
corresponding volume of vehicle. 
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3.3.3. Carotid haemodynamic changes following capsaicin infusion 
The carotid haemodynamic effects observed after the highest infusion (10 µg.kg-1.min-1) of 
capsaicin were examined in more detail in animals receiving vehicle or BIBN4096BS. 
3.3.3.1. Effect on carotid blood flow and pulsations 
As shown in Figure 3.2, i.c. infusions of capsaicin (10 µg.kg-1.min-1) clearly increased carotid 
blood flow and conductance (both depicted as maximum absolute changes) as well as 
pulsations.  In animals treated with the vehicle, there was some decrease in the responses to 
capsaicin, but these responses were significantly more attenuated in animals treated with 
BIBN4096BS, particularly the two highest doses. 
3.3.3.2. Fractionation of carotid blood flow and vascular conductance 
In both vehicle and BIBN4096BS groups, capsaicin (10 µg.kg-1.min-1, i.c.) significantly 
increased total carotid blood flow and conductance as well as those distributed to 
arteriovenous anastomoses and capillaries.  The increases from baseline values in blood flows 
and vascular conductances were, respectively: total carotid, 494±59% and 362±40%; 
arteriovenous anastomotic fraction, 726±282% and 505±188% and capillary fraction, 
526±48% and 389±32% (n=13 in each case). 
The effects of BIBN4096 as well as of its vehicle on the carotid haemodynamic 
responses to capsaicin are illustrated in Figure 3.3.  Compared to the corresponding volumes 
of vehicle, the increases in total, arteriovenous anastomotic as well as capillary blood flows 
and vascular conductances were clearly antagonised after the two highest infusions (300 and 
1000 µg.kg-1.min-1) of BIBN4096BS. 
Figure 3.2.  Maximum changes in 
carotid blood flow, vascular 
conductance and pulsations 
measured at baseline and following 
infusions of capsaicin (10 
µg.kg-1.min-1, i.c.) given in 
anaesthetised pigs before (Control) 
and after i.v. administrations of 
vehicle (V, 5 ml three times; n=11) 
or BIBN4096BS (100, 300 and 1000 
µg.kg-1, n=11).  All values are 
expressed as mean±s.e.mean.  a.u., 
Arbitrary units.  *, P < 0.05 vs. 
baseline values;   #, P<0.05 vs. 
response after the corresponding 
volume of vehicle. 
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Figure 3.4 shows that capsaicin (10 µg.kg-1.min-1, i.c.) increased vascular conductances 
to the different cranial tissues, including the skin, ear, skeletal muscles, fat, bone, eye, tongue 
and dura mater, but not in the brain or salivary glands.  As has been described with 
5-hydroxytryptamine (33), the increase in skin blood flow was most likely responsible for the 
redness of skin on the side of capsaicin infusion (not shown in the figure). These effects of 
capsaicin were significantly and dose-dependently antagonised by BIBN4096BS (100, 300 
and 1000 µg.kg-1.min-1, i.v.), but not by the corresponding volumes of vehicle. 
Figure 3.3.  Total carotid, arteriovenous 
anastomotic (AVA) and capillary blood 
flows (left panel) and vascular 
conductances (right panel) measured at 
baseline and following infusions of 
capsaicin (10 µg.kg-1.min-1, i.c.) given in 
anaesthetised pigs before (Control) and 
after i.v. administrations of vehicle (V, 5 
ml three times; n=7) or BIBN4096BS (100, 
300 and 1000 µg.kg-1, n=6).  All values are 
expressed as mean±s.e.mean.  *, P < 0.05 
vs. baseline values;   #, P<0.05 vs. 
response after the corresponding volume of 
vehicle. 
Figure 3.4.  Distribution of carotid 
vascular conductances to head tissues 
measured at baseline (Bas) and 
following infusions of capsaicin 
(10 µg kg-1.min-1, i.c.) given in 
anaesthetised pigs before (Con) and 
after i.v. administrations of vehicle (V, 5 
ml three times; n=7) or BIBN4096BS 
(100, 300 and 1000 µg.kg-1, n=6).  All 
values are expressed as mean±s.e.mean.  
*, P < 0.05 vs. baseline values;   #, 
P<0.05 vs. response after the 
corresponding volume of vehicle. 
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3.3.4. A-V SO2 difference 
Consistent with the increase in arteriovenous anastomotic blood flow, capsaicin 
(10 µg.kg-1.min-1, i.c.) significantly decreased A-V SO2 difference from baseline values of 
38±2% to 4.5±0.4% (n=22).  This response remained unaffected in animals treated with the 
vehicle, but was dose-dependently antagonised by BIBN4096BS (Figure 3.5). 
 
3.3.5. Jugular venous plasma concentrations of CGRP 
In the 12 pigs used for this purpose, the baseline value of CGRP concentration in jugular 
venous plasma was 27±2 pg ml-1 and following capsaicin infusion (10 µg.kg-1.min-1, i.c.) it 
increased by 119±17% to 58±5 pg ml-1. 
Figure 3.6 shows the effects of capsaicin (10 µg.kg-1.min-1, i.c.) on jugular venous 
plasma concentration of CGRP in pigs receiving either three i.v. infusions of vehicle (5 ml 
each) or BIBN4096BS (100, 300 and 1000 µg.kg-1).  Capsaicin increased plasma CGRP 
concentration in both animal groups by a similar magnitude and this increase was not 
attenuated in either vehicle- or BIBN4096BS-treated group of animals.  Interestingly, 
following the two highest doses of BIBN4096BS (300 and 1000 µg.kg-1, i.v.) there was even 
a potentiation of capsaicin-induced increases in plasma CGRP concentrations (control 
response: 138±29%; response after BIBN4096BS: 211±30% and 211±38%, respectively; 
n=6). 
Figure 3.6.  Jugular venous plasma CGRP 
concentrations measured at baseline and after 
infusions of capsaicin (10 µg kg-1.min-1, i.c.) 
given in anaesthetised pigs before (Control) 
and after i.v. administrations of the vehicle (V, 
5 ml three times; n=6) or BIBN4096BS (100, 
300 and 1000 µg.kg-1, i.v., n=6).  All values 
are expressed as mean±s.e.mean.  *, P < 0.05 
vs. baseline values;   #, P<0.05 vs. response 
after the corresponding volume of the vehicle.
Figure 3.5.  Difference between arterial and 
jugular venous oxygen saturations (A-V 
SO2 difference) measured at baseline and 
following infusions of capsaicin (10 µg. 
kg-1.min-1, i.c.) given in anaesthetised pigs 
before (Control) and after i.v. 
administrations of the vehicle (V, 5 ml three 
times; n=11) or BIBN4096BS (100, 300 and 
1000 µg.kg-1, n=11).  All values are 
expressed as mean±s.e.mean.  *, P < 0.05 vs. 
baseline values;   #, P<0.05 vs. response 
after the corresponding volume of the 
vehicle. 
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3.4. Discussion 
3.4.1. General 
Although there is much debate about the pathogenesis of migraine, there seems to be a 
general agreement regarding its neurovascular nature (1, 2, 39, 40).  Thus, there is a release 
of vasoactive peptides producing intense cranial vasodilatation, increased arterial pulsations 
and a sterile inflammatory reaction with pain (1, 41).  Amongst these neuropeptides, CGRP is 
considered as a biological marker in migraine pathogenesis (2, 42, 43).  Moreover, 
stimulation of trigeminal sensory neurones with electrical procedures or chemical substances, 
like capsaicin, releases endogenously-stored CGRP (26, 44) that, in turn, dilates cranial 
vessels (12), including carotid arteriovenous anastomoses (45).  In addition, CGRP may also 
facilitate sensory nerve transmission between the first and second order afferent input from 
these vessels during migraine headache (2, 10, 11).  On this basis, it is reasonable to assume 
that CGRP receptor antagonists can be a novel approach to antimigraine therapy.  In this 
respect, recent in vitro studies have shown that, BIBN4096BS, a potent and ‘silent’ CGRP 
receptor antagonist (13), inhibits CGRP-induced dilatation of isolated cranial blood vessels 
(16, 18).  BIBN4096BS can also effectively antagonise CGRP-induced carotid vasodilatation 
in anaesthetised pigs (46).  Therefore, it seems important to investigate the effects of 
BIBN4096BS on the carotid haemodynamic responses produced by endogenous CGRP 
released by capsaicin in a porcine model predictive of antimigraine activity (1, 22, 23).  Our 
results show that: (i) i.c. administration of capsaicin increased blood pressure, but dilated 
carotid arteriovenous anastomoses and arterioles, together with an increase in carotid 
pulsations and a narrowing of A-V SO2 difference as well as an elevation of jugular venous 
plasma CGRP concentration; and (ii) BIBN4096BS dose-dependently antagonised the 
changes in carotid haemodynamics and A-VSO2 difference caused by capsaicin, but it 
enhanced the capsaicin-induced increase in jugular venous plasma CGRP concentration. 
3.4.2. Systemic haemodynamic responses to capsaicin 
The widespread distribution of CGRP immunoreactivity in cardiovascular tissues suggests 
that CGRP may play a role in the regulation of systemic and regional haemodynamics (42, 
47).  In fact, several in vivo studies have evidenced a hypotensive response to CGRP due to 
its potent vasodilator action (47, 48).  In contrast, our study shows a significant increase in 
mean blood pressure following i.c. capsaicin, and this increase was not abolished by 
BIBN4096BS.  Despite the absence of clear tachycardic responses to i.c. capsaicin, the 
simplest interpretation of these findings may be that the vasopressor response to capsaicin is 
not mediated via CGRP receptors, but is rather due to an interaction with vasoconstrictor 
mechanisms.  Indeed, not only do high subcutaneous doses (50 mg.kg-1) of capsaicin increase 
plasma CGRP concentrations, but also plasma catecholamines, neurokinin A and 
neuropeptide Y concentrations (25). 
3.4.3. Carotid haemodynamics 
Stimulation of the trigeminal ganglion increases cerebral blood flow and releases endogenous 
vasoactive neuropeptides, including CGRP (49).  Vasoactive neuropeptides are also released 
from sensory afferent nerves by capsaicin, but its relaxant effect on isolated cerebral blood 
vessels is mediated by CGRP, rather than by substance P or neurokinin A (27, 50, 51).  These 
findings are in full agreement with our results in anaesthetised pigs showing dose-dependent 
vasodilator responses to capsaicin in the carotid circulation, including arteriovenous 
anastomoses and arterioles.  Admittedly, as reported earlier (24), vasodilator responses to 
capsaicin tended to wear off in vehicle-treated animals, suggestive of tachyphylaxis.  This 
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tachyphylaxis was rather limited, possibly due to a neuronal reuptake of released CGRP into 
capsaicin-sensitive perivascular nerves (52).  However, compared to the vehicle-treated 
animals, the carotid haemodynamic effects of capsaicin were clearly much more attenuated 
by the potent and selective CGRP receptor antagonist BIBN4096BS (13-15, 53).   
BIBN4096BS has also been demonstrated to effectively block the relaxation of blood vessels 
by CGRP, both in vitro (13, 16-18, 53) and in vivo (13), including the porcine carotid 
vascular bed (46).  Therefore, it is clear that carotid vasodilatation by capsaicin in the present 
investigation is mediated by the release of CGRP. 
3.4.4. A-V SO2 difference 
During the headache phase of migraine, the A-V SO2 difference is abnormally low, 
presumably due to an opening of arteriovenous shunts (54).  Thus, a reduction of carotid 
arteriovenous anastomotic blood flow, with a consequent normalisation of the A-V SO2 
difference, makes our porcine vascular model highly predictive of antimigraine activity (1, 
22, 31).  In the present study, i.c. infusions of capsaicin significantly decreased A-V SO2 
difference together with dilatation of carotid arteriovenous anastomoses.  Since both these 
effects of capsaicin were effectively blocked by BIBN4096BS, it confirms that 
capsaicin-induced responses are mediated via the release of CGRP.  Indeed, CGRP also 
decreases A-V SO2 difference and this effect is antagonised by BIBN4096BS (46). 
3.4.5. Plasma concentrations of CGRP 
The release of CGRP by capsaicin is mediated by selective activation of the Aδ- and C-fibre 
sensory neurones via vanilloid receptors (26, 55, 56).  Our results showing an increase in 
plasma concentrations of CGRP after capsaicin (see Figure 3.6) are consistent with the above 
observations.  Interestingly, not only did BIBN4096BS fail to block capsaicin-induced CGRP 
release, but also there was a modest enhancement of CGRP release.  There is evidence for 
uptake of CGRP into perivascular, capsaicin-sensitive neurones in the guinea-pig isolated 
basilar artery (52).  Therefore, it may well be that blockade of prejunctional ‘inhibitory’ 
CGRP autoreceptors by BIBN4096BS led to increased release of CGRP by capsaicin, similar 
to the modulation of sympathetic neurotransmission by presynaptic α-adrenoceptors (57). 
It may be noted that plasma CGRP concentrations measured by us at baseline (27±2 
pmol ml-1, n=12) as well as after capsaicin treatment (58±5 pmol ml-1, n=12) are in 
agreement with those previously reported in pigs (Table 3.1) (25, 58, 59). 
 
Table 3.1.  Plasma CGRP concentration range (pmol.ml-1) in pigs  
Baseline Capsaicin Sampled from Reference 
10 36 Femoral artery Alving et al. (25) 
11-16 Not measured Femoral artery and 
interventricular vein 
Kallner et al. (58) 
4-12 Not measured Carotid artery Arden et al. (59) 
14-38 27-88 External jugular vein Present investigation 
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3.4.6. Possible clinical implications 
Lastly, we would like to consider the possible clinical implications of our results with 
BIBN4096BS within the context of antimigraine therapy.  Indeed, the trigeminovascular 
system, a functional network of cranial blood vessels and their trigeminal innervation, seems 
to be activated during migraine (2), thereby provoking CGRP release and cranial blood vessel 
dilatation.  Thus, a blockade of the release and/or the effects of CGRP are likely to provide 
novel avenues for developing antimigraine drugs without associated vasoconstriction.  
BIBN4096BS may be such a compound and the present findings demonstrating that it 
effectively antagonises the carotid vasodilator responses elicited by capsaicin are indeed 
encouraging.  Obviously, the results of currently undergoing clinical trials with BIBN4096BS 
are awaited with great interest; these would be crucial in determining not only the role of 
CGRP in the pathophysiology of migraine, but also of such compounds as therapeutic agents. 
 
References 
 
1. De Vries P, Villalón CM, Saxena PR. Pharmacological aspects of experimental 
headache models in relation to acute antimigraine therapy. Eur J Pharmacol 
1999;375:61-74. 
2. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N 
Engl J Med 2002;346:257-270. 
3. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral 
circulation of humans during migraine headache. Ann Neurol 1990;28:183-187. 
4. Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Evidence for increased plasma 
levels of calcitonin gene-related peptide in migraine outside of attacks. Pain 
2000;86:133-138. 
5. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. Calcitonin gene-related 
peptide is a potent vasodilator. Nature 1985;313:54-56. 
6. Juaneda C, Dumont Y, Quirion R. The molecular pharmacology of CGRP and related 
peptide receptor subtypes. Trends Pharmacol Sci 2000;21:432-438. 
7. Van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, 
pharmacological characterization and functions of CGRP-related peptides and their 
receptors. Neurosci Biobehav Rev 1997;21:649-678. 
8. Poyner D, Marshall I. CGRP receptors: beyond the CGRP1-CGRP2 subdivision? Trends 
Pharmacol Sci 2001;22:223. 
9. Gulbenkian S, Barroso CP, Cunha e Sa M, Edvinsson L. The peptidergic innervation of 
human coronary and cerebral vessels. Ital J Anat Embryol 1995;100:317-327. 
10. Gulbenkian S, Uddman R, Edvinsson L. Neuronal messengers in the human cerebral 
circulation. Peptides 2001;22:995-1007. 
11. Smith D, Hill RG, Edvinsson L, Longmore J. An immunocytochemical investigation of 
human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor 
immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia 
2002;22:424-431. 
12. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. 
Microsc Res Tech 2001;53:167-178. 
13. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W. 
Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP 
antagonist. Br J Pharmacol 2000;129:420-423. 
14. Doods H. Development of CGRP antagonists for the treatment of migraine. Curr Opin 
Investig Drugs 2001;2:1261-1268. 
64 Chapter 3: Capsaisin-BIBN4096BS 
 
15. Wu D, Eberlein W, Rudolf K, Engel W, Hallermayer G, Doods H. Characterisation of 
calcitonin gene-related peptide receptors in rat atrium and vas deferens: evidence for a 
[Cys(Et)(2,7)]hCGRP-preferring receptor. Eur J Pharmacol 2000;400:313-319. 
16. Edvinsson L, Alm R, Shaw D, Rutledge RZ, Koblan KS, Longmore J, Kane SA. Effect 
of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and 
omental arteries and in SK-N-MC cells. Eur J Pharmacol 2002;434:49-53. 
17. Moreno MJ, Abounader R, Hebert E, Doods H, Hamel E. Efficacy of the non-peptide 
CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human 
and bovine cerebral arteries: potential implications in acute migraine treatment. 
Neuropharmacology 2002;42:568-576. 
18. Verheggen R, Bumann K, Kaumann AJ. BIBN4096BS is a potent competitive 
antagonist of the relaxant effects of alpha-CGRP on human temporal artery: 
comparison with CGRP(8-37). Br J Pharmacol 2002;136:120-126. 
19. Spierings EL, Saxena PR. Effect of isometheptene on the distribution and shunting of 
15 µM microspheres throughout the cephalic circulation of the cat. Headache 
1980;20:103-106. 
20. Villalón CM, Terrón JA. Characterization of the mechanisms involved in the effects of 
catecholamines on the canine external carotid blood flow. Can J Physiol Pharmacol 
1994;72:165. 
21. Saxena PR, De Vries P, Heiligers JP, Bax WA, Maassen VanDenBrink A, Yocca FD. 
BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of 
antimigraine activity and coronary side-effect potential. Eur J Pharmacol 
1998;351:329-339. 
22. Saxena PR. Cranial arteriovenous shunting, an in vivo animal model for migraine. In: 
Olesen J, Moskowitz MA, eds. Experimental headache models. Philadelphia, USA: 
Lippincott-Raven Publishers, 1995:189-198. vol 27). 
23. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of 
pharmacology, pharmacokinetics and efficacy. Drugs 2000;60:1259-1287. 
24. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol 
Rev 1999;51:159-212. 
25. Alving K, Matran R, Lundberg JM. Capsaicin-induced local effector responses, 
autonomic reflexes and sensory neuropeptide depletion in the pig. Naunyn-
Schmiedeberg's Arch Pharmacol 1991;343:37-45. 
26. Eltorp CT, Jansen-Olesen I, Hansen AJ. Release of calcitonin gene-related peptide 
(CGRP) from guinea pig dura mater in vitro is inhibited by sumatriptan but unaffected 
by nitric oxide. Cephalalgia 2000;20:838-844. 
27. Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released 
from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral 
arteries concomitant with activation of adenylyl cyclase. Cephalalgia 1996;16:310-316. 
28. Kapoor K, Heiligers JPC, Willems EW, Saxena PR. Effects of BIBN4096BS - a novel 
CGRP antagonist on the capsaicin-induced haemodynamic changes in anaesthetized 
pigs. Pharmacologist 2002;44 (Suppl. 1):A151. 
29. Den Boer MO, Van Woerkens LJ, Somers JA, Duncker DJ, Lachmann B, Saxena PR, 
Verdouw PD. On the preservation and regulation of vascular tone in arteriovenous 
anastomoses during anesthesia. J Appl Physiol 1993;75:782-789. 
30. Willems EW, Trion M, De Vries P, Heiligers JPC, Villalón CM, Saxena PR. 
Pharmacological evidence that α1- and α2-adrenoceptors mediate vasoconstriction of 
carotid arteriovenous anastomoses in anaesthetized pigs. Br J Pharmacol 
1999;127:1263-1271. 
 Chapter 3: Capsaisin-BIBN4096BS 65  
31. Saxena PR. Arteriovenous anastomoses and veins in migraine research. In: Blau JN, ed. 
Migraine, clinical, therapeutic, conceptual and research aspects. London, UK: 
Chapman and Hall medicin, 1987:581-596.  
32. Saxena PR, Schamhardt HC, Forsyth RP, Hoeve J. Computer programs for the 
radioactive microsphere technique. Determination of regional blood flows and other 
haemodynamic variables in different experimental circumstances. Comput Programs 
Biomed 1980;12:63-84. 
33. Saxena PR, Verdouw PD. Redistribution by 5-hydroxytryptamine of carotid arterial 
blood at the expense of arteriovenous anastomotic blood flow. J Physiol (Lond) 
1982;332:501-520. 
34. Dwenger A. Radioimmunoassay: an overview. J Clin Chem Clin Biochem 
1984;22:883-894. 
35. Ludbrook J. Repeated measurements and multiple comparisons in cardiovascular 
research. Cardiovasc Res 1994;28:303-311. 
36. Overall JE, Doyle SR. False-positive error rates in routine application of repeated 
measurements ANOVA. J Biopharm Stat 1996;6:69-81. 
37. Overall JE, Doyle SR. Implications of chance baseline differences in repeated 
measurement designs. J Biopharm Stat 1994;4:199-216. 
38. Overall JE, Atlas RS. Power of univariate and multivariate analyses of repeated 
measurements in controlled clinical trials. J Clin Psychol 1999;55:465-485. 
39. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies 
characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann 
Neurol 1993;33:48-56. 
40. Villalón CM, Centurión D, Valdivia LF, De Vries P, Saxena PR. An introduction to 
migraine: from ancient treatment to functional pharmacology and antimigraine therapy. 
Proc West Pharmacol Soc 2002;45:199-210. 
41. Moskowitz MA, Buzzi MG, Sakas DE, Linnik MD. Pain mechanisms underlying 
vascular headaches. Progress Report 1989. Rev Neurol (Paris) 1989;145:181-193. 
42. Hagner S, Stahl U, Knoblauch B, McGregor GP, Lang RE. Calcitonin receptor-like 
receptor: identification and distribution in human peripheral tissues. Cell Tissue Res 
2002;310:41-50. 
43. Van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, 
pharmacological characterization and functions of CGRP, related peptides and their 
receptors. Neurosci Biobehav Rev 1997;21:649-678. 
44. Buzzi MG, Bonamini M, Moskowitz MA. Neurogenic model of migraine. Cephalalgia 
1995;15:277-280. 
45. Van Gelderen EM, Du XY, Schoemaker RG, Saxena PR. Carotid blood flow 
distribution, haemodynamics and inotropic responses following calcitonin gene-related 
peptide in the pig. Eur J Pharmacol 1995;284:51-60. 
46. Kapoor K, Arulmani U, Heiligers JPC, Willems EW, Doods H, Villalón CM, Saxena 
PR. Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced 
carotid haemodynamic changes in the pig. Eur J Pharmacol 2003:In press. 
47. Bell D, McDermott BJ. Calcitonin gene-related peptide in the cardiovascular system: 
characterization of receptor populations and their (patho)physiological significance. 
Pharmacol Rev 1996;48:253-288. 
48. Shen YT, Pittman TJ, Buie PS, Bolduc DL, Kane SA, Koblan KS, Gould RJ, Lynch JJ, 
Jr. Functional role of alpha-calcitonin gene-related peptide in the regulation of the 
cardiovascular system. J Pharmacol Exp Ther 2001;298:551-558. 
66 Chapter 3: Capsaisin-BIBN4096BS 
 
49. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral 
circulation of humans and the cat during activation of the trigeminovascular system. 
Ann Neurol 1988;23:193-196. 
50. Jansen I, Alafaci C, Uddman R, Edvinsson L. Evidence that calcitonin gene-related 
peptide contributes to the capsaicin-induced relaxation of guinea pig cerebral arteries. 
Regul Pept 1990;31:167-178. 
51. O'Shaughnessy CT, Waldron GJ, Connor HE. Lack of effect of sumatriptan and UK-
14,304 on capsaicin-induced relaxation of guinea-pig isolated basilar artery. Br J 
Pharmacol 1993;108:191-195. 
52. Sams-Nielsen A, Orskov C, Jansen-Olesen I. Pharmacological evidence for CGRP 
uptake into perivascular capsaicin sensitive nerve terminals. Br J Pharmacol 
2001;132:1145-1153. 
53. Wu D, Doods HN, Arndt K, Schindler M. Development and potential of non-peptide 
antagonists for calcitonin-gene-related peptide (CGRP) receptors: evidence for CGRP 
receptor heterogeneity. Biochem Soc Trans 2002;30:468-473. 
54. Heyck H. Pathogenesis of migraine. Res Clin Stud Headache 1969;2:1-28. 
55. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The 
capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 
1997;389:816-824. 
56. Ebersberger A, Averbeck B, Messlinger K, Reeh PW. Release of substance P, 
calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali 
following electrical and chemical stimulation in vitro. Neuroscience 1999;89:901-907. 
57. Langer SZ. Presynaptic regulation of the release of catecholamines. Pharmacol Rev 
1980;32:337-362. 
58. Kallner G, Gonon A, Franco-Cereceda A. Calcitonin gene-related peptide in 
myocardial ischaemia and reperfusion in the pig. Cardiovasc Res 1998;38:493-499. 
59. Arden WA, Fiscus RR, Wang X, Yang L, Maley R, Nielsen M, Lanzo S, Gross DR. 
Elevations in circulating calcitonin gene-related peptide correlate with hemodynamic 
deterioration during endotoxic shock in pigs. Circ Shock 1994;42:147-153. 
 
  
 
CHAPTER 4 
 
α1-Adrenoceptor subtypes 
mediating vasoconstriction in 
the carotid circulation of 
anaesthetised pigs: possible 
avenues for antimigraine drug 
development 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on:  Willems EW, Heiligers JPC, De Vries P, Kapoor K, Tom B, Villalón 
CM, Saxena PR.  α1-adrenoceptor subtypes mediating 
vasoconstriction in the carotid circulation of anaesthetized pigs: 
possible avenues for anti-migraine drug development.  Cephalalgia 
2001;21:110-119.
 
    
Table 4.1.  Binding affinity constants (pKi
values) for cloned human α1-adrenoceptor 
subtypes. 
Compound α1a α1b α1d 
Prazosin 9.4a 10.2a 9.8a 
5-Methylurapidil 8.7a 7.6a 7.5a 
L-765,314 6.4b 8.7b 7.5b 
BMY 7378 6.6c 7.2c 9.4c 
Data from: a, Weinberg et al. (1); b, Patane et al. 
(2); c, Goetz et al. (3). 
 
4. α1-Adrenoceptor subtypes mediating 
vasoconstriction in the carotid circulation of 
anaesthetised pigs: possible avenues for 
antimigraine drug development 
 
4.1. Introduction 
Although the pathophysiology of migraine has not yet been completely unravelled, there is 
little doubt that dilatation of large cephalic arteries and, possibly, arteriovenous anastomoses 
is involved in the headache phase of migraine (4-7).  Indeed, over the years we have shown 
that two important groups of drugs that are highly effective in the acute treatment of 
migraine, i.e. the triptans and ergot alkaloids, potently constrict carotid arteriovenous 
anastomoses (7-9).  While the carotid vasoconstrictor effect of sumatriptan as well as some 
other triptans is mediated by the 5-HT1B receptor (7, 9, 10), the ergot-induced 
vasoconstriction involves, in addition to 5-HT1B receptors (11), also α-adrenoceptors (12). 
There are several reasons to believe that α-adrenoceptors may regulate vascular tone of 
carotid arteriovenous anastomoses, providing a potential avenue for the development of new 
antimigraine drugs.  It is well known that α-adrenoceptors play an important role in the 
regulation of vascular tone and blood pressure (13) and that stimulation of the receptors 
results in constriction of the isolated carotid artery (14-18).  Furthermore, administration of 
α-adrenoceptor antagonists to conscious pigs as well as pigs under thiopentone anaesthesia 
results in an increase in arteriovenous anastomotic blood flow (19, 20).  More recently, we 
have shown that both α1- and α2-adrenoceptors mediate the constriction of carotid 
arteriovenous anastomoses in anaesthetised pigs (21). 
The objective of the present study 
was to elucidate the subtype(s) of 
α1-adrenoceptors –α1A-, α1B- and 
α1D-adrenoceptor subtypes (22-25) – 
involved in the constriction of carotid 
arteriovenous anastomoses in anaesthe-
tised pigs.  For this purpose, we investi-
gated the effects of 5-methylurapidil, 
L-765,314 and BMY 7378, which are 
preferential antagonists, respectively, at 
α1A-, α1B- and α1D-adrenoceptors (see 
Table 4.1 for affinity constants) (1-3), on 
the carotid vasoconstriction induced by 
the α1-adrenoceptor agonist 
phenylephrine in a well-defined in vivo 
animal model predictive for antimigraine activity (8, 26).  Unfortunately, selective agonists at 
the α1-adrenoceptor subtypes are not available. 
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4.2. Materials and methods 
4.2.1. General 
After an overnight fast, 41 domestic pigs (Yorkshire x Landrace; female; 10-14 kg) were 
anaesthetised with azaperone (120 mg, i.m.), midazolam hydrochloride (5 mg, i.m.) and 
sodium pentobarbital (600 mg, i.v.).  After tracheal intubation, the animals were connected to 
a respirator (BEAR 2E, BeMeds AG, Baar, Switzerland) for intermittent positive pressure 
ventilation with a mixture of room air and oxygen.  Respiratory rate, tidal volume and oxygen 
supply were adjusted to keep arterial blood gas values within physiological limits 
(pH: 7.35-7.48; pCO2: 35-48 mmHg; pO2: 100-120 mmHg).  Anaesthesia was maintained 
with a continuous i.v. infusion of sodium pentobarbital (20 mg.kg-1.h-1).  It may be pointed 
out that this anaesthetic regimen, together with bilateral vagosympathectomy (see below), 
leads to an increase in heart rate and dilatation of arteriovenous anastomoses due to a loss of 
parasympathetic and sympathetic tone, respectively.  Indeed, basal arteriovenous anastomotic 
blood flow is considerably higher in sodium pentobarbital-anaesthetised pigs (70-80% of 
carotid blood flow; present results) than in conscious (<5% of carotid blood flow; 19) or 
fentanyl/thiopental anaesthetised (~19% of carotid blood flow; 20) pigs.  A high basal carotid 
arteriovenous anastomotic blood flow is particularly useful for investigating the effects of 
drugs that constrict these 'shunt' vessels. 
A catheter was placed in the inferior vena cava via the left femoral vein for the 
administration of sodium pentobarbital, vehicle (distilled water) or the antagonists.  Another 
catheter was placed in the aortic arch via the left femoral artery for the measurement of 
arterial blood pressure (Combitrans disposable pressure transducer; Braun, Melsungen, 
Germany) and arterial blood withdrawal for the measurement of blood gases (ABL-510; 
Radiometer, Copenhagen, Denmark).  Subsequently, bilateral vagosympathectomy was 
performed in order to prevent the possible influence via baroreceptor reflexes on 
phenylephrine-induced carotid vascular responses.  Two hub-less needles, each connected to 
a polyethylene tube, used for the administration of radioactive microspheres and 
phenylephrine, respectively, were inserted into the right common carotid artery against the 
direction of blood flow for uniform mixing. 
Total common carotid blood flow was measured with a flow probe (internal diameter: 
2.5 mm) connected to a sine-wave electromagnetic flow meter (Transflow 601-system, 
Skalar, Delft, The Netherlands), as describe elsewhere (8, 27).  Heart rate was measured with 
a tachograph (CRW, Erasmus University, Rotterdam, The Netherlands) triggered by 
electrocardiogram signals.  Arterial blood pressure, heart rate and total carotid blood flow 
were continuously monitored on a polygraph (CRW, Erasmus University, Rotterdam, The 
Netherlands).  During the experiment, body temperature was kept about 37 °C and the animal 
was continuously infused with physiological saline to compensate fluid losses. 
The Ethics Committee of the Erasmus University Rotterdam, dealing with the use of 
animals in scientific experiments, approved the protocols followed in this investigation. 
4.2.2. Distribution of carotid blood flow 
As described in detail previously (27-29), the distribution of carotid blood flow was 
determined with 15.5±0.1 µm (s.d.) diameter microspheres labelled with 141Ce, 113Sn, 103Ru, 
95Nb or 46Sc (NEN Dupont, Boston, USA).  For each measurement, about 200,000 
microspheres, labelled with one of the radioisotopes, were mixed and injected into the right 
common carotid artery.  At the end of the experiment, the animal was killed by an overdose 
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of sodium pentobarbital and the heart, lungs, kidneys and all ipsilateral cranial tissues were 
dissected out, weighed and put in plastic vials.  The radioactivity in these vials was counted 
for 10 min in a γ-scintillation counter (Packard, Minaxi autogamma 5000), using suitable 
windows to discriminate the different isotopes (141Ce: 120-167 KeV, 113Sn: 355-435 KeV, 
103Ru: 450-548 KeV, 95Nb: 706-829 KeV and 46Sc: 830-965 KeV).  All data were processed 
by a set of specially designed computer programs (27). The fraction of carotid blood flow 
distributed to the different tissues (CaBFtis) was calculated by the following equation: CaBFtis 
= (Itis/Itot) x CaBF, where Itis and Itot denote the tissue and total (i.e. the sum of all tissue) 
radioactivity, respectively, of each radioisotope and CaBF represents the common carotid 
artery blood flow at the time of microsphere injection.  Since little or no radioactivity was 
detected in the heart and kidneys, all microspheres trapped in lungs reached this tissue from 
the venous side after escaping via carotid arteriovenous anastomoses.  Therefore, the amount 
of radioactivity in the lungs was used as an index of the arteriovenous anastomotic fraction of 
the total carotid blood flow (8).  Vascular conductance (ml.min-1.mmHg-1) was calculated by 
dividing blood flow (ml.min-1) by mean arterial blood pressure (mmHg). 
4.2.3. Experimental protocol 
After a stabilisation period of at least 60 min, baseline values of heart rate, mean arterial 
blood pressure, total carotid blood flow and its distribution into arteriovenous anastomotic 
and capillary fractions, as well as arterial blood gases were measured.  Thereafter, the 
animals were divided into seven groups, receiving i.v. infusions (0.5 ml.min-1 for 10 min) of 
either vehicle (distilled water; n=8), 5-methylurapidil (300 or 1000 µg.kg-1; n=6 each dose), 
L-765,314 (300 or 1000 µg.kg-1; n=6 and 3, respectively) or BMY 7378 (300 or 
1000 µg.kg-1; n=6 each dose).  After a waiting period of 15 min, all variables were 
reassessed.  Subsequently, the animals received cumulative doses of phenylephrine (1, 3 and 
10 µg.kg-1.min-1) infused into the right common carotid artery (0.1 ml.min-1 for 10 min).  All 
variables were collated again 10 min after the start of each agonist infusion. 
At least 90 min after the last microsphere injection, the animals received i.v. bolus 
injections of phenylephrine (3 and 10 µg.kg-1) and peak changes in mean arterial blood 
pressure were noted. 
4.2.4. Data presentation and statistical analysis 
All data have been expressed as mean±s.e.m.  In order to correct for potential baseline 
differences caused by the antagonists or vehicle, the percent changes induced by 
phenylephrine from the values after administration of the different antagonists or vehicle 
were calculated in each group.  The significance of the percent changes induced by the 
different doses of phenylephrine within one group was evaluated with Duncan's new multiple 
range test, once an analysis of variance (randomised block design) had revealed that the 
samples represented different populations (30).  Percent changes caused by phenylephrine in 
the different treatment groups were compared to the percent changes caused by the 
corresponding phenylephrine dose in the vehicle-treated group using Student's unpaired t-test.  
Statistical significance was accepted at P<0.05 (two-tailed). 
4.2.5. Drugs 
Apart from the anaesthetics azaperone (Stresnil®; Janssen Pharmaceuticals, Beerse, Belgium), 
midazolam hydrochloride (Dormicum®; Hoffmann La Roche b.v. Mijdrecht, 
The Netherlands) and sodium pentobarbital (Apharmo, Arnhem, The Netherlands), the 
compounds used in this study were: L-phenylephrine hydrochloride, 5-methylurapidil, 
BMY 7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro [4,5]decane-
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7,9-dione dihydrochloride) dihydrochloride (all from Sigma-Aldrich Chemie b.v., 
Zwijndrecht, The Netherlands) and L-765,314 (4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)-
[[(1,1-dimethylethyl)amino] carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline hydrochloride; 
Merck & Co., Inc., West Point, PA 19486, USA).  Finally, heparin sodium (Leo 
Pharmaceutical Products, Weesp, The Netherlands) was used to prevent clotting of blood in 
the catheters. 
All drugs were dissolved in distilled water.  A short period of heating was needed to 
dissolve 5-methylurapidil (acidified to pH=6.8-7.0 with 0.1 M HCl) and L-765,314.  The 
doses of the drugs refer to their respective salts. 
4.3. Results 
4.3.1. Baseline values and effect of antagonists per se 
Baseline values of haemodynamic variables in anaesthetised pigs (n=41) were: heart rate 
(100±2 beats.min-1), mean arterial blood pressure (93±2 mmHg), total carotid blood flow 
(123±6 ml.min-1) and conductance (132±6 10-2 ml.min-1.mmHg-1), arteriovenous anastomotic 
blood flow (95±6 ml.min-1) and conductance (102±6 10-2 ml.min-1.mmHg-1) and capillary 
blood flow (28±2 ml.min-1) and conductance (30±2 10-2 ml.min-1.mmHg-1).  There were no 
major differences between the baseline values in the different groups of animals (data not 
shown). 
No haemodynamic changes were observed with the vehicle or BMY 7378 (data not 
shown).  5-Methylurapidil (1000 µg.kg-1) slightly decreased mean arterial blood pressure 
(-8±4%) and increased heart rate (9±1%) as well as capillary blood flow (35±4%) and 
conductance (49±9%).  L-765,314 (1000 µg.kg-1) decreased mean arterial blood pressure 
(-9±4%) and increased capillary conductance (27±11%). 
4.3.2. Systemic haemodynamic responses to intracarotid infusions of phenylephrine 
As shown in Table 4.2, after treatment with the vehicle intracarotid infusions of 
phenylephrine (1, 3 and 10 µg.kg-1.min-1) caused a dose-dependent increase in heart rate by 
up to 28±5%, without affecting mean arterial blood pressure.  This phenylephrine-induced 
tachycardia was slightly less (maximal increase: 11±3%) after 300 µg.kg-1 of 
5-methylurapidil (probably due to higher initial value), but was not different after the highest 
dose of 5-methylurapidil (1000 µg.kg-1).  In animals treated with either 1000 µg.kg-1 of 
L-765,314 or BMY7378, a small decrease in mean arterial blood pressure (9±1 or 8±4%, 
respectively) was observed with phenylephrine; however, when compared to the 
corresponding blood pressure change in vehicle-treated animals, statistical significance was 
not reached. 
4.3.3. Carotid haemodynamic responses to intracarotid infusions of phenylephrine 
Absolute values of total carotid, arteriovenous anastomotic and capillary vascular 
conductances in the different groups of animals before and after intracarotid infusions of 
phenylephrine are shown in Figure 4.1.  In animals treated with vehicle, phenylephrine 
produced a dose-dependent decrease in total carotid conductance by up to 75±4%.  Since 
phenylephrine did not change the vascular conductance in the capillary fraction, the decrease 
in total carotid conductance was exclusively caused by a decrease in the arteriovenous 
anastomotic fraction (maximal response: 92±3%). 
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As shown in Figures 4.1 and 4.2, the constrictor effect of phenylephrine on carotid 
arteriovenous anastomoses was not affected by 300 µg.kg-1 of either 5-methylurapidil or 
BMY 7378, but was significantly attenuated by 300 µg.kg-1 of L-765,314 and1000 µg.kg-1 of 
5-methylurapidil and BMY 7378.  Furthermore, after the highest dose of L-765,314, the 
responses to phenylephrine were clearly abolished and the values did not significantly differ 
from  those  before  phenylephrine  infusion.   Since mean arterial blood pressure was little 
affected by the intracarotid infusions of phenylephrine, the responses of vascular 
conductances were qualitatively and quantitatively similar to those of blood flow (data not 
shown).  
Table 4.2.  Changes in heart rate and mean arterial blood pressure induced by 10-min 
intracarotid infusions of phenylephrine in anaesthetised pigs treated i.v. with either vehicle, 
5-methylurapidil, L-765,314 or BMY 7378. 
 
Phenylephrine (µg.kg-1.min-1) Variables and 
Treatment 
groups 
Dose 
(µg.kg-1) 
Values before 
phenylephrine*
1 3 10 
Heart rate (beats.min-1) 
Vehicle 5 ml 95±2 98±2 105±3a 121±5a 
5-Methylurapidil  300 112±5 111±6b 112±5b 123±4ab 
 1000 101±3 103±4 106±4 117±3a 
L-765,314  300 98±5 101±5 107±5a 129±7a 
 1000 93±2 93±3 97±4 112±6a 
BMY 7378  300 99±4 101±3 104±3 119±5a 
 1000 109±6 112±6 117±6a 127±6a 
Mean arterial blood pressure (mmHg) 
Vehicle 5 ml 97±2 97±3 96±3 99±5 
5-Methylurapidil 300 80±5 82±5 79±6 83±6 
 1000 95±5 89±5b 87±5 89±6 
L-765,314  300 84±6 83±7 84±8 87±8 
 1000 84±3 80±4a 78±2a 79±4a 
BMY 7378  300 85±3 85±4 84±3 90±3 
 1000 91±5 88±5 86±4 84±4a 
*, Values after treatment with respective antagonist or vehicle. 
a, P<0.05 vs. baseline. 
b, P<0.05 vs. response (% response from respective baseline) to the corresponding 
phenylephrine dose in animals treated with vehicle. 
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Figure 4.2. Percent changes in arteriovenous anastomotic (AVA) conductance induced by 10-min 
intracarotid infusions of phenylephrine in anaesthetised pigs treated i.v. with either vehicle (Veh; 
n=8), 5-methylurapidil (5-MU; 300 or 1000 µg.kg-1; n=6 each dose; left graph), L-765,314  (L; 300 
or 1000 µg.kg-1; n=6 and 3, respectively; middle graph) or BMY 7378 (BMY; 300 or 1000 µg.kg-1; 
n=6 each dose; right graph).  a, P<0.05 vs. baseline (B; values after treatments);  b, P<0.05 vs. 
response (% response from respective baseline) of the corresponding phenylephrine dose in 
vehicle-treated animals.  Note that the control curves are identical in each graph. 
Figure 4.1. Effects of 10-min 
intracarotid infusions of phenylephrine 
on total carotid, arteriovenous 
anastomotic (AVA) and capillary 
vascular conductances in anaesthetised 
pigs treated i.v. with either vehicle 
(Veh; n=8), 5-methylurapidil (5-MU; 
300 or 1000 µg.kg-1; n=6 each dose), 
L-765,314 (L; 300 or 1000 µg.kg-1; n=6 
and 3, respectively) or BMY 7378 
(BMY; 300 or 1000 µg.kg-1; n=6 each 
dose).  a, P<0.05 vs. baseline (B; values 
after treatment); b, P<0.05 vs. response 
(% response from respective baseline) 
of the corresponding phenylephrine 
dose in vehicle-treated animals. 
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4.3.4. Changes in mean arterial blood pressure by i.v. bolus administration of 
phenylephrine 
In vehicle-treated animals, bolus injections of phenylephrine (3 and 10 µg.kg-1, i.v) produced 
a dose-dependent increase in mean arterial blood pressure, yielding peak responses of 28±3 
and 51±3%, respectively (Figure 4.3). These phenylephrine-induced vasopressor responses 
were significantly attenuated by 1000 µg.kg-1 of 5-methylurapidil (peak responses: 17±3 and 
31±4%, respectively), but were not affected by L-765,314 (300 or 1000 µg.kg-1), BMY 7378 
(300 or 1000 µg.kg-1) or 300 µg.kg-1 of 5-methylurapidil. 
4.4. Discussion 
4.4.1. General 
We have recently shown that both α1- and α2-adrenoceptors mediate constriction of 
arteriovenous anastomoses within the carotid vascular bed in anaesthetised pigs (21).  This 
conclusion was based on the findings that (i) intracarotid administration of phenylephrine 
(α1-adrenoceptor agonist) and BHT933 (α2-adrenoceptor agonist) decreased the total carotid 
blood flow exclusively confined to the arteriovenous anastomotic fraction, without affecting 
mean arterial blood pressure; and (ii) these effects of phenylephrine and BHT933 were 
selectively antagonised by the α1- and α2-adrenoceptor antagonists, prazosin and 
rauwolscine, respectively (21).  This is also in agreement with recent findings demonstrated 
in the external carotid vascular bed of anaesthetised dogs (31). 
Figure 4.3. Peak changes in mean arterial blood pressure (MAP) induced by bolus injection of 
phenylephrine (3 or 10 µg.kg-1, i.v.) in animals treated i.v. with either vehicle (Veh; n=8), 
5-methylurapidil (5-MU; 300 or 1000 µg.kg-1; n=6 each dose), L-765,314 (L; 300 or 
1000 µg.kg-1; n=6 and 3, respectively) or BMY 7378 (BMY; 300 or 1000 µg.kg-1; n=6 each 
dose).  a, P<0.05 vs. percent response of the corresponding phenylephrine dose in vehicle-treated 
animals. 
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Based on radioligand binding, molecular biology and isolated tissue experiments, it is 
known that α1-adrenoceptors are a heterogeneous group of receptors, currently subdivided 
into α1A, α1B and α1D subtypes (24, 32).  As reviewed by Vargas and Gorman (13), the 
α1A-adrenoceptor subtype, which is widely distributed throughout the body and is the major 
subtype regulating systemic vascular resistance and blood pressure; α1D-adrenoceptors seem 
to play only a minor role in blood pressure regulation (33).  Whereas there is limited 
information concerning the vascular effects mediated by α1B-adrenoceptors, it has been 
shown that constriction of the isolated carotid artery of the dog and rabbit mainly resembles 
the cloned α1B-adrenoceptor (13).  However, no information is available on the subtype 
mediating vasoconstrictor effects within the carotid arterial bed in vivo.  Therefore, the 
objective of the present study was to identify the α1-adrenoceptor subtype(s) that mediate 
constriction in the carotid vasculature in anaesthetised pigs, with particular emphasis on the 
arteriovenous anastomotic fraction, which may be of relevance to migraine therapy (4, 8, 10). 
In recent years, several selective antagonists at α1-adrenoceptor subtypes have been 
developed (Table 4.1).  In the present study, we made use of 5-methylurapidil and 
BMY 7378, which have frequently been used to characterise α1A- and α1D-adrenoceptors, 
respectively (Table 4.1; 3, 25, 32, 34, 35-37).  To block α1B-adrenoceptors, we employed 
L-765,314, which shows a moderate to high selectivity for cloned α1b-adrenoceptors over 
cloned α1a- or α1d-adrenoceptors (2).  Many studies have used the clonidine derivative, 
chloroethylclonidine, for this purpose (32, 38).  However, it is now evident that 
chloroethylclonidine alkylates several other receptors as well (32, 39, 40). 
4.4.2. Systemic and carotid haemodynamic effects of different antagonists 
Whereas the vehicle was devoid of any systemic and carotid haemodynamic effects, 
administration of the α1A-adrenoceptor antagonist 5-methylurapidil produced a small 
hypotension and tachycardia (Table 4.2).  Similar hypotensive effect was observed earlier 
with 5-methylurapidil (41) and may be related to either blockade of vascular smooth muscle 
α1A-adrenoceptors, which play an important role in the maintenance of vascular tone (13) or 
to its agonist properties at central 5-HT1A receptors (42).  Admittedly, we do not have a 
clear-cut explanation for the slight hypotension and increase in capillary conductance 
produced by L-765,314, since it has been shown by Piascik et al. (43) that α1B-adrenoceptors 
play only a minor role in the contraction of peripheral blood vessels in vitro. 
4.4.3. Changes in heart rate and mean arterial blood pressure by phenylephrine 
Intracarotid infusions of phenylephrine produced only minor systemic haemodynamic 
responses in vehicle-treated animals.  The tachycardia (Table 4.2), which was also observed 
with i.v. phenylephrine (data not shown), most likely involves an interaction with 
β-adrenoceptors (21).  Furthermore, i.v. administration of phenylephrine (3 and 10 µg.kg-1) 
induced a dose-dependent increase in blood pressure (Figure 4.3), which was antagonised by 
100 µg.kg-1 of prazosin, but not by 300 µg.kg-1 of rauwolscine (Willems et al., unpublished 
observations).  In view of the antagonism of this response by 5-methylurapidil, but not by 
L-765,314 (α1B-adrenoceptor antagonist) or BMY 7378 (α1D-adrenoceptor antagonist) 
(Figure 4.3), the pressor response to phenylephrine is likely to be mediated by 
α1A-adrenoceptors.  In keeping with the approximately 10-fold higher affinity at the cloned 
α1a-adrenoceptor displayed by prazosin compared to 5-methylurapidil (Table 4.1), a 10-fold 
higher dose of 5-methylurapidil (1000 µg.kg-1) was needed to produce antagonism of the 
phenylephrine-induced vasopressor response.  Thus, as previously discussed (13), these 
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results support the role of α1A-adrenoceptors in the increase in peripheral vascular resistance 
and concomitant hypertensive effect upon activation. 
4.4.4. Carotid haemodynamic responses to intracarotid infusions of phenylephrine 
As previously reported (21), phenylephrine caused a pronounced and dose-dependent 
decrease in total carotid conductance, which was exclusively caused by constriction of 
carotid arteriovenous anastomoses; nutrient vascular conductance was not modified 
(Figure 4.1). These carotid vasoconstrictor responses were not affected by treatment with 
300 µg.kg-1 of the α1D-adrenoceptor antagonist BMY 7378.  This dose of BMY 7378 should 
be sufficient to block α1D-adrenoceptors in view of comparable affinities of prazosin and 
BMY 7378 at the cloned human α1d-adrenoceptor (Table 4.1) and the fact that 100  µg.kg-1 of 
prazosin abolished this response (21).  On this basis, the involvement of α1D-adrenoceptors in 
the cranial vasoconstriction induced by phenylephrine in anaesthetised pigs seems highly 
unlikely.  Nevertheless, as shown in Figures 4.1 and 4.2, the higher dose of BMY 7378 
(1000 µg.kg-1) produced a slight, but significant, attenuation in the phenylephrine-induced 
total carotid and arteriovenous anastomotic vasoconstriction.  Since BMY7378 displays a 
moderate affinity at α1A- and α1B-adrenoceptors (pKi: 6.6 and 7.2, respectively; Table 4.1), a 
non-selective blockade of these receptors (which can mediate carotid vasoconstriction; see 
below) is a likely explanation.  Indeed, in 2 experiments a combination of 5-methylurapidil 
(1000 µg.kg-1) and BMY 7378 (1000 µg.kg-1) did not cause any more attenuation of the 
phenylephrine-induced arteriovenous constriction than 5-methylurapidil (1000 µg.kg-1) alone 
(see below). 
The α1B-adrenoceptor antagonist L-765,314 abolished the constriction of carotid 
arteriovenous anastomoses by phenylephrine, a finding that supports the role of 
α1B-adrenoceptors in this effect.  Interestingly, the α1A-adrenoceptor antagonist, 
5-methylurapidil was also able to antagonise the cranial vasoconstrictor effects of 
phenylephrine, but in contrast to L-765,314, the highest dose of phenylephrine still elicited a 
50% decrease in arteriovenous anastomotic conductance (Figures 4.2 and 4.3).  Thus, at 
similar doses, L-765,314 acted as a more potent antagonist when compared to 
5-methylurapidil.  The above findings lead us to conclude that both α1A- and 
α1B-adrenoceptors mediate the phenylephrine-induced constriction of carotid arteriovenous 
anastomoses, whereas the α1D-adrenoceptor plays a minor role, if any. 
Admittedly, a critique of the above conclusion may be that, unlike in vitro studies, the 
exact concentration of α1-adrenoceptor antagonists at the receptor site can be influenced by 
pharmacokinetic differences in such an in vivo investigation.  However, current techniques do 
not allow us to study carotid arteriovenous anastomoses in vitro and, to some extent, we have 
tried to ensure effective antagonist concentration at the receptor site by using as high dose of 
antagonists as possible.  Moreover, we would like to emphasis the fact that selective agonists 
at the different α1-adrenoceptor subtypes are currently unavailable. Since porcine 
α1-adrenoceptor subtypes have not yet been cloned, the selectivity of the subtype-selective 
antagonists (see Table 4.1) is based on their affinity for human cloned receptors. 
4.4.5. Possible clinical implications 
Lastly, we would like to consider possible clinical implications of the present results showing 
that α1A- and α1B-adrenoceptors mediate the constriction of carotid arteriovenous 
anastomoses in anaesthetised pigs.  To date all acutely acting antimigraine agents, such as the 
triptans and ergot alkaloids, potently constrict carotid arteriovenous anastomoses (44, 45).  
Moreover, dilatation of these 'shunt' vessels may be involved in the pathophysiology of the 
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headache phase of migraine (4, 8, 10).  Since a vasoconstrictor effect in this experimental 
model seems to be highly predictive for antimigraine efficacy, a α1A- (such as A61603, see 
ref. 46) or α1B-adrenoceptor agonist (which is yet to be developed) should be able to abort 
migraine headaches.  Of the two α1-adrenoceptor subtypes, the α1B-adrenoceptor is an 
interesting target for future antimigraine drugs, especially when considering that this 
receptor, unlike the α1A-adrenoceptor, does not seem to be much involved in the constriction 
of the peripheral blood vessels (13, 43).  Indeed, our results suggest that the hypertensive 
effect produced by intravenous administration of phenylephrine is predominantly mediated 
via the α1A-, but not α1B-adrenoceptor (Figure 4.3).  An α1B-adrenoceptor agonist may have a 
major advantage over the currently available acute antimigraine drugs, which all constrict 
human isolated coronary artery (47), where, importantly, the α1B-adrenoceptor is not present 
(48). 
In conclusion, the present study shows that both α1A- and α1B-adrenoceptors mediate 
constriction of porcine carotid arteriovenous anastomoses produced by phenylephrine.  Since 
the α1B-adrenoceptor subtype is not much involved in constriction of the systemic 
vasculature, a cranioselective vasoconstriction may be achieved using selective 
α1B-adrenoceptor agonists, which may prove effective in migraine. 
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 5. A61603-induced vasoconstriction in porcine 
carotid vasculature: involvement of a 
non-adrenergic mechanism 
 
5.1. Introduction 
There seems to be little doubt that the headache phase of migraine is associated with 
dilatation of cranial blood vessels.  Indeed, sumatriptan as well as all ‘second-generation’ 
triptans potently constrict human isolated cranial arteries as well as carotid arteriovenous 
anastomoses in anaesthetised animals, mainly via the 5-HT1B receptor (1, 2).  In an attempt to 
explore new avenues for the development of antimigraine agents, we recently reported that 
phenylephrine and BHT933 (6-ethyl- 5,6,7,8-tetrahydro-4H-oxazolo [4,5-d] azepin-2-amine 
dihydrochloride) constrict carotid arteriovenous anastomoses in anaesthetised pigs via α1- 
and α2-adrenoceptors, respectively (3).  Subsequent studies suggest that the 
phenylephrine-induced response is mediated by the α1A- and α1B- adrenoceptor subtypes, but 
not by the α1D subtype (4). 
To confirm the involvement of α1A-adrenoceptors, in the present study we studied the 
effects of a potent and selective α1A-adrenoceptor agonist, A61603 (N-[5-(4,5-dihydro-
1H-imidazol-2yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl] methane sulphonamide) (see 
Table 5.1, 5, 6), on regional carotid blood flow in anaesthetised pigs.  The response to 
A61603 was characterised by using selective α-adrenoceptor antagonists, 5-methylurapidil 
(α1A), prazosin (α1) and a combination of prazosin (α1) and rauwolscine (α2).  Similarly, the 
effects of GR127935 (N-[4-methoxy-3-(4-methyl-1-piperazinyl) phenyl]-2'-methyl-4' 
(5-methyl-1, 2,4-oxadiazol-3-yl) [1,1,-biphenyl]-4-carboxamide hydrochloride monohydrate; 
5-HT1B/1D), ketanserin (5-HT2, α1) and methiothepin (5-HT1/2), in doses sufficient to block 
their respective receptors (3, 7, 8), were also investigated.  Surprisingly, the results suggest 
that A61603 constricts porcine arteriovenous anastomoses by a non-adrenergic mechanism. 
Table 5.1.  Chemical structure and binding affinity (pKi), potency (pEC50) and intrinsic 
activity (i.a.), of A61603 at several cloned human receptor subtypes (22). 
1.1.1.1. Chemical 
structure 
 α1a α1b α1d α2a α2b α2c 5-HT1B 5-HT1D
pKi 7.1 4.8 4.9 7.3 6.5 6.2 5.2 5.6 
pEC50 8.9 4.4 4.6 7.5 7.1 7.7 ND ND 
Br
HN
S
N NH
C H3
O O
HO
 i.a. 1.2 0.1 0.1 0.8 0.8 0.9 ND ND 
At other receptor subtypes (histamine H1/2, dopamine D1/2/3, 5-HT1/2/7 or β), pKi < 5.5. 
pEC50 was determined in phosphoinositol breakdown assay. ND, not determined. 
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5.2. Materials and Methods 
5.2.1. General 
After an overnight fast, 33 domestic pigs (Yorkshire x Landrace; female; 10-14 kg) were 
anaesthetised with azaperone (120 mg, i.m.), midazolam hydrochloride (5 mg, i.m.) and 
sodium pentobarbital (600 mg, i.v.).  After tracheal intubation, the animals were connected to 
a respirator (BEAR 2E, BeMeds AG, Baar, Switzerland) for intermittent positive pressure 
ventilation with a mixture of room air and oxygen.  Respiratory rate, tidal volume and oxygen 
supply were adjusted to keep arterial blood gas values within physiological limits 
(pH: 7.35-7.48; pCO2: 35-48 mmHg; pO2: 100-120 mmHg).  Anaesthesia was maintained 
with a continuous i.v. infusion of sodium pentobarbital (20 mg.kg-1.h-1).  It may be pointed 
out that this anaesthetic regimen, together with bilateral vagosympathectomy (see below), 
leads to an increase in heart rate and dilatation of carotid arteriovenous anastomoses due to a 
loss of parasympathetic and sympathetic tone, respectively.  Indeed, basal carotid 
arteriovenous anastomotic blood flow is considerably higher in sodium 
pentobarbital-anaesthetised pigs (70-80% of carotid blood flow; present results) than in 
conscious (<5% of carotid blood flow; 9) or fentanyl/thiopental anaesthetised pigs (~19% of 
carotid blood flow; 10).  A high basal carotid arteriovenous anastomotic blood flow is 
particularly useful for investigating the effects of drugs that constrict these 'shunt' vessels. 
A catheter was placed in the inferior vena cava via the left femoral vein for infusion of 
vehicle (distilled water), the antagonists and sodium pentobarbital.  Another catheter was 
placed in the aortic arch via the left femoral artery for the measurement of arterial blood 
pressure (Combitrans disposable pressure transducer; Braun, Melsungen, Germany) and 
arterial blood withdrawal for the measurement of blood gases (ABL-510; Radiometer, 
Copenhagen, Denmark).  Subsequently, the right common carotid artery was dissected free 
and bilateral vagosympathectomy was performed in order to prevent a possible influence via 
baroreceptor reflexes on A61603-induced carotid vascular responses.  Two hub-less needles, 
each connected to a polyethylene tube, used for the administration of radioactive 
microspheres and A61603, respectively, were inserted into the right common carotid artery 
against the direction of blood flow for uniform mixing. 
Total common carotid blood flow was measured with a flow probe (internal diameter: 
2.5 mm) connected to a sine-wave electromagnetic flow meter (Transflow 601-system, 
Skalar, Delft, The Netherlands).  Heart rate was measured with a tachograph (CRW, Erasmus 
University, Rotterdam, The Netherlands) triggered by electrocardiogram signals.  Arterial 
blood pressure, heart rate and carotid blood flow were continuously monitored on a 
polygraph (CRW, Erasmus University, Rotterdam, The Netherlands).  During the experiment, 
body temperature was kept at about 37 °C and the animal was continuously infused with 
physiological saline to compensate fluid losses. 
The Ethics Committee of the Erasmus University Medical Centre Rotterdam, dealing 
with the use of animals in scientific experiments, approved the protocols followed in this 
investigation. 
5.2.2. Distribution of total common carotid blood flow 
The distribution of total common carotid blood flow was determined with 15.5±0.1 µm (S.D.) 
diameter microspheres labelled with 141Ce, 113Sn, 103Ru, 95Nb or 46Sc (NEN Dupont, Boston, 
USA).  For each measurement, about 200,000 microspheres, labelled with one of the 
radioisotopes, were mixed and injected into the right common carotid artery.  At the end of 
the experiment, the animal was killed by an overdose of sodium pentobarbital and the heart, 
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lungs, kidneys and all ipsilateral cranial tissues were dissected out, weighed and put in vials.  
The radioactivity in these vials was counted for 10 min in a γ-scintillation counter (Packard, 
Minaxi autogamma 5000), using suitable windows to discriminate the different isotopes 
(141Ce: 120-167 KeV, 113Sn: 355-435 KeV, 103Ru: 450-548 KeV, 95Nb: 706-829 KeV and 
46Sc: 830-965 KeV).  All data were processed by a set of specially designed programs (11).  
The fraction of right common carotid blood flow distributed to the different tissues was 
calculated by multiplying the ratio of tissue and total radioactivity of each radioisotope by the 
common carotid blood flow at the time of the injection of microspheres, labeled with the 
respective isotope.  Since little or no radioactivity was detected in the heart and kidneys, all 
microspheres trapped in lungs reached this tissue from the venous side after escaping via 
carotid arteriovenous anastomoses.  Therefore, the amount of radioactivity in the lungs was 
used as an index of the arteriovenous anastomotic fraction of the total common carotid blood 
flow (12).  Vascular conductance (10-2 ml.min-1.mmHg-1) was calculated by dividing blood 
flow (ml.min-1) by mean arterial blood pressure (mmHg) multiplied by hundred. 
5.2.3. Experimental protocol 
After a stabilisation period of at least 60 min, values of heart rate, mean arterial blood 
pressure, total common carotid blood flow, as well as arterial blood gases were measured.  
Thereafter, the animals (n=33) were divided into seven groups, receiving i.v. infusions 
(0.5 ml.min-1 for 10 min) of either vehicle (distilled water; 5 ml, n=6), 5-methylurapidil (1000 
µg.kg-1, n=6), prazosin (100 µg.kg-1, n=3), a combination of prazosin and rauwolscine (100 
and 300 µg.kg-1, respectively, n=6), GR127935 (500 µg.kg-1, n=3), ketanserin (500 µg.kg-1, 
n=3) or methiothepin (3000 µg.kg-1, n=6).  After 15 min, baseline values of heart rate, mean 
arterial blood pressure, arterial blood gases, total common carotid blood flow and its 
distribution into arteriovenous anastomotic and capillary fractions (injection of the first batch 
of microspheres) were measured.  Subsequently, all animals received of A61603 (cumulative 
total doses: 0.3, 1, 3 and 10 µg.kg-1 at the rate of 0.1 ml.min-1 over 10 min infused into the 
right common carotid artery).   Ten min after the start of each A61603 infusion, the animals 
received a different batch of microspheres and all variables were collated again. 
After the carotid and systemic haemodynamic variables had returned to baseline values, 
we analysed the systemic haemodynamic effects of i.v. bolus injections of A61603 (1, 3, 10 
and 30 µg.kg-1) in the different groups of animals. 
5.2.4. Data presentation and statistical analysis 
All data are presented as the mean ± S.E.M.  Percent changes from baseline values (i.e. after 
vehicle or the antagonists) caused by the different doses of A61603 within each group of 
animals were calculated.  Duncan new multiple-range test, together with two-way Analysis of 
Variance (ANOVA; SigmaStat 1.0, Jandel Corporation, Chicago, IL, USA), was used to 
establish whether these changes were statistically significant (P<0.05, two-tailed) when 
compared to the baseline in each group as well as with the corresponding dose of A61603 in 
the vehicle-treated group. 
5.2.5. Drugs 
Apart from the anaesthetics azaperone (Stresnil®; Janssen Pharmaceuticals, Beerse, Belgium), 
midazolam hydrochloride (Dormicum®; Hoffmann La Roche b.v., Mijdrecht, The 
Netherlands) and sodium pentobarbital (Apharmo, Arnhem, The Netherlands), the 
compounds used in this study were: A61603 hydrobromide (Tocris Cookson Ltd., Bristol, 
UK), rauwolscine hydrochloride (Sigma-Aldrich Chemie b.v., Zwijndrecht, The 
Netherlands), 5-methylurapidil (Byk Gulden, Konstanz, Germany), prazosin hydrochloride 
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(Bufa Chemie b.v., Castricum, The Netherlands), GR127935, sumatriptan succinate (both 
from GlaxoWellcome, Herts, UK; courtesy: Dr. H.E. Connor), ketanserin tartrate (Janssen 
Pharmaceutica, Beerse, Belgium) and methiothepin maleate (Hoffman La Roche b.v., 
Mijndrecht, The Netherlands).  Finally, heparin sodium (Leo Pharmaceutical Products, 
Weesp, The Netherlands) was used to prevent clotting of blood in the catheters. 
All drugs were dissolved in distilled water (vehicle).  A short period of heating was needed to 
dissolve prazosin, rauwolscine, GR127935, 5-methylurapidil (acidified to pH=6.8-7.0 with 
0.1 M HCl) and methiothepin (1 % of ascorbic acid was added).  The doses of the drugs refer 
to their respective salts. 
5.3. Results 
5.3.1. Systemic and carotid haemodynamic variables after different antagonists 
Baseline values of these variables in the 33 pigs used in the present investigation were: mean 
arterial blood pressure, 94±3 mmHg; heart rate, 101±3 beats.min-1; total common carotid 
blood flow, 133±7 ml.min-1 and total common carotid conductance, 144±8 
10-2 ml.min-1.mmHg-1.  No significant differences were observed between the values of 
haemodynamic variables collated before and after the administration of the vehicle (distilled 
water) or different antagonists used in this study (Table 5.2). 
5.3.2. Systemic haemodynamic responses to A61603 
A61603 (0.3, 1, 3 and 10 µg.kg-1, i.c.) produced a dose-dependent increase in mean arterial 
blood pressure (Figure 5.1; upper panel), without affecting heart rate (data not shown).  This 
Table 5.2.  Absolute values in mean arterial blood pressure, heart rate and total carotid blood 
flow before and after i.v. administration of vehicle and various antagonists used in 
anaesthetised pigs. 
Treatment Dose 
(µg.kg-1)  
Mean arterial 
blood pressure 
(mmHg) 
Heart rate 
(beats.min-1) 
Total carotid 
blood flow 
(ml.min-1) 
  Before After Before After Before After 
Vehicle 5 ml 96±4 94±5 106±3 105±3 145±13 139±12 
5-Methylurapidil 1000 102±4 95±7 103±5 116±6 149±12 152±15 
Prazosin 100 92±5 77±7 112±6 108±5 147±11 128±13 
Prazosin and 
Rauwolscine 
100 and 
300 
105±4 93±5 104±6 100±6 125±12 104±14 
GR127935 500 102±3 91±7 96±3 92±3 183±31 178±26 
Ketanserin 500 105±5 98±5 94±4 89±5 134±10 129±7 
Methiothepin 3000 103±4 108±4 105±6 105±6 134±10 120±10 
No significant (P<0.05) differences were noticed in corresponding values either when 
compared to the vehicle-treated group or between those ‘Before’ and ‘After’ treatments. 
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vasopressor response was antagonised (even reverted to hypotension) after treatment with 
methiothepin (3000 µg.kg-1), but remained by 5-methylurapidil (1000 µg.kg-1), prazosin 
(100 µg.kg-1), a combination of prazosin and rauwolscine (100 and 300 µg.kg-1, respectively), 
GR127935 (500 µg.kg-1) or ketanserin (500 µg.kg-1). 
The pressor responses following i.v. bolus injection of A61603 (1, 3, 10 and 30 µg.kg-1) 
are shown in Figure 5.1 (lower panel); heart rate remained unaffected (data not shown).  
Treatment with 5-methylurapidil slightly attenuated these responses, which were markedly 
reduced by methiothepin; the other antagonists were ineffective. 
5.3.3. Carotid haemodynamic responses to A61603 
Absolute values of total carotid, arteriovenous anastomotic and capillary conductances before 
and after i.c. infusions of A61603 (0.3-10 µg.kg-1) in the seven groups of animals are shown 
in Figure 5.2.  In animals treated with vehicle, A61603 produced a dose-dependent decrease 
in total carotid conductance.  This effect was restricted to the carotid arteriovenous 
anastomotic fraction, since the capillary fraction remained unmodified.  The A61603-induced 
changes were clearly attenuated in animals treated with methiothepin, but not in those treated 
with prazosin, GR127935 or ketanserin.  5-Methylurapidil only attenuated the decrease in the 
total carotid blood flow by the highest dose of A61603.  The treatment with prazosin and 
rauwolscine combination affected the A61603-induced decreases in the total carotid (highest 
two doses) and its carotid arteriovenous anastomotic fraction (highest dose). 
Figure 5.1.    Changes in mean 
arterial blood pressure (MABP) 
following i.c. (upper panel) or i.v. 
(lower panel) administration of 
A61603 in anaesthetised pigs 
treated i.v. with either vehicle 
(Veh; 5 ml distilled water), 
5-methylurapidil (5-MU; 
1000 µg.kg-1), prazosin (Praz; 
100 µg.kg-1), a combination of 
prazosin and rauwolscine (P+R; 
100 and 300 µg.kg-1, 
respectively), GR127935 (GR; 
500 µg.kg-1), ketanserin (KET; 
500 µg.kg-1) or methiothepin 
(MET; 3000 µg.kg-1).  Data are 
presented as mean ± S.E.M.  a, 
P<0.05 vs. baseline; b, P<0.05 vs. 
the response produced by the 
corresponding dose of A61603 in 
the vehicle-treated group. 
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Figure 5.3 compares decreases in carotid arteriovenous anastomotic blood flow by 
A61603 as percent changes from baseline values in control pigs (vehicle-treatment) and in 
pigs treated with the different antagonists.  It can be observed that the responses to A61603 
were clearly antagonised by methiothepin and only slightly by the combination of prazosin 
and rauwolscine; 5-methylurapidil, prazosin, GR127935 and ketanserin were ineffective. 
5.4. Discussion 
5.4.1. Consideration of known receptors that mediate carotid vasoconstriction 
A number of studies have shown that sumatriptan produces vasoconstriction in the carotid 
vasculature of several species via GR127935-sensitive 5-HT1B/1D receptors; these species 
include the dog (13), pig (14) and rabbit (15, 16).  It is now known that the receptor 
mediating vasoconstriction is of the 5-HT1B subtype (for references, see 17, 18).  In line with 
this proposal, the therapeutic efficacy of sumatriptan in migraine can be explained by carotid 
vasoconstriction mediated by the 5-HT1B receptor.  Furthermore, the canine external carotid 
vasoconstriction by ergotamine and dihydroergotamine involves 5-HT1B/1D receptors as well 
as α-adrenoceptors (19).  Since the ergots display reasonable affinity at α-adrenoceptors (20), 
their carotid vasoconstrictor effects in the pig may also be explained by these receptors.  In 
this respect, we recently showed that: (i) both α1- and α2-adrenoceptors mediate constriction 
of porcine carotid arteriovenous anastomoses (3); and (ii) these α1-adrenoceptors belong to 
α1A and α1B subtypes, but not the α1D subtype (4). 
Except for A61603 (α1A-adrenoceptor agonist), potent and selective agonists at 
α1-adrenoceptor  subtypes are unfortunately not available in order  to  verify  this  hypothesis. 
Figure 5.2.    Total carotid, 
arteriovenous anastomotic and 
capillary vascular conductances 
before and after i.c. administration 
of A61603 in anaesthetised pigs 
treated i.v. with either vehicle 
(Veh; 5 ml distilled water), 
5-methylurapidil (5-MU; 
1000 µg.kg-1), prazosin (Praz; 
100 µg.kg-1), a combination of 
prazosin and rauwolscine (P+R; 
100 and 300 µg.kg-1, 
respectively), GR127935 (GR; 
500 µg.kg-1), ketanserin (KET; 
500 µg.kg-1) or methiothepin 
(MET; 3000 µg.kg-1).  Data are 
presented as mean ± S.E.M.  a, 
P<0.05 vs. baseline; b, P<0.05 vs. 
the response produced by the 
corresponding dose of A61603 in 
the vehicle-treated group. 
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Therefore, in the present study we used A61603 to confirm the possible involvement of 
α1A-adrenoceptors in the constriction of porcine carotid arteriovenous anastomoses. 
5.4.2. Pharmacological profile of A61603 
A61603 (Table 5.1) is a tetrahydro-1-napthyl imidazoline derivative that has been reported to 
show potent α1A-adrenoceptor-agonist properties (5, 6).  As described previously (5, 21), 
A61603 is 35-fold more potent at human cloned α1a- than at α1b- or α1d-adrenoceptors in 
radioligand binding studies and 100 to 300-fold more potent than noradrenaline and 
phenylephrine in isolated canine prostate strips and rat vas deferens (α1A-adrenoceptors).  In 
contrast, A61603 is only 40-fold more potent than phenylephrine at α1B-adrenoceptors (rat 
spleen) and 35-fold less potent at α1D-adrenoceptors (rat aorta) (5, 21).  Although the 
compound displays low affinity (pKi<6) for other receptors, it has a reasonable affinity and 
agonist property at α2-adrenoceptor subtypes (see Table 5.1; 22).  In anaesthetised dogs, 
A61603 increases intra-urethral as well as diastolic arterial blood pressure (5).  In agreement 
with the latter, A61603 produces pressor responses in conscious rats at 50- to 100-fold lower 
doses than those of phenylephrine, and tamsulosin (α1A-adrenoceptor antagonist) causes a 
marked shift of the A61603-induced response curve (5). 
5.4.3. Possible involvement of a novel mechanism? 
A61603 produced a dose-dependent increase in blood pressure when administered by either 
i.c. (0.3-10 µg.kg-1) or i.v. (1-30 µg.kg-1) routes (Figure 5.1).  In view of the high affinity of 
A61603 at the α1A-adrenoceptor (Table 5.1) and the important role of α-adrenoceptors in the 
regulation of vascular tone (see review by 23), it was surprising that the hypertensive 
response to A61603 was little affected by 5-methylurapidil, prazosin or a combination of 
prazosin and rauwolscine.  On the other hand, A61603-induced pressor response was 
markedly attenuated (i.v.) or even converted to hypotension (i.c.) by methiothepin. 
Similar results were obtained with respect to the carotid haemodynamics.  As shown in 
Figure 5.2, A61603 (0.3-10 µg.kg-1, i.c.) produced a dose-dependent decrease in the porcine 
carotid blood flow, exclusively due to a constriction of carotid arteriovenous anastomoses.  
Figure 5.3.  Changes in carotid 
arteriovenous anastomotic (AVA) 
conductance following i.c. 
administration of A61603 in 
anaesthetised pigs treated i.v. with 
either vehicle (Veh; 5 ml distilled 
water), 5-methylurapidil (5-MU; 
1000 µg.kg-1), prazosin (Praz; 
100 µg.kg-1), a combination of 
prazosin and rauwolscine (P+R; 100 
and 300 µg.kg-1, respectively), 
GR127935 (GR; 500 µg.kg-1), 
ketanserin (KET; 500 µg.kg-1) or 
methiothepin (MET; 3000 µg.kg-1).  
Data are presented as mean ± S.E.M. 
a, P<0.05 vs. baseline; b, P<0.05 vs. 
the response produced by the 
corresponding dose of A61603 in the 
vehicle-treated group. 
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This selective carotid vasoconstriction was apparently maximal because a higher dose of 
A61603 (30 µg.kg-1) did not produce an additional decrease in total carotid conductance 
(maximal change: 80±4%; n=6). 
The A61603-induced constriction of carotid arteriovenous anastomoses was, 
unexpectedly, resistant to blockade by the potent and selective α1A-adrenoceptor antagonist 
5-methylurapidil (24, 25).  Since prazosin was also ineffective in attenuating this response, it 
seems plausible to conclude that α1-adrenoceptors do not play an important role.  As 
mentioned before, both α1- and α2-adrenoceptors can mediate vasoconstriction in the porcine 
carotid arterial bed (Willems et al., 1999).  For this reason and for the fact that A61603 also 
has affinity for α2-adrenoceptors (see Table 5.1, 22), we applied a combination of prazosin 
and rauwolscine to investigate the possible involvement of α2-adrenoceptors.  The 
combination of prazosin and rauwolscine produced only a slight attenuation in the 
A61603-induced constriction of carotid arteriovenous anastomoses, which implies, at most, a 
limited involvement of α2-adrenoceptors.  Similarly, the fact that GR127935 as well as 
ketanserin did not significantly modify this response excludes the possible involvement of 
5-HT1B/1D and 5-HT2 receptors, respectively.  Although A61603 shows only a low affinity at 
these receptors (see Table 5.1; 22), the exclusion of 5-HT1B/1D receptors is of interest, 
considering the affinity of benzylimidazoline derivatives related in structure to A61603 at 
5-HT1B/1D receptors (26).  As reported elsewhere, the involvement of 5-HT1F receptors in the 
carotid vasoconstriction of pigs and dogs (external) carotid vascular bed has been 
categorically excluded (14, 18).  Moreover, an endothelium-dependent vasoconstriction via 
the release of pro-constrictor cyclo-oxygenase products (27, 28) also seems unlikely, based 
on the lack of effect of indomethacin (3000 µg.kg-1, i.v.; data not shown) on A61603-induced 
decrease in total carotid conductance.  Similarly, a combination of indomethacin, prazosin, 
rauwolscine, GR127935 and ketanserin, at the doses previously mentioned, also failed to 
attenuate the decreases in total carotid conductance produced by i.c. infusions of A61603 
(data not shown). 
Methiothepin displays high affinity at 5-HT1/2 receptors (29) as well as α1/2 
adrenoceptors (20).  Therefore, we decided to test methiothepin against the A61603-induced 
constriction of arteriovenous anastomoses in this porcine model.  It may be noted that a 
relatively high dose of methiothepin (3000 µg.kg-1) was required to abolish sumatriptan-
induced carotid vasoconstriction in anaesthetised dogs and pigs (8, 18, 30); while a lower 
dose (1000 µg.kg-1) was ineffective.  As shown in Figures. 5.2 and 5.3, treatment of the 
animals with methiothepin (3000 µg.kg-1) markedly attenuated the A61603-induced 
vasoconstriction in the porcine carotid vascular bed.  Since all currently known 
vasoconstrictor receptors/mechanisms (α1/2-adrenoceptors, 5-HT1B/1D, 5-HT2 and eicosanoid 
receptors) had already been excluded (see above), this latter finding implies the involvement 
of another, possibly novel mechanism in the constriction of carotid arteriovenous 
anastomoses by A61603.  Because this in vivo animal model is predictive for antimigraine 
activity (12), this novel mechanism could be a potential new target for the development of 
antimigraine agents in the future.  Admittedly, as an antimigraine drug, such an agonist must 
be devoid of systemic vasoconstrictor properties. 
In conclusion, the present results show that A61603 does not behave as a potent and 
selective α1A-adrenoceptor agonist in the pig and that the constriction of porcine carotid 
arteriovenous anastomoses by A61603 is primarily mediated by a novel non-adrenergic 
mechanism. 
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6.1. Introduction 
Vasodilatation of cranial large arteries and arteriovenous anastomoses has been proposed to 
play an important role in the pathophysiology of migraine headache (1, 2).  Indeed, to date all 
acutely acting antimigraine agents, i.e. the triptans and ergots, constrict isolated cranial 
vessels as well as arteriovenous anastomoses within the carotid vasculature (3, 4).  While the 
vasoconstrictor effect of triptans seems to be mediated by the 5-HT1B receptor, that of ergot 
alkaloids also involves other receptors (5, 6), including the α-adrenoceptors, which mediate 
the carotid vasoconstriction in anaesthetised dogs (7). 
Stimulation of α-adrenoceptors produces contraction of the isolated carotid artery of 
several species, including the dog (8, 9), rabbit (10, 11) and pig (12).  Also, in vivo studies 
have shown that sympathetic nerve stimulation as well as administration of the 
α-adrenoceptor agonists, phenylephrine and BHT 933, constrict carotid arteriovenous 
anastomoses (13) and there is evidence that α-adrenoceptors may regulate vascular tone of 
carotid arteriovenous anastomoses (14).  Thus, it is possible that α-adrenoceptors may 
provide a target for the development of new antimigraine drugs (15). 
Cordi and his coworkers (16) described a series of compounds with α-adrenoceptor 
agonist activity and one such compound, S18148 ((5S)-spiro[(1,3-diazacyclopent-
1-ene)-5:2’-(7’-methyl-1’,2’,3’,4’-tetrahydronaphthalene)] fumarate) decreased carotid and 
cutaneous blood flows via activation of  α2-adrenoceptors (17).  The follow-up compound, 
S19014 (spiro[(1,3-diazacyclopent-1-ene)-5:2’-(4’,5’-dimethylindane)] fumarate), which 
exhibited a high affinity at both α1- and α2-adrenoceptor subtypes (Table 6.1), interestingly 
showed a wide variation in efficacy (maximum effect: Emax) and potency (concentration 
needed to elicit 50% of Emax: EC50) in contracting rabbit, dog and human saphenous vein 
(EC50: 18, 79 and 8500 nM, respectively; Emax: 92, 49 and 36% of K+-induced contraction, 
Table 6.1.  Chemical structure of S19014 and its binding affinities (pKi) at human cloned α1- and 
α2-adrenoceptor subtypes. 
pKia Chemical structure 
α1-adrenoceptors α2-adrenoceptors 
α1a: 7.66 α2a: 8.98 
α1b: 7.80 α2b: 8.33 
 
α1d: 7.65 α2c: 8.75 
a, Unpublished data from the Institut de Recherches Internationales Servier, Courbevoie Cedex, France. 
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respectively), rabbit aorta (EC50: 816 nM; Emax: 36% of K+-induced contraction) and dog 
femoral artery (practically inactive) (18). 
Over the years, the constriction of porcine carotid arteriovenous anastomoses has 
served as a predictive model for the antimigraine efficacy of triptans, which have an agonist 
action at the 5-HT1B receptor (2, 3, 19).  In addition, ergot alkaloids, which act via both 
5-HT1B receptor and α2-adrenoceptors (5, 7) and isometheptene, which acts via 
α-adrenoceptors (20, 21), constrict carotid arteriovenous anastomoses.  Therefore, the present 
study in anaesthetised pigs we set out to (i) investigate the effects of S19014 on the 
distribution of carotid blood flow into nutrient (capillary) and non-nutrient (arteriovenous 
anastomotic) fractions; and (ii) establish the cardiovascular safety of S19014 analysing its 
effects on cardiac output and its regional distribution to vital organs.  The cardiovascular 
safety was also assessed in the human isolated coronary artery (22, 23). 
6.2. Methods 
6.2.1. Anaesthetised pigs 
6.2.1.1. General 
After an overnight fast, 39 domestic pigs (Yorkshire x Landrace; 10-14 kg) were sedated with 
intramuscular injections of azaperone (120 mg) and midazolam hydrochloride (10 mg) and 
then anaesthetised with sodium pentobarbital (600 mg, i.v.).  After tracheal intubation, the 
animals were connected to a respirator (BEAR 2E, BeMeds AG, Baar, Switzerland) for 
intermittent positive pressure ventilation with a mixture of room air and oxygen.  Respiratory 
rate, tidal volume and oxygen supply were adjusted to keep arterial blood gas values within 
physiological limits (pH: 7.35-7.48; pCO2: 35-48 mmHg; pO2: 100-120 mmHg).  Anaesthesia 
was maintained with a continuous i.v. infusion of sodium pentobarbital (12-20 mg.kg-1.h-1).  
This anaesthetic regimen, together with bilateral vagosympathectomy (see below), increases 
heart rate and dilates carotid arteriovenous anastomoses.  Thus, arteriovenous anastomotic 
blood flow is considerably high (70-80% of carotid blood flow) in these animals compared to 
pigs in a conscious state or under fentanyl/thiopental anaesthesia (~19% of carotid blood 
flow, 14), thereby producing one of the putative features of migraine (1, 2). 
Heart rate was measured with a tachograph (CRW, Erasmus University, Rotterdam, 
The Netherlands) triggered by electrocardiogram signals.  A catheter was placed in the 
inferior vena cava via the right femoral vein for the administration of vehicle and S19014.  
Another catheter was placed in the aortic arch via the left femoral artery for the measurement 
of arterial blood pressure (Combitrans disposable pressure transducer; Braun, Melsungen, 
Germany) and arterial blood withdrawal for the measurement of blood gases (ABL-510; 
Radiometer, Copenhagen, Denmark).  During the experiment, body temperature was kept 
around 37°C and the animal was continuously infused with physiological saline to 
compensate for fluid losses. 
6.2.1.2. Carotid blood flow experiments 
The common carotid arteries, external jugular veins and vagosympathetic trunks were 
identified.  The vagosympathetic trunks were cut between two ligatures to avoid 
reflex-mediated cardiovascular changes.  Subsequently, the right common carotid artery was 
dissected free and a hub-less needle, connected to a polyethylene tube, was inserted against 
the direction of blood flow for the administration and uniform mixing of radioactive 
microspheres.  Another catheter was placed in the right external jugular vein for the 
withdrawal of venous blood samples to determine blood gases and, subsequently, the 
difference between arterial and jugular venous oxygen saturations (A-V SO2 difference).  
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Blood flow was measured in the right common carotid artery with a flow probe (internal 
diameter: 2.5 mm) connected to a sine-wave electromagnetic flow meter (Transflow 
601-system, Skalar, Delft, The Netherlands) and continuously monitored on a polygraph 
(CRW, Erasmus University, Rotterdam, The Netherlands). 
The distribution of common carotid blood flow was determined with 15.5±0.1 µm (s.d.) 
diameter microspheres labelled with 141Ce, 113Sn, 103Ru, 95Nb or 46Sc (NEN Dupont, Boston, 
USA).  For each measurement, about 200,000 microspheres, labelled with one of the 
radioisotopes, were mixed and injected into the right common carotid artery.  At the end of 
the experiment, the animal was killed by an overdose of sodium pentobarbital and the heart, 
lungs, kidneys and all ipsilateral cranial tissues were dissected out, weighed and put in vials.  
The radioactivity in these vials was counted for 5 min in a γ-scintillation counter (Packard, 
Minaxi autogamma 5000), using suitable windows to discriminate the different isotopes 
(141Ce: 120-167 KeV, 113Sn: 355-435 KeV, 103Ru: 450-548 KeV, 95Nb: 706-829 KeV and 
46Sc: 830-965 KeV).  All data were processed by a set of specially designed computer 
programs (24).  The fraction of carotid blood flow distributed to the different tissues was 
calculated by multiplying the ratio of tissue and total radioactivity of each radioisotope by the 
total common carotid blood flow at the time of the injection of the microspheres labelled with 
the respective isotope.  Since little or no radioactivity was detected in the heart and kidneys, 
all microspheres trapped in lungs reached this tissue from the venous side after escaping via 
carotid arteriovenous anastomoses.  Therefore, the amount of radioactivity in the lungs was 
used as an index of the arteriovenous anastomotic fraction of the common carotid blood flow 
(24, 25).  Vascular conductance was calculated by dividing blood flow (ml.min-1) by mean 
arterial blood pressure (mmHg), multiplied by hundred. 
6.2.1.3. Cardiac output experiments 
A 6F Swan-Ganz thermodilution catheter (Braun Melsungen AG, Melsungen, Germany) was 
introduced into the pulmonary artery via the right femoral vein to measure cardiac output 
using a computerised cardiac output monitor (Erasmus MC, Rotterdam, The Netherlands).  
Another catheter, connected to a pressure transducer (Combitrans disposable pressure 
transducer; Braun, Melsungen, Germany), was guided via the left carotid artery into the left 
ventricle for the injection of radioactive microspheres.  Lastly, a catheter was placed into the 
right femoral artery and connected to a Harvard pump for the withdrawal of reference blood 
samples during the injection of radioactive microspheres. 
The distribution of cardiac output was determined using radioactive microspheres (see 
above).  For each measurement about 1,000,000 microspheres, labelled with one of the 
isotopes, were injected into the left ventricle against the direction of blood flow over a 10 s 
period.  Starting 10 s before microsphere injection and lasting 70 s, an arterial reference 
blood sample was withdrawn from the right femoral artery at a constant rate of 6 ml.min-1.  
Blood loss during the experiment was compensated by infusing the corresponding volume of 
haemaccel.  At the end of the experiments the animals were killed as described above and a 
number of tissues (lungs, kidneys, heart, stomach, small intestine, spleen, liver, adrenals, 
brain, skin and skeletal muscles) were dissected out, weighed and put into vials for counting 
radioactivity.  As described by Saxena et al. (24), tissue blood flow was calculated by 
multiplying the ratio of tissue and reference blood sample radioactivity by the blood 
withdrawal rate (6 ml.min-1) and normalised to 100 g tissue.  Radioactivity in the lungs 
mainly represents the peripheral arteriovenous anastomotic blood flow (i.e. the non-nutrient 
part of the cardiac output), although a small amount (1-1.5% of cardiac output) is derived 
from the bronchial arteries (26).  Vascular conductance was calculated by dividing blood 
flow (ml.min-1.100 g-1) or cardiac output (ml.min-1) by mean arterial blood pressure (mmHg), 
multiplied by hundred.  Stroke volume (cardiac output divided by heart rate) and nutrient 
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cardiac output (cardiac output minus lung blood flow, i.e. mainly total arteriovenous 
shunting) were also calculated. 
6.2.1.4. Experimental protocols 
After a stabilisation period of about 1 h, the animals were divided into two groups used for 
either carotid blood flow (n=27) or cardiac output (n=12) experiments. 
This first group (carotid blood flow experiments) was divided into four subgroups.  
Whereas the first and second subgroups (n=6, each) remained untreated, the animals in the 
third (n=8) and fourth subgroups (n=7) received i.v. infusions (rate: 0.5 ml.min-1 for 10 min) 
of prazosin (100 µg.kg-1) or rauwolscine (300 µg.kg-1) to block α1- and α2-adrenoceptors, 
respectively (13).  Fifteen min later, baseline values of blood pressure, heart rate and total 
carotid blood flow were collated and the distribution of carotid blood flow into arteriovenous 
anastomotic and capillary fractions and A-V SO2 difference were determined.  Subsequently, 
the animals in the first subgroup received four consecutive i.v. infusions (1 ml.min-1 for 3 min 
plus 2 min flush) of distilled water (vehicle), whereas those in the second (control), third  
(prazosin) and fourth (rauwolscine) subgroups received intravenous infusions of S19014 
(cumulative doses: 1, 3, 10 and 30 µg.kg-1) over a period of 3 min (1 ml.min-1) plus 2 min 
flush.  Systemic and carotid haemodynamic variables were reassessed 10 min after each 
administration of vehicle (first subgroup) or S19014 dose (other three subgroups). 
The second group (cardiac output experiments) was divided into two subgroups (n=6, 
each).  Whereas the first subgroup was treated with four consecutive infusions of 5 ml of 
distilled water (vehicle), the second subgroup received four cumulative doses of S19014 (1, 
3, 10 and 30 µg.kg-1) at the rate of 1 ml.min-1 for 3 min plus 2 min of flushing.  Systemic and 
regional haemodynamic variables were reassessed 10 min after every administration of 
vehicle or S19014 dose. 
6.2.2. Human isolated coronary artery 
6.2.2.1. Tissue preparation 
The right epicardial coronary artery was obtained from eight heart-beating organ donors who 
died of noncardiac disorders less than 24 h before the tissue was taken to the laboratory 
(7 cerebrovascular accident, 1 hydrocephalus; 4 males, 4 females; age: 24-57 years).  The 
hearts were provided by the Rotterdam Heart Valve Bank after donor mediation by Bio 
Implant Services Foundation / Eurotransplant Foundation (Leiden, The Netherlands) after 
removal of the aortic and pulmonary valves for homograft valve transplantation.  The hearts 
were stored at 0 to 4°C in a sterile organ protecting solution (UW, EuroCollins, or 
HTK-Bretschneider) immediately following circulatory arrest.  After arrival in the laboratory, 
the right coronary artery was removed and placed in a cold, oxygenated Krebs buffer solution 
of the following composition: 118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 
1.2 mM KH2PO4, 25 mM NaHCO3 and 8.3 mM glucose; pH 7.4.  
Ring segments of approximately 3-4 mm length were prepared from the blood vessels, 
excluding macroscopically visible atherosclerotic lesions.  The segments were suspended on 
stainless steel hooks in 15-ml organ baths containing Krebs buffer solution, aerated with 
95% O2 and 5% CO2 and maintained at 37°C.  After equilibration for at least 30 min and 
wash every 15 min, isometric tension was measured with a force transducer (Harvard, South 
Natick, MA, USA) and recorded on a flatbed recorder (Servogor 124, Goerz, Neudorf, 
Austria).  The rings were stretched to a stable pre-tension of about 15 mN. 
6.2.2.2. Experimental protocol 
Segments were exposed to K+ (30 mM) twice.  After pre-contraction with prostaglandin F2α 
(1 µM), the functional integrity of the endothelium was verified by observing relaxation to 
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substance P (1 nM).  Following wash, the tissue was exposed to K+ (100 mM) to determine 
the maximal contractile response to K+.  After a 30-min incubation period, concentration 
response curves to S19014 or sumatriptan (both from 1 nM to 100 µM) were constructed in a 
paired, parallel set-up (22).  The contractions are expressed as a percentage of contraction to 
100 mM K+ to correct for differences in wall thickness or segment length between individual 
artery segments.  In four out of eight experiments, concentration response curves to S19014 
and sumatriptan were also constructed in the presence of the thromboxane A2 analogue 
U46619 (9,11–dideoxy-11α,9α-epoxy-methano-prostaglandin F2α) in a concentration 
(30-100 nM) eliciting about 10% of the K+-induced contraction.  The contraction induced by 
U46619 was similar for the blood vessel segments that were used for concentration response 
curves to S19014 (10±2% of the contraction to K+) or sumatriptan (10±5%).   
6.2.3. Statistical analysis and data presentation  
The significance of the difference between the haemodynamic variables within one group 
was evaluated with Duncan’s new multiple range test, once an analysis of variance 
(randomised block design) had revealed that the samples represented different populations 
(27).  Percent changes (from baseline values) caused by S19014 (1, 3, 10 and 30 µg.kg-1) in 
the animals treated with either prazosin or rauwolscine were compared with the 
corresponding doses in the control group using Student's unpaired t-test. 
The concentration response curves obtained with S19014 and sumatriptan in the 
coronary artery rings were analysed using the GraphPad software (GraphPad software Inc., 
San Diego, CA, USA) to determine pEC50 values.  In case that a concentration response curve 
did not reach a plateau, the contraction in response to the highest concentration was 
considered as Emax.  Emax and pEC50 values of S19014 and sumatriptan were compared by 
paired t-test.  Correlation coefficients were calculated according to Pearson (27).  
Experiments in the presence of U46619 were compared with paired experiments in the 
absence of U46619. 
All data are presented as mean±SEM and differences were assumed to be significant 
when P<0.05. 
6.2.4. Compounds 
The following compounds were used: azaperone (Stresnil®; Janssen Pharmaceuticals, Beerse, 
Belgium), haemaccel® (Hoechst Marion Roussel b.v., Hoevelaken, The Netherlands), heparin 
sodium (to prevent blood clotting in catheters; Leo Pharmaceutical Products, Weesp, 
The Netherlands), midazolam hydrochloride (Dormicum®; Hoffmann La Roche b.v., 
Mijdrecht, The Netherlands), phenylephrine hydrochloride (Sigma-Aldrich Chemie b.v., 
Zwijndrecht, The Netherlands), prazosin hydrochloride (Bufa Chemie b.v., Castricum, 
The Netherlands), Prostaglandin F2α tris salt (Sigma-Aldrich Chemie), rauwolscine 
dihydrochloride (RBI, Natick, USA), S19014 (Institut de Recherches Internationales Servier, 
Courbevoie Cedex, France), sodium pentobarbital (Sanofi Sante b.v., Maasluis, The 
Netherlands), substance P acetate (Sigma-Aldrich Chemie), sumatriptan hemisuccinate 
(Institut de Recherches Internationales Servier), and U46619 (Sigma-Aldrich Chemie). 
Except U46619, all drugs were dissolved in distilled water (vehicle); however a short 
period of heating was needed to dissolve prazosin.  U46619 was dissolved in ethanol and 
further diluted in distilled water.   Solutions of S19014 and sumatriptan were freshly prepared 
for every experiment.  The doses of the drugs refer to their respective salts. 
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6.2.5. Ethical approval 
The local Ethics Committees dealing with the use of animals and humans in scientific 
experiments approved the protocol. 
6.3. Results 
6.3.1. Carotid blood flow distribution in anaesthetised pigs 
6.3.1.1. Baseline values 
Baseline values in the 27 anaesthetised pigs used for this protocol were: heart rate 
(104±2 beats.min-1), mean arterial blood pressure (97±2 mmHg), total carotid blood flow 
(138±6 ml.min-1) and total carotid vascular conductance (144±6 10-2 ml.min-1mmHg-1). 
6.3.1.2. Effects of antagonists 
Table 6.2 shows the values of systemic and carotid haemodynamics as well as the A-V SO2 
difference before and after pre-treatment with vehicle (control animals), prazosin 
(100 µg.kg-1) or rauwolscine (300 µg.kg-1).  Whereas vehicle and prazosin did not produce 
any changes, rauwolscine elicited only a small, but significant, decrease in mean arterial 
blood pressure (9±2%). 
 
Table 6.2  Absolute values of heart rate, mean arterial blood pressure and total carotid blood 
flow in anaesthetised pigs, before and after intravenous infusions of vehicle (control), 
prazosin or rauwolscine 
Treatment groups 
Vehicle (Control) 
(5 ml, n=6) 
Prazosin 
(100 µg.kg-1, n=8) 
Rauwolscine 
(300 µg.kg-1, n=7) 
Haemodynamic 
variables 
Before After Before After Before After 
Heart rate (beats.min-1)  102±2 101±3 114±3 112±3 98±4 99±5 
MABP (mmHg)  97±3 95±3 98±3 91±4 108±2 99±2* 
Total CBF (ml.min-1) 140±13 142±13 140±14 126±12 154±7 136±6 
A-V SO2 difference (%) 9±2 8±2 8±2 10±2 6±3 6±2 
MABP, mean arterial blood pressure; Total CBF, total carotid artery blood flow; A-V SO2 
difference, difference between arterial and jugular venous oxygen saturations. *, P<0.05 vs. 
before treatment. 
 
6.3.1.3. Systemic haemodynamics and A-V SO2 difference 
In control animals, S19014 (1, 3, 10 and 30 µg.kg-1, i.v.) produced dose-dependent initial 
increases in mean arterial blood pressure that lasted for about 3 min (Figure 6.1).  Prazosin 
neither affected the magnitude nor the duration of these pressor responses.  On the other 
hand, in rauwolscine-treated animals mean arterial blood pressure increased only with the 
highest dose of S19014; the lowest two doses of S19014 caused a hypotension that lasted 
10-15 min. 
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Table 6.3 presents the values of heart rate, mean arterial blood pressure and A-V SO2 
differences measured before (baseline) and 15-min after vehicle (4 times 5 ml each) or 
S19014 (1, 3, 10 and 30 µg.kg-1).  In both vehicle and S19014 treated animals, similar small 
decreases in heart rate (maximum change: 4±1% and 3±1%, respectively) and mean arterial 
blood pressure (maximum change: 7±2% and 5±2%, respectively) were noticed.  These small 
changes were probably time-related.  However, S19014 caused a significant, but moderate, 
increase in the A-V SO2 difference after the two highest doses of S19014 and this effect was 
attenuated by rauwolscine but not prazosin. 
Table 6.3  Systemic haemodynamic effects of vehicle (n=6) per se and S19014 in the absence (n=6; 
control) or presence of either prazosin (100 µg.kg-1; n=8) or rauwolscine (300 µg.kg-1; n=7) 
Vehicle (four times 5 ml, i.v.) or S19014 (µg.kg-1, i.v.) 
Treatment groups 
Baseline 1 3 10 30 
Heart rate (beats.min-1) 
Vehicle† 102±2 101±3 99±3* 98±3* 98±4* 
Control 102±4 102±4 101±4* 100±4* 100±4* 
Prazosin 112±3 110±3 110±3 109±3 108±2 
Rauwolscine 99±5 98±5 98±5 98±6 98±6 
Mean arterial blood pressure (mmHg) 
Vehicle† 97±3 95±3 96±3 95±3 90±3* 
Control 101±3 99±3 96±4* 96±4* 96±3* 
Prazosin 91±4 88±4 86±4* 84±4* 83±3* 
Rauwolscine 98±2 94±2 93±3 93±3 91±3 
A-V SO2 difference (%) 
Vehicle† 9±2 8±2 8±2 8±2 10±3 
Control 7±2 8±2 8±2 9±3* 10±2* 
Prazosin 10±2 11±3 13±2* 12±2* 15±2* 
Rauwolscine 6±2 6±2 6±1 7±2 8±2*# 
A-V SO2 difference, difference between arterial and jugular venous oxygen saturations.   *, P<0.05 
vs. baseline.  #, P<0.05 vs. the corresponding change with S19014 in control animals.  †, Four 
infusions of 5 ml distilled water were given after baseline measurements. 
Figure 6.1.  Magnitude (as 
percent change from baseline 
values; left panel) and duration 
(as min; right panel) of the 
initial change in mean arterial 
blood pressure following 
administration of S19014 (1, 3, 
10 and 30 µg.kg-1, i.v.) in control 
pigs (n=6) and in pigs treated 
with prazosin (n=8) or 
rauwolscine (n=7).  All values 
are expressed as mean±s.e.mean. 
*, P<0.05 vs. baseline.  
#, P<0.05 vs. the corresponding 
response with S19014 in control 
animals. 
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6.3.1.4. Carotid haemodynamic effects of S19014 
Absolute values of total carotid, arteriovenous anastomotic and capillary blood flows and 
conductances in the different groups of animals are shown in Figure 6.2.  Whereas vehicle 
was devoid of any carotid haemodynamic effects, S19014 (1, 3, 10 and 30 µg.kg-1) produced 
dose-dependent decreases in total carotid and arteriovenous anastomotic blood flows 
(maximum change: 18±2% and 34±5%, respectively) and conductances (maximum 
change: 14±2% and 30±4%, respectively).  In contrast, S19014 increased capillary blood 
flow and conductance (maximum change: 40±23% and 49±27%, respectively).  These effects 
of S19014 remained largely unchanged in animals treated with prazosin, but were clearly 
attenuated by rauwolscine. 
Figure 6.3 depicts the percent changes (from baseline values) in carotid arteriovenous 
anastomotic conductance by S19014 (1, 3, 10 and 30 µg.kg-1) in control, and prazosin 
(100 µg.kg-1)- or rauwolscine (300 µg.kg-1)-treated animals.  While prazosin did not modify 
the constrictor effect of S19014 on arteriovenous anastomoses, rauwolscine clearly did. 
The changes caused by vehicle (four doses) and S19014 (1, 3, 10 and 30 µg.kg-1) in 
vascular conductance in the different cranial tissues are depicted in Figure 6.4.  Whereas 
Figure 6.2.  Total carotid, arteriovenous
anastomotic (AVA) and capillary blood flows
(left panels) and vascular conductances (right
panels) measured in groups of pigs receiving
either vehicle (Veh; n=6) or S19014; the latter
were either untreated controls (Con; n=6) or
treated with prazosin (Praz; 100 µg.kg-1; n=8)
or rauwolscine (Rauw; 300 µg.kg-1; n=7).  The
measurements were made sequentially at
baseline (Bas) and 15-min following infusions
of the vehicle (four times each 5 ml, i.v., V5)
or S19014 (1, 3, 10 and 30 µg.kg-1, i.v. as
indicated by S1, S3, S10 and S30,
respectively).  All values are expressed as
mean±s.e.mean.  *, P<0.05 vs. baseline;
#, P<0.05 vs. the corresponding response with
S19014 in control animals. 
 
Figure 6.3.  Percent changes (compared 
to baseline value) in porcine 
arteriovenous anastomotic (AVA) 
conductance 15-min following 
administration of S19014 (1, 3, 10 and 
30 µg.kg-1, i.v.) in control pigs (n=6) and 
in pigs treated with prazosin (n=8) or 
rauwolscine (n=7).  All values are 
expressed as mean±s.e.mean.  *, P<0.05 
vs. baseline.  #, P<0.05 vs. the 
corresponding response with S19014 in 
control animals. 
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administration of the vehicle did not elicit any changes, S19014 moderately increased the 
vascular conductance in several tissues, including the skeletal muscle, bone, fat, salivary 
gland and dura mater, while those in the others (skin, eye, brain, ear or tongue) remained 
unchanged.  These effects of S19014 on tissue vascular conductance were similar in animals 
treated with prazosin, but relatively less marked in animals treated with rauwolscine, 
suggesting that the vasodilator effects of S19014 may be partly passive following constriction 
of arteriovenous anastomoses. 
6.3.2. Distribution of cardiac output 
6.3.2.1. Baseline values 
Baseline values in the 12 anaesthetised pigs used for this protocol before any treatment were: 
heart rate (112±3 beats.min-1), mean arterial blood pressure (105±1 mmHg), cardiac output 
(1588±47 ml.min-1), nutrient cardiac output (1354±49 ml.min-1), stroke volume (14.3±0.5 ml) 
and systemic vascular conductance (1511±44 10-2 ml.min-1mmHg-1). 
6.3.2.2. Systemic haemodynamics 
The values of systemic haemodynamic variables in anaesthetised pigs collated at baseline and 
after i.v. treatments with vehicle or S19014 (1, 3, 10 and 30 µg.kg-1) are presented in 
Figure 6.5.  Mean arterial blood pressure did not change, but there were small decreases in 
other variables in both vehicle- and S19014-treated groups.  The maximum changes, which 
did not significantly differ in the two group were, respectively: heart rate, 4±1% and 4±2%; 
cardiac output, 14±3% and 14±2%; stroke volume, 10±3% and 10±3%; and systemic 
vascular conductance, 10±2% and 11±3%.  A small decrease in the nutrient cardiac output 
(maximal change: 14±3 %) was also observed in the vehicle subgroup. 
6.3.2.3. Regional haemodynamics 
As depicted in Figure 6.6, there were no significant changes in regional vascular 
conductances in the vehicle group other than a decrease in vascular conductance in the 
Figure 6.4.  Carotid regional 
vascular conductances measured in 
groups of pigs receiving either 
vehicle (Veh; n=6) or S19014; the 
latter were either untreated controls 
(Con; n=6) or treated with prazosin 
(Praz; 100 µg.kg-1; n=8) or 
rauwolscine (Rauw; 300 µg.kg-1; 
n=7).  The measurements were made 
sequentially at baseline (Bas) and 
15-min following infusions of 
vehicle (four times each 5 ml, i.v., 
V5) or S19014 (1, 3, 10 and 
30 µg.kg-1, i.v. as indicated by S1, 
S3, S10 and S30, respectively).  All 
values are expressed as 
mean±s.e.mean.  *, P<0.05 vs. 
baseline;  #, P<0.05 vs. the 
corresponding response with S19014 
in control animals. 
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Figure 6.6.  Regional vascular conductances 
measured in groups of pigs receiving either 
vehicle (n=6) or S19014 (n=6).  The 
measurements were made sequentially at 
baseline (Bas) and 15-min following 
infusions of vehicle (four times each 5 ml, 
i.v., V5) or S19014 (1, 3, 10 and 30 µg.kg-1, 
i.v. as indicated by S1, S3, S10 and S30, 
respectively).  All values are expressed as 
mean±s.e.mean.  *, P<0.05 vs. baseline;  
#, P<0.05 vs. the corresponding response 
with S19014 in control animals. 
adrenals (maximal change: -30±11%), and increases in the brain with the highest dose 
(25±9%) and skin with the last two doses (maximal change: 54±16%); this latter effect was 
also observed in the animals receiving S19014.  In addition, S19014 decreased vascular 
conductances in lungs (mainly peripheral arteriovenous anastomoses; maximal change: 
50±5%), skeletal muscles (maximal change: -16±4%) and liver (maximal change: 50±5%).  
Except in the lungs, the changes with 
S19014 were not significantly different 
from those in the vehicle group. 
6.3.3. Human isolated coronary artery 
6.3.3.1. Basic contractile properties 
The coronary artery contraction to 
100 mM K+ was 52±6 mN.  Relaxation to 
substance P (1 nM) was 40±10% of the 
precontraction (30±5 mN) induced by 1 µM prostaglandin F2α (n=8). 
6.3.3.2. Contractile responses to S19014 and sumatriptan 
Both S19014 and sumatriptan induced a concentration-dependent contraction of the human 
isolated coronary artery (Figure 6.7, left panel).  Whereas the maximal contraction to S19014 
was considerable smaller than that to sumatriptan (3±1% and 19±10% of the contraction to 
K+, respectively), the difference was not statistically significant (p=0.13).  This lack of 
Figure 6.5.  Systemic haemodynamic values 
of heart rate (HR), mean arterial pressure 
(MAP), cardiac output (CO), nutrient cardiac 
output (NCO), stroke volume (SV) and 
systemic vascular conductance (SVC) 
measured in groups of pigs receiving either 
vehicle (n=6) or S19014 (n=6).  The 
measurements were made sequentially at 
baseline (Bas) and 15-min following 
infusions of vehicle (four times each 5 ml, 
i.v., V5) or S19014 (1, 3, 10 and 30 µg.kg-1, 
i.v. as indicated by S1, S3, S10 and S30, 
respectively).  All values are expressed as 
mean±s.e.mean.  *, P<0.05 vs. baseline;  
#, P<0.05 vs. the corresponding response 
with S19014 in control animals (none were 
significant). 
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significance may be explained by the large variability of contraction to sumatriptan 
(Emax: 3-77% of contraction to K+), which is in accordance with our previous findings (28).  
The pEC50 values for S19014 (5.55±0.24) and sumatriptan (5.99±0.14 respectively) were 
similar.  The Emax of S19014 and sumatriptan did not correlate to the endothelial quality of 
the blood vessel segments as assessed with the relaxation to 1 nM substance P after 
precontraction with 1 µM prostaglandin F2α (Pearson rS: -0.243 and 0.364, respectively, 
p>0.05). 
As depicted in Figure 6.7 (right panel), the contractions to S19014 were not different in 
the presence of U46619 (Emax: 4±1% of the contraction to K+: pEC50 6.55±0.77) compared to 
that in quiescent blood vessel segments (Emax: 3±1%, pEC50: 5.34±0.24).  In contrast, the Emax 
of sumatriptan was significantly augmented in the presence of U46619 (76±22% vs. 33±1% 
of the contraction to K+, p<0.05), while the pEC50 remained unaffected (6.77±0.49 vs. 
6.14±0.23).  In the presence of U46619, the maximal contraction to S19014 was significantly 
lower than that to sumatriptan (p<0.05). 
6.4. Discussion 
It is generally agreed that both α1- and α2-adrenoceptors play an important role in the 
regulation of the vascular resistance and blood pressure (29-33).  Recently, we showed that 
both these receptors mediate canine (external) and porcine (arteriovenous anastomotic) 
carotid vasoconstriction (13, 34, 35).  In this context, several lines of evidence demonstrate 
that vasoconstriction in the carotid vascular bed is predictive for antimigraine activity (2, 3).  
Therefore, the present study was designed to assess the antimigraine potential of the novel 
α-adrenoceptor agonist S19104 in anaesthetised pigs and human isolated coronary artery, as 
previously described (22, 36, 37). 
6.4.1. Systemic haemodynamics 
Other than a moderate initial pressor effect, intravenous administrations of S19014 did not 
cause significant changes in systemic haemodynamics.  This initial pressor effect of S19014 
was short-lasting (~3 min) and, being amenable to blockade by rauwolscine but not prazosin, 
involves α2-adrenoceptors (see Figure 6.1).  Although pressor responses can be elicited via 
both α1- and α2-adrenoceptor subtypes (33), the involvement of α2-adrenoceptors in the 
action of S19014 is in accordance with its higher affinity at α2-adrenoceptor (pKi: 8.33-8.98) 
than at α1-adrenoceptors (pKi: 7.65-7.80) subtypes (Table 6.1).  Further, it may be pointed 
out that in our previous experiments (13) no pressor changes were observed with either 
Figure 6.7.  Human isolated 
coronary artery contractions to 
sumatriptan (circles) and S19014 
(squares), expressed as % of the 
response to 100 mM K+, observed in 
the absence (open symbols) or 
presence of the thromboxane A2 
analogue U46619 (30-100 nM; 
closed symbols).  The two panels 
(left, n=8; right, n=4) present data 
obtained in vessel segments studied 
in parallel.  Data are mean±SEM. 
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phenylephrine (α1-adrenoceptor agonist) or BHT933 (α2-adrenoceptor agonist) in 
anaesthetised pigs.  One of the reasons for this apparent discrepancy may be that in these 
experiments phenylephrine and BHT933 were slowly infused into the carotid artery (13), 
while we injected S19014 i.v. 
6.4.2. Carotid haemodynamics 
As reported previously (13), i.v. administration of vehicle, prazosin (100 µg.kg-1) and 
rauwolscine (300 µg.kg-1) did not produce major carotid haemodynamic changes (Table 6.2).  
On the other hand, S19014 produced a dose-dependent constriction within the porcine carotid 
vasculature, which was confined to arteriovenous anastomoses; the vascular conductance in 
the capillary fraction was increased.  In accordance with the constriction of carotid 
arteriovenous anastomoses (1, 2), S19014 increased A-V SO2 difference.  Both effects of 
S19014 were antagonised by rauwolscine and not at all by prazosin, thus establishing the 
involvement of one or more α2-adrenoceptor subtypes.  As mentioned above, the 
involvement of α2-adrenoceptors in the action of S19014 is in accordance with its higher 
affinity at α2-adrenoceptor (pKi: 8.33-8.98) than at α1-adrenoceptors (pKi: 7.65-7.80) 
subtypes (Table 6.1) and it is possible that S19014 lacks efficacy, being a partial agonist or 
antagonist action at α1-adrenoceptors.  Interestingly, it has been reported that the 
venoconstrictor responses to S19014 are variable in potency and efficacy (18), suggesting 
that the tissue distribution of α-adrenoceptor (most likely α2-adrenoceptor) subtypes at which 
S19014 is efficacious may be uneven. 
6.4.3. Cardiac output and regional haemodynamics 
Acutely acting antimigraine drugs (triptans and ergot alkaloids) have been shown to decrease 
cardiac output and systemic vascular conductance in anaesthetised pigs (38).  In the present 
study with S19014, no changes in cardiac output, systemic vascular conductance and vascular 
conductances in many body organs, including the heart, kidneys, intestines, stomach, 
adrenals, were observed when compared with the vehicle subgroup.  Admittedly, S19014 
produced a decrease in the vascular conductance of the liver, but it is difficult to predict 
whether this decrease in the hepatic blood flow would be important in the clinical setting.  
Interestingly, a transient decrease in hepatic blood flow has also been observed in humans 
after i.v. ergotamine, unlike its prolonged constrictor property on large arteries (39). 
As found in the carotid artery experiments, S19014 decreased the ‘lung’ blood flow and 
vascular conductance.  This is due to constriction of arteriovenous anastomoses, because the 
contribution via the bronchial artery to the ‘lung’ blood flow is rather limited (26, 40).  
Indeed, the nutrient part of cardiac output remained unchanged. 
6.4.4. Human coronary artery contraction 
To further predict the cardiovascular safety of S19014, we decided to analyse its effects on 
the human isolated coronary artery as compared to those to sumatriptan.  Thus, in quiescent 
blood vessel segments, i.e. in the absence of U46619, the coronary artery contraction to 
S19014 and sumatriptan was not significantly different, although contraction to S19014 
tended to be less than that to sumatriptan.  In the presence of U46619, the contraction to 
sumatriptan was significantly augmented, while that to S19014 remained unaffected. 
The pEC50 value of S19014 in the human coronary artery (5.55) was found to be 100 to 
1000-fold lower than its pKi values at either α1- or α2-adrenoceptor subtypes (Table 6.1).  
However, it must be emphasised that agonist pKi values do not necessarily correlate to the 
potency of a compound in inducing a functional response (41).  Secondly, the pEC50 values 
may have been overestimated because the contraction observed at the highest concentration 
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of the agonists was considered as Emax when, in some cases, a plateau had not been reached.  
However, when we calculated the pEC50 values with the curves extrapolated to estimate Emax 
(sumatriptan, 5.65±0.35; S19014, 5.66±0.44), these did not differ significantly from those 
reported in the Results section (5.99±0.14, and 5.55±0.24; p=0.19 and 0.53, respectively, 
paired t-test).  Finally, the fact that the contraction to S19014 was very low in the coronary 
artery may have possibly affected the accuracy of estimation of the pEC50 values.  Although 
further experiments with subtype selective agonists and antagonists might elucidate which 
α-adrenoceptor subtype(s) mediates the S19014-induced contraction of the human coronary 
artery, such experiments would be difficult to interpret because of the small contractions 
elicited by S19014. 
In the present study, the Emax of contraction to S19014 or sumatriptan was not related to 
the endothelial quality of the blood vessel segments.  This suggests that the contraction to 
S19014 and sumatriptan might not solely depend on blood vessel wall characteristics, such as 
the presence of atherosclerosis.  However, our study sample was fairly small (n=8) for such 
an analysis.  Moreover, we only included blood vessel segments without macroscopically 
visible atherosclerotic lesions in our study.  Indeed, we have previously demonstrated in a 
large post-hoc study that the contraction to sumatriptan is larger in human coronary artery 
segments with intact endothelium than in blood vessel segments with functionally impaired 
endothelium (42).  In contrast, it has been reported that constriction to α-adrenoceptor 
agonists is augmented in atherosclerotic human coronary arteries (43). 
6.4.5. Possible clinical implications 
Both in vitro (44, 45) and in vivo (2, 3, 7) experimental models demonstrating cranial 
vasoconstrictor properties have consistently shown their value in predicting therapeutic 
potential of drugs in the acute treatment of migraine.  Therefore, the results obtained with 
S19014 in the present experiments suggest that this compound may well have antimigraine 
properties.  Since S19014 had little systemic and regional haemodynamic effects, this 
compound appears to be well tolerated.  However, as is the case with the currently available 
antimigraine agents (22, 23, 46), we are aware of the potential liability of α-adrenoceptor 
agonists in constricting coronary arteries (47, 48).  Nevertheless, the distribution of cardiac 
output to various body organs, including the heart, was not affected by S19014.  This is 
further reinforced in this study, where S19014 was clearly less effective than sumatriptan in 
contracting the human isolated coronary arteries and, contrary to sumatriptan, its effect was 
not augmented by the thromboxane A2 analogue U46619.  This may be clinically relevant, 
since the plasma concentration of thromboxane A2 increases in patients with myocardial 
infarction and unstable angina (49-51).  Although the augmentation between 5-HT1B receptor 
agonists and thromboxane A2 has been well characterised (28), it is not yet clear whether such a 
mechanism also operates for α-adrenoceptor agonists in the human coronary artery.  However, 
the α2-adrenoceptor-mediated contraction of the porcine isolated ear artery is enhanced by 
U46619 (52).  Thus, the coronary side-effect potential of S19014 may be less than that of 
sumatriptan.  However, considering that S19014 induces constriction of the coronary artery, 
albeit only to a small degree, the compound might remain contraindicated in patients with 
coronary artery disease. 
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 7. Effects of donitriptan on carotid 
haemodynamics and cardiac output 
distribution in anaesthetised pig 
 
7.1. Introduction 
The last decade has seen a tremendous progress in migraine therapy, with sumatriptan, 
belonging to a new class of drugs designated as 5-HT1B/1D/1F receptor agonists, providing the 
lead (1-3).  Several studies have clearly established the therapeutic value of sumatriptan as 
well as of other triptans (4-7).  Pharmacologically, triptans inhibit dural plasma protein 
extravasation, suppress action potentials in trigeminal nucleus caudalis, constrict isolated 
cranial blood vessels and decrease carotid arteriovenous anastomotic blood flow in 
anaesthetised animals (6, 8, 9).  Although the trigeminal neural effects of triptans may be 
involved to some extent in their antimigraine action (7, 10, 11), the efficacy of triptans is 
primarily attributed to cranial vasoconstriction (6, 10).  Using compounds selective at 
5-HT1B, 5-HT1D or 5-HT1F receptors, it is now well established that the vasoconstrictor effect 
of triptans is mediated via 5-HT1B receptors (12-18). 
Despite its success in the treatment of migraine headaches, sumatriptan has several 
shortcomings, such as low bioavailability, headache recurrence and propensity to elicit chest 
symptoms (6).  Several newer triptans display better pharmacokinetic profile, but this has not 
been translated into any substantial improvement in either the efficacy or side-effect potential 
compared to sumatriptan (for reviews, see 6, 7).  Recently, another triptan, donitriptan, 
(F11356 or F12640), has been synthesised by Centre de Recherche, Pierre Fabre, Castres, 
France; Figure 7.1).  Donitriptan displays a very high affinity at recombinant human as well 
as porcine 5-HT1B/1D receptors with little affinity for the 5-HT1F receptor and, more 
importantly, it has uniquely high intrinsic efficacy (inhibition of cAMP accumulation and 
enhancement of [35S]GTPγS binding) at human 5-HT1B/1D receptors (Table 7.1, 19, 20-23).  
John et al. (19, 24) have hypothesised that the relatively low intrinsic activity of the currently 
available triptans at 5-HT1B/1D receptors may explain this ceiling effect in therapeutic 
response and, therefore, donitriptan may show a high therapeutic efficacy. 
In the present study, we report on the effects of donitriptan on the distribution of carotid 
blood flow into nutrient (capillary) and non-nutrient (arteriovenous anastomotic) fractions in 
the anaesthetised pig.  Previous investigations from our laboratory have established that 
F12640: mesylate salt
F11356: hydrochloride salt
Donitriptan
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O NH2N
N
C
O
N
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S
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CH3 N
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Sumatriptan
Figure 7.1.  Chemical structures of 
donitriptan and sumatriptan. 
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Table 7.1.  Affinity and efficacy of donitriptan, sumatriptan and 5-HT at human (h) 
and porcine (p) 5-HT receptors. 
Receptors Donitriptana Sumatriptanb 5-HTb 
Ligand binding affinity (pKi) 
h5-HT1A 7.6 6.0 7.9 
h5-HT1B 
p5-HT1B 
9.4-10.1 
9.0c 
7.4 
7.3d 
8.0 
7.8e 
h5-HT1D 
p5-HT1D 
9.3-10.2 
9.7c 
8.3 
8.1d 
8.4 
8.4e 
h5-ht1E 5.9 5.7 8.2 
h5-ht1F 
p5-ht1F 
5.5 
5.5g 
7.6 
5.4g 
8.0 
7.8g 
h5-HT2A 6.7 <5.0 6.5 
h5-ht6 5.6 <5.5 7.2 
h5-HT7 6.4 6.0 8.1 
Inhibition of forskolin-evoked cAMP accumulation (pEC50) 
h5-HT1B 8.91 7.16f 7.81a 
h5-HT1D 9.57 8.79f 8.62a 
Enhancement of [35S]GTPγS binding (pEC50) 
h5-HT1B 8.74 6.63f 7.04a 
h5-HT1D 9.08 7.75f 7.84a 
pKi, Negative logarithm of the dissociation equilibrium constant; pEC50, negative logarithm 
of the molar concentration that elicits 50% of its maximum effect. a, John et al. (19); 
b, IUPHAR Compendium (20); c, Pauwels et al., Unpublished; d, Bhalla et al. (21); e, Bhalla 
et al. (22); f, Pauwels et al. (23); g, Bhalla et al., Unpublished. 
 
constriction of carotid arteriovenous anastomoses in the anaesthetised pig serves as a 
predictive model for the antimigraine efficacy of 5-HT-based drugs (10, 25).  Moreover, to 
establish the cardiovascular safety, we studied the effects of donitriptan on cardiac output and 
its regional distribution to vital organs. 
 
7.2. Materials and methods 
7.2.1. General 
After an overnight fast, 36 pigs (Yorkshire x Landrace; 10-15 kg) were anaesthetised with 
azaperone (140 mg, i.m.), midazolam hydrochloride (7.5 mg, i.m.) and pentobarbitone 
sodium (600 mg, i.v.).  The animals were intubated and connected to a respirator (BEAR 2E, 
BeMeds AG, Baar, Switzerland) for intermittent positive pressure ventilation with a mixture 
of room air and oxygen.  Respiratory rate, tidal volume and oxygen supply were adjusted to 
keep arterial blood gas values within physiological limits (pH: 7.35-7.48; 
pCO2: 35-48 mmHg; pO2: 100-120 mmHg).  Anaesthesia was maintained with a continuous 
i.v. infusion of pentobarbitone sodium at 12-20 mg.kg-1.h-1.  It may be noted that with this 
anaesthetic regimen, arteriovenous anastomotic blood flow is considerably higher than that in 
pigs in a conscious state or under thiopentone anaesthesia (26), thereby producing one of the 
putative features of migraine, i.e. dilatation of carotid arteriovenous anastomoses (25, 27). 
Heart rate was measured with a tachograph (CRW, Erasmus University, Rotterdam, The 
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Netherlands) triggered by electrocardiographic signals.  Catheters were placed in the inferior 
vena cava via the left femoral vein for the administration of drugs and fluids, and in the aortic 
arch via the left femoral artery for the measurement of arterial blood pressure (Combitrans 
disposable pressure transducer; Braun, Melsungen, Germany) and the withdrawal of arterial 
blood for determining blood gases (ABL-510, Radiometer, Copenhagen, Denmark).  Body 
temperature was kept at about 37ºC and the animals were continuously infused with saline to 
compensate for fluid losses during the experiment. 
In the case of the carotid artery experiments, both common carotid arteries, external 
jugular veins and vagosympathetic trunks were identified.  The vagosympathetic trunks were 
cut between two ligatures in order to avoid reflex-mediated cardiovascular changes.  
Subsequently, the right common carotid artery was dissected free and a needle was inserted 
against the direction of blood flow for the administration and uniform mixing of radioactive 
microspheres.  Another catheter was placed in the right external jugular vein for the 
withdrawal of venous blood samples.  Blood flow was measured in the right common carotid 
artery with a flow probe (internal diameter: 2.5 mm) connected to a sine-wave 
electromagnetic flow meter (Transflow 601-system, Skalar, Delft, The Netherlands). 
In the case of the cardiac output experiments, a 6F Swan-Ganz thermodilution catheter 
(Braun Melsungen AG, Melsungen, Germany) was introduced into the pulmonary artery via 
the right femoral vein to measure cardiac output.  Another catheter, connected to a pressure 
transducer (Combitrans disposable pressure transducer; Braun, Melsungen, Germany), was 
guided through the left carotid artery into the left ventricle for the injection of radioactive 
microspheres.  The presence of the tip of the catheter in the left ventricle was confirmed by 
the observation of the sudden switch from an arterial to a ventricular pressure profile.  Lastly, 
a catheter was placed into the right femoral artery and connected to a Harvard pump for the 
withdrawal of reference blood samples during the injection of radioactive microspheres. 
Heart rate, systolic, diastolic and mean arterial blood pressure as well as carotid blood 
flow were continuously monitored on a polygraph (CRW, Erasmus University, Rotterdam, 
The Netherlands).  Vascular conductance was calculated by dividing blood flow or cardiac 
output (ml.min-1) by mean arterial blood pressure (mmHg), multiplied by hundred and 
expressed as 10-2 ml.min-1.mmHg-1.  Stroke volume (cardiac output dividing by heart rate) 
and nutrient cardiac output (cardiac output minus lung blood flow, i.e. mainly total 
arteriovenous shunting) were calculated. 
7.2.2. Distribution of carotid blood flow  
The distribution of common carotid blood flow was determined with 15.5±0.1 (S.D.) µm 
diameter microspheres labelled with 141Ce, 113Sn, 103Ru, 95Nb or 46Sc (NEN Dupont, Boston, 
USA).  For each measurement, a suspension of about 200,000 microspheres, labelled with 
one of the isotopes, was mixed and injected into the carotid artery.  At the end of the 
experiment, the animal was killed, using an overdose of pentobarbital, and the heart, kidneys, 
lungs and the different cranial tissues were dissected out, weighed and put in vials.  The 
radioactivity in these vials was counted for 5 min in a γ-scintillation counter (Minaxi 
autogamma 5000; Packard Instruments, Downers Grove, IL, USA), using suitable windows 
for discriminating the different isotopes (141Ce: 120-167, KeV, 113Sn: 355-435 KeV, 
103Ru: 450-548 KeV, 95Nb: 706-829 KeV and 46Sc: 830-965 KeV).  All data were processed 
by a set of specially designed programs (28), using a personal computer. 
The fraction of carotid blood flow distributed to different tissues was calculated by 
multiplying the ratio of tissue and total radioactivities by the total common carotid blood flow 
at the time of the injection of microspheres.  Since little or no radioactivity is detected in the 
heart or kidneys, all microspheres trapped in lungs reach lungs from the venous side after 
escaping via carotid arteriovenous anastomoses.  Therefore, the amount of radioactivity in the 
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lungs can be used as an index of the arteriovenous anastomotic fraction of carotid blood flow 
(28, 29). 
7.2.3. Distribution of cardiac output  
The distribution of cardiac output was also determined with radioactive microspheres (see 
above).  For each measurement, about 1,000,000 microspheres, labelled with one of the 
isotopes, were injected into the left ventricle.  Starting 15 s before microsphere injection and 
lasting 70 s, a reference arterial blood sample was drawn at the rate of 6 ml.min-1.  Blood loss 
during this procedure was compensated by infusing the corresponding volume of haemaccel.  
At the end of the experiments, the animals were killed as described above and a number of 
tissues (lungs, kidneys, heart, stomach, small intestine, spleen, liver, adrenals, brain, skin and 
skeletal muscles) were dissected out, weighed, put into vials for counting radioactivity (see 
above).  As described by Saxena et al. (28), tissue blood flow was calculated by multiplying 
the ratio of tissue and reference blood sample radioactivity by the blood withdrawal rate 
(6 ml.min-1).  Radioactivity in the lungs mainly represents peripheral arteriovenous 
anastomotic blood flow (non-nutrient part of the cardiac output), although a small part 
(1-1.5% of cardiac output) is derived from the bronchial arteries (30). 
7.2.4. Experimental protocol 
After a stabilisation period of about 1 h, the animals were divided into two groups (n=18 
each) used for either carotid blood flow or cardiac output experiments.  The two experimental 
groups, where an identical experimental protocol was followed, were subdivided into three 
subgroups (n=6 each).  The first and second subgroups received physiological saline, whereas 
the third subgroup was pretreated with 0.5 mg.kg-1 of the 5-HT1B/1D receptor antagonist 
GR127935 (31-33); both were given intravenously over a period of 10 min at a rate of 
0.5 ml.min-1.  Ten min after the end of these infusions, baseline values of heart rate, mean 
arterial blood pressure, carotid blood flow or cardiac output and their distributions, as well as 
arterial and jugular venous blood gases were measured.  Then, the first group received four 
consecutive infusions of vehicle (5 ml of distilled water, containing 40% polyethylene 
glycol, v.v-1), whereas the second and third groups received consecutive doses of donitriptan 
(0.16, 2.5, 40 and 100 µg.kg-1).  Both vehicle and donitriptan were administered 
intravenously over a period of 10 min at a rate of 0.5 ml.min-1, given every 20 min.  Ten min 
after the end of each infused dose of vehicle or donitriptan, all haemodynamic variables were 
again collated. 
The Ethics Committee of the Erasmus University Rotterdam dealing with the use of 
animals in scientific experiments approved the protocol for this investigation. 
7.2.5. Data presentation and statistical analysis 
All data have been expressed as the mean±SE mean.  The significance of changes within one 
group was evaluated with Duncan's new multiple range test, once an analysis of variance 
(randomised block design) had revealed that the samples represented different populations 
(34).  The percent changes from baseline values caused by donitriptan in the GR127935 
pretreated group were compared to those with the corresponding doses of donitriptan in the 
saline-pretreated group by using Student's unpaired t-test.  Statistical significance was 
accepted at P<0.05 (two-tailed). 
In the saline pretreated group, the dose of donitriptan needed to decrease baseline 
values of carotid arteriovenous anastomotic blood flow or vascular conductance by 50% 
(ED50%) was calculated using linear regression analysis. 
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Table 7.2.  Values of heart rate (HR), mean arterial blood pressure (MAP) and arterio-jugular 
venous oxygen saturation difference (A-V SO2) at baseline and after 10 min intravenous 
infusions (0.5 ml.min-1) of either donitriptan or the corresponding volumes of vehicle (n=6).  The 
effects of donitriptan were analysed in animals pretreated with saline (n=6) or the 5-HT1B/1D 
receptor antagonist GR127935 (0.5 mg.kg-1; n=6). 
Pretreatment  HR 
(beats.min-1) 
MAP (mmHg) A-V SO2 (%) 
Vehicle (ml) 
Baseline 92±5 93±4 8±4 
5 91±6 87±4 9±3 
5 90±6 84±5* 10±4 
5 89±5 84±6* 10±4 
Saline 
5 89±5 89±6 10±5 
Donitriptan (µg.kg-1) 
Baseline 100±3 98±3 6±2 
0.16 99±3 98±3 6±1 
2.5 99±3 98±5 8±2 
40 99±3 93±6 17±4* 
Saline 
100 99±4 88±7 18±3* 
Donitriptan (µg.kg-1) 
Baseline 103±1 96±3 6±3 
0.16 103±2 97±5 6±3 
2.5 103±2 97±4 7±3 
40 103±2 92±4 10±3* 
GR127935 
100 104±1 88±3* 13±4* 
All values have been presented as the mean±SE mean.  *, P<0.05 vs baseline. 
7.2.6. Drugs 
Apart from the anaesthetics, azaperone (Janssen Pharmaceutica, Beerse, Belgium), 
midazolam hydrochloride (Hoffmann La Roche b.v., Mijdrecht, The Netherlands) and 
pentobarbitone sodium (Apharma, Arnhem, The Netherlands), the compounds used in this 
study were: donitriptan (4-[4-[2-[3-(2-aminoethyl)-1H-indol-5-yloxy]-acetyl]-piperazin-1-
yl] benzonitrile mesylate; F12640) and GR127935 (N-[methoxy-3-(4-methyl-1-piperazinyl) 
phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl) [1,1-biphenyl]-4-carboxamide hydro-
chloride; both from Centre de Recherche Pierre Fabre, Castres, France), haemaccel® (Hoechst 
Marion Roussel b.v., Hoevelaken, The Netherlands) and heparin sodium (Leo Pharmaceutical 
Products, Weesp, The Netherlands) for preventing clotting of the catheters.  Donitriptan was 
dissolved in distilled water, containing 40% polyethylene glycol (v.v-1).   
7.3. Results 
7.3.1. Carotid blood flow experiments 
7.3.1.1. Systemic haemodynamics and arterio-jugular venous oxygen saturation difference 
As shown in Table 7.2, donitriptan as well as its vehicle did not change heart rate.  There was 
a slight decrease in mean arterial blood pressure after second and third infusions of vehicle.  
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Figure 7.2.  Values of total carotid, 
arteriovenous anastomotic (AVA) and 
nutrient blood flow (left panels) and 
conductance (right panels) at baseline and 
after 10 min intravenous infusions 
(0.5 ml.min-1) of either donitriptan (0.16, 
2.5, 40 and 100 µg.kg-1) or the 
corresponding volumes of vehicle (5 ml; 
n=6).  The effects of donitriptan were 
analysed in animals pretreated with either 
saline (n=6) or GR127935 (0.5 mg.kg-1; 
n=6).  All values are presented as the 
mean±SE mean.  *, P<0.05 vs baseline.  
+, P<0.05 vs response (% change from 
baseline) by corresponding dose of 
donitriptan in animals pretreated with 
saline. 
In the saline pretreated group donitriptan did not change mean arterial blood pressure, but 
there was a moderate hypotensive response (-7.4±1.9%) following the highest dose of the 
drug in the GR127935 pretreated animals.  Donitriptan produced a dose-dependent increase 
in arterio-jugular venous oxygen saturation difference in both saline and GR127935 
pretreated animals; vehicle was devoid of this effect. 
7.3.1.2. Carotid haemodynamics 
As shown in Figures 7.2 (absolute values) and 7.3 (percent changes from baseline), except for 
an increase in total carotid vascular conductance after the third infusion and a decrease in 
arteriovenous anastomotic conductance after the last infusion, the vehicle did not produce any 
changes in carotid haemodynamics.  On the other hand, donitriptan dose-dependently 
decreased total carotid and arteriovenous anastomotic blood flow and concomitant 
Figure 7.3.  Percent changes from baseline 
values in total carotid, arteriovenous 
anastomotic (AVA) and nutrient blood flow 
(upper panels) and conductance (lower 
panels) after 10 min intravenous infusions 
(0.5 ml.min-1) of either donitriptan (0.16, 
2.5, 40 and 100 µg.kg-1) or the correspon-
ding volumes of vehicle (5 ml; n=6).  The 
effects of donitriptan were analysed in 
animals pretreated with either saline (n=6) 
or GR127935 (0.5 mg.kg-1; n=6).  All 
values are presented as the mean± 
SE mean.  *, P<0.05 vs baseline.  +, P<0.05 
vs response (% change from baseline) by 
corresponding dose of donitriptan in 
animals pretreated with saline. 
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conductances; nutrient blood flow and conductance increased.  The dose of donitriptan that 
was needed to decrease baseline values of arteriovenous anastomotic blood flow and 
conductance by 50% (ED50%) was found to be 58±27 µg.kg-1 (113±52 nmol.kg-1) and 47±16 
µg.kg-1 (92±31 nmol.kg-1), respectively. 
The maximum changes observed in total carotid, arteriovenous anastomotic and 
nutrient vascular conductances with the highest dose of donitriptan were -25±3%, -63±3% 
and +87±21%, respectively.  After treatment with GR127935, donitriptan-induced decreases 
in the total carotid and arteriovenous anastomotic blood flows and vascular conductances 
were significantly less; the maximum decreases in total carotid and arteriovenous 
anastomotic vascular conductances were -12±2% and -35±5%, respectively (see Figures 7.2 
and 7.3).  Compared to saline-treated animals, GR127935 appeared to reduce 
donitriptan-induced increases in nutrient blood flow and vascular conductance, but statistical 
significance (based on percentage changes from the baseline in the two groups) was achieved 
only in the case of blood flow increase observed with 40 µg.kg-1 of donitriptan. 
The distribution of carotid blood flow to the head tissues in the three groups of animals 
is shown in Figure 7.4.  Donitriptan produced significant increases in vascular conductance to 
the skin, ear, skeletal muscle, tongue, bone, fat, salivary gland, dura mater and brain; no 
change was observed in the eyes.  In animals treated with GR127935, these increases were 
attenuated, but statistical significance (based on percentage changes from the baseline in the 
two groups) was reached only in skeletal muscle and fat.  The corresponding volumes of the 
vehicle did not produce changes in vascular conductance values. 
Figure 7.4.  Values of carotid vascular 
conductance in different cranial tissues 
at baseline and after 10 min 
intravenous infusions (0.5 ml.min-1) of 
either donitriptan (0.16, 2.5, 40 and 
100 µg.kg-1) or the corresponding 
volumes of vehicle (5 ml; n=6).  The 
effects of donitriptan were analysed in 
animals pretreated with either saline 
(n=6) or GR127935 (0.5 mg.kg-1; n=6). 
All values are presented as the mean± 
SE mean.  *, P<0.05 vs baseline.  
+, P<0.05 vs response (% change from 
baseline) by corresponding dose of 
donitriptan in animals pretreated with 
saline. 
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7.3.2. Cardiac output experiments 
7.3.2.1. Systemic haemodynamics 
The effects of vehicle and donitriptan on systemic haemodynamic variables are presented in 
Figure 7.5.  No changes were observed with vehicle.  In animals pretreated with saline, 
donitriptan did not change heart rate, mean arterial blood pressure, nutrient cardiac output or 
systemic vascular conductance, but it moderately decreased cardiac output (maximum 
change: -10±6%) and stroke volume (maximum change: -12±6%).  These changes in cardiac 
output and stroke volume were absent in animals pretreated with GR127935, where 
donitriptan did decrease blood pressure by up to 18±3%. 
7.3.2.2. Regional haemodynamics 
Apart from a slight decrease in skeletal muscle vascular conductance, vehicle did not change 
tissue vascular conductances (Table 7.3).  Donitriptan decreased vascular conductance in 
lungs (maximum change: -75±6%), which was significantly less in GR127935 pretreated 
animals (maximum change: -32±13%).  Whereas no changes were observed in vascular 
conductances in the kidneys, heart and portal tissues (liver, spleen, stomach, adrenals and 
small intestines), donitriptan slightly increased brain, skin and skeletal muscle vascular 
conductances. 
7.4. Discussion 
John et al. (19, 24) have reported that donitriptan equals 5-HT in potency and efficacy in 
contracting rabbit isolated saphenous vein and in increasing outward K+-current in guinea-pig 
trigeminal ganglion cells.  Donitriptan also decreases carotid blood flow in anaesthetised pigs 
and conscious dogs.  In both in vitro and in vivo experiments, the responses to donitriptan can 
be antagonised by GR127935 and, thus, donitriptan shows a high affinity as well as efficacy 
at 5-HT1B/1D receptors (Table 7.1). 
Figure 7.5.  Systemic haemodynamic values 
of heart rate (HR), mean arterial blood 
pressure (MAP), cardiac output (CO), 
nutrient cardiac output (NCO), stroke volume 
(SV) and systemic vascular conductance 
(SVC) at baseline and after 10 min 
intravenous infusions (0.5 ml.min-1) of either 
donitriptan (0.16, 2.5, 40 and 100 µg.kg-1) or 
the corresponding volumes of vehicle (5 ml; 
n=6).  The effects of donitriptan were 
analysed in animals pretreated with either 
saline (n=6) or GR127935 (0.5 mg.kg-1; 
n=6).  All values are presented as the mean± 
SE mean.  *, P<0.05 vs baseline; +, P<0.05 vs 
response (% change from baseline) by 
corresponding dose of donitriptan in animals 
pretreated with saline. 
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7.4.1. Heart rate and blood pressure 
In contrast to the clinical experience (for references, see 6), sumatriptan as well as other 
triptans exert small bradycardic and hypotensive responses in anaesthetised pigs (17, 35).  
Donitriptan was devoid of these systemic effects in saline-treated animals.  The exact reason 
for the difference between donitriptan and other triptans is not clear.  However, this 
difference may be partly related to the slightly higher affinity of donitriptan at the 5-HT2A 
receptor (Table 7.1), which, by virtue of its capacity to mediate hypertension, could annul a 
potential hypotensive effect of donitriptan.  This view seems to be supported by the 
appearance of hypotension with donitriptan in animals treated with GR127935 (see Table 7.2; 
Figure 7.5), which can moderately attenuate 5-HT2A receptor-mediated hypertension in rats 
(33). 
7.4.2. Carotid haemodynamics 
In agreement with earlier findings (19, 24), donitriptan dose-dependently decreased total 
porcine carotid blood flow and conductance in the present experiments.  In addition, we 
observed that this vasoconstrictor effect of donitriptan, as is the case with other triptans, 
including sumatriptan, avitriptan and eletriptan (see 36), was exclusively confined to cephalic 
Table 7.3.  Effects of 10 min intravenous infusions (0.5 ml.min-1) of either donitriptan or the 
corresponding volumes of vehicle (n=6) on regional vascular conductance in anaesthetised pigs.  
The effects of donitriptan were analysed in animals pretreated with either saline (n=6) or the 
5-HT1B/1D receptor antagonist GR127935  (0.5 mg.kg-1; n=6). 
Vascular Conductance (10-2 ml.min-1.mmHg-1.100 g-1) Pretreat-
ment 
 
Lungs Kidneys Heart Portal Brain Skin Muscles 
Vehicle (ml)       
Baseline 236±72 234±18 98±12 44±3 34±4 15±4 4±1 
5 202±50 223±20 94±15 41±3 31±6 12±4 3±1 
5 201±45 248±17 98±18 45±3 35±6 15±5 4±1 
5 218±61 254±15 107±18 47±4 38±5 16±4 4±1 
Saline 
5 173±39 215±21 93±13 43±4 33±4 12±3 3±0* 
Donitriptan (µg.kg-1)      
Baseline 175±31 231±13 100±8 52±4 31±3 12±3 3±0 
0.16 176±28 247±4.2 111±8 56±5 35±2 11±3 4±0* 
2.5 108±18* 225±12 111±10 49±5 36±1* 12±3 3±0 
40 46±7* 241±11 112±9 57±5 41±2* 17±3* 4±0* 
Saline  
100 39±5* 223±5 112±12 57±4 40±2* 18±4* 3±0 
Donitriptan (µg.kg-1)      
Baseline 161±29 266±30 117±17 40±4 30±2 25±5 3±0 
0.16 149±34 278±29 115±8 44±5 35±2* 26±7 4±0 
2.5 137±38 268±21 106±6 46±5* 38±2* 25±6 4±0* 
40 131±34+ 265±23 105±7 48±5* 42±3* 27±6 4±0* 
GR127935  
100 101±22*+ 233±23* 106±5 46±5* 39±2* 27±5 4±0* 
All values have been presented as the mean±SE mean.  *, P<0.05 vs baseline. +, P<0.05 vs response by 
corresponding dose of donitriptan in animals pretreated with saline. 
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arteriovenous anastomoses; the total nutrient fraction distributed to the head tissues increased. 
In this respect donitriptan exhibited the highest potency amongst several triptans that we have 
examined in this porcine model; the mean±SE mean ED50% (nmol.kg-1) of donitriptan in 
decreasing arteriovenous anastomotic vascular conductance (92±31) was lower than that of 
avitriptan (150±37), sumatriptan (156±54), eletriptan (400±91) or GMC2021 (2317±734) 
(36).  The increase in the arterio-jugular venous oxygen saturation difference with donitriptan 
confirmed its constriction action on arteriovenous anastomoses. 
It is now well recognised that the vasoconstrictor effect of triptans is mediated via 
5-HT1B receptors (12, 13, 15-18).  Accordingly, in the present experiments, GR127935 
(0.5 mg.kg-1) antagonised the constriction of cephalic arteriovenous anastomoses elicited by 
donitriptan.  However, unlike sumatriptan, but as observed with some other triptans, for 
example eletriptan and GMC2021 (36), this dose of GR127935 did not completely abolish 
the donitriptan-induced arteriovenous constriction, suggesting the involvement of another, yet 
uncharacterised, receptor to some extent.  Indeed, this is also the case for the arteriovenous 
anastomotic constriction elicited by ergotamine, dihydroergotamine and 5-HT (36, 37).  On 
the other hand, it is possible that higher doses of GR127935 may be needed for a complete 
blockade of the effects of donitriptan.  Unfortunately, the partial agonist property of 
GR127935 precludes the use of much higher doses of this antagonist in our experiments (33). 
Similar to other 5-HT1B/1D agonists, donitriptan produced a dilatation of carotid 
arterioles (nutrient vascular bed) and, as a result, blood flow and vascular conductance in 
many cranial tissues increased (see Figure 7.4).  In view of the partial antagonism by 
GR127935, this dilatation seems to be at least partly due to the activation of the 5-HT1B 
receptor, probably mediating endothelium-dependent relaxation in different vascular 
preparations.  Indeed, the 5-HT1B receptor has been located on vascular endothelium (12) and 
there is some evidence 5-HT1B/D receptors may mediate endothelium-dependent 
vasodilatation (38-40).  Alternatively or in addition, it may be due to an indirect consequence 
of the closure of arteriovenous anastomoses. 
7.4.3. Cardiac output and regional haemodynamics 
In previous studies in anaesthetised pigs, it has been shown that sumatriptan reduces total 
cardiac output and systemic vascular conductance, including decreases in vascular 
conductances in the kidneys and spleen (41).  A decrease in renal vascular conductance by 
sumatriptan has also been reported in anaesthetised dogs (42).  In our study, no decrease in 
blood flows to or vascular conductances in vital organs (brain, heart, kidneys and portal 
tissues) were observed with donitriptan; in fact there was a small increase in vascular 
conductance in the skin, skeletal muscle and brain.  Donitriptan was also devoid of any effect 
on the total systemic vascular conductance, but cardiac output decreased.  However, as was 
the case with carotid blood flow, the decrease in cardiac output was also entirely in the 
non-nutrient part, i.e. lung blood flow, which mainly reflects peripheral arteriovenous 
shunting (29).  Indeed, the nutrient fraction of cardiac output (blood distributed to peripheral 
tissues) remained unchanged (Figure 7.5). 
7.4.4. Therapeutic implications 
Our study shows that donitriptan selectively constricts porcine carotid arteriovenous 
anastomoses, with a higher potency compared to several other triptans.  Since constriction of 
cephalic arteriovenous anastomoses is of high predictive value for antimigraine activity (6), 
donitriptan should be effective in the treatment of migraine.  The drug does not decrease 
blood flows to vital organs, including the heart, brain and kidneys; sumatriptan can decrease 
renal blood flow in dogs (42).   Lastly, it may be mentioned here that donitriptan has little 
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affinity at the 5-HT1F receptor, which, in view of the effects of the 5-HT1F receptor agonist 
LY334370 (43, 44), may be responsible for side-effects, such as somnolence, asthenia, 
numbness and paresthesia. 
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8. General discussion 
 
8.1. Newer agents in migraine treatment 
8.1.1. 5-HT1B/1D receptors 
It has previously been demonstrated that 5-HT is able to induce a vasoconstriction within the 
external carotid vascular bed of the dog (1, 2).  Similarly, 5-HT constricts the porcine carotid 
vasculature (3).  The decrease in the carotid blood flow is exclusively confined to the 
arteriovenous anastomotic fraction (4-6).  This 5-HT-induced cranial vasoconstriction has 
been demonstrated to be mediated primarily by sumatriptan-sensitive 5-HT1 like receptors (1, 
7-9).  Due to development of 5-HT1B/1D receptor antagonists, particularly GR127935 (10-12), 
5-HT1 like receptors showed pharmacological resemblance to 5-HT1B/1D receptors.  The 
launch of the first 5-HT1B/1D-receptor agonist sumatriptan (13) has been hailed as the most 
significant advance in the acute treatment of migraine.  The precise mechanisms by which it 
alleviates migraine are still not fully elucidated, but three distinct pharmacological actions on 
the vasculature and neurones have been invoked viz. vasoconstriction of cranial blood vessels 
(13-15), inhibition of neurogenic inflammation due to reduced vasodilator neuropeptide 
release from the sensory trigeminal sensory neurones (16, 17) and/or inhibition of firing of 
trigeminal neurones (18).  Major limitations associated with sumatriptan include low oral 
bioavailability (19), low responders after 2 hours post drug administration and headache 
recurrence within 48 hours (20) and cardiovascular side effects (21-23).  The room for 
improvement over the clinical effectiveness of sumatriptan is therefore substantial.  Thus, 
newer triptans (tryptamine derivatives) though having improved oral bioavailability (19), 
have not superseded sumatriptan in terms of therapeutic effectiveness (19).  Hence, 
donitriptan (F11356; F12650) has been developed (24, 25) as a selective 5-HT1B/1D agonist 
with some higher intrinsic activity in comparison to the well described tryptamine 
derivatives, naratriptan, zolmitriptan and sumatriptan (26).   
As described in Chapter 7, donitriptan is a new triptan that possesses a uniquely high 
affinity as well as efficacy at 5-HT1B/1D receptors.  We investigated the effects of donitriptan 
on carotid haemodynamics and complete distribution of cardiac output in anaesthetised pigs 
(27).  Donitriptan dose-dependently decreased total carotid blood flow and vascular 
conductance.  This effect was entirely due to a selective reduction in the cephalic 
arteriovenous anastomotic fraction.  Donitriptan did not decrease vascular conductances or 
blood flows to a number of organs, including the heart and kidneys; in fact vascular 
conductances in the skin, brain and skeletal muscles increased.  Cardiac output was slightly 
decreased by donitriptan, but this effect was also confined to the non-nutrient part (peripheral 
arteriovenous anastomoses).  The 5-HT1B/1D receptor antagonist GR127935 substantially 
reduced the haemodynamic effects of donitriptan.  These results show that donitriptan 
selectively constricts arteriovenous anastomoses via 5-HT1B receptor activation (27).  
Additionally, in vitro studies on human coronary arteries demonstrated a similar coronary 
side-effect profile as sumatriptan.  It was, therefore, thought to explore novel receptor areas 
for migraine treatment apart from 5-HT receptors. 
8.1.2. α-Adrenoceptors 
Role of α-adrenoceptors in migraine has seldom been explored despite the fact that 
therapeutic efficacy of ergot alkaloids in moderate to severe migraine is due to their 5-HT 
and α-adrenergic agonistic activity (28).  Some initial reports suggest a deranged central 
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noradrenergic activity in migraine as evidenced by disinhibition of the hypothalamopituitary-
adrenal axis (29).  Interestingly, a lack of hormonal response to clonidine in menstrual 
migraine may suggest a postsynaptic α2-adrenoreceptor hyposensitivity during the 
premenstrual period, which demonstrates a transient vulnerability of the 
neuroendocrine/neurovegetative systems (30).  However, he question remains open, whether 
additional receptors and/or mechanisms play a role in antimigraine effects.  It is suggested 
that sensitisation of blood vessels, reinforced by a direct vasoconstriction through activation 
of smooth muscle α-adrenoceptors, may contribute to the mechanism of action of clonidine 
and methysergide in migraine (31).  Additionally, the inhibitory effect of clonidine in 
neurosympathetic transmission (32) might also explain the efficacy of the drug in the 
treatment of migraine.  Many clinical studies have been done to elucidate possible role of 
α-adrenoceptors in migraine.  For this reason recently, it has been shown that both α1- and 
α2-adrenoceptors mediate constriction of arteriovenous anastomoses within the carotid 
vascular bed in anaesthetised pigs (33).  Additionally, a role of α1-adrenoceptor subtypes in 
mediating constriction in the carotid circulation of anaesthetised pigs was further explored 
(34).  As mentioned in Chapter 4, α1A- and α1B-adrenoceptors mediate constriction of carotid 
arteriovenous anastomoses in anaesthetised pigs.  This conclusion is based on the findings 
that intracarotid infusions of phenylephrine induced a dose-dependent decrease in total 
carotid and arteriovenous anastomotic conductance, accompanied by a small tachycardia.  
These carotid vascular effects were abolished by L-765,314 (α1B-antagonist), while these 
responses were only attenuated by 5-methylurapidil (α1A-antagonist) as well as BMY 7378 
(α1D-antagonist).  Furthermore, intravenous bolus injections of phenylephrine produced a 
dose-dependent vasopressor response, which was only affected by 5-methylurapidil, while 
the other antagonists were ineffective.  Of the two α1-adrenoceptor subtypes, the 
α1B-adrenoceptor is an interesting target for future antimigraine drugs, especially when 
considering that this receptor, unlike the α1A-adrenoceptor, does not seem to be much 
involved in the constriction of the peripheral blood vessels leading to an increase in blood 
pressure (35).  Interestingly, the hypertensive effect produced by intravenous administration 
of phenylephrine is predominantly mediated via the α1A-, but not α1B-adrenoceptor.   
To further confirm any involvement of α1A-adrenoceptors in migraine, we studied the 
effects of a potent and selective α1A-adrenoceptor agonist, A61603 (N-[5-(4,5-dihydro-
1H-imidazol-2yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl] methane sulphonamide) (36, 
37), on regional carotid blood flow in anaesthetised pigs (Chapter 5).  The response to 
A61603 was characterised by using selective α-adrenoceptor antagonists, 5-methylurapidil 
(α1A), prazosin (α1) and a combination of prazosin (α1) and rauwolscine (α2).  Similarly, the 
effects of GR127935 (N-[4-methoxy-3-(4-methyl-1-piperazinyl) phenyl]-2'-methyl-4' 
(5-HT1B/1D), ketanserin (5-HT2, α1) and methiothepin (5-HT1/2), in doses sufficient to block 
their respective receptors  were also investigated.  It is known that a relatively high dose of 
methiothepin is required to abolish sumatriptan-induced carotid vasoconstriction in 
anaesthetised dogs and pigs (7, 38), while a lower dose is ineffective.  In our study too, a 
higher dose of methiothepin markedly attenuated the A61603-induced vasoconstriction in the 
porcine carotid vascular bed.  Since all currently known vasoconstrictor receptors/ 
mechanisms (α1/2-adrenoceptors, 5-HT1B/1D, 5-HT2 and eicosanoid receptors) had already 
been excluded in this study (Chapter 5), it points to some novel receptor mechanisms being 
involved in the mediation of constriction of carotid arteriovenous anastomoses.  Because this 
in vivo porcine model is predictive for antimigraine activity (39), the above-mentioned novel 
mechanism could be a potential target for the development of antimigraine agents in the 
future.  Admittedly, as an antimigraine drug, such an agonist must be devoid of systemic 
vasoconstrictor properties leading to an increase in arterial blood pressure. 
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Further, we explored another α-adrenoceptor agonist compound, S19014, for its 
antimigraine potential.  As described in Chapter 6, S19014 causes a dose-dependent 
vasoconstriction in the carotid vasculature of anaesthetised pigs, an effect exclusively caused 
by vasoconstriction of carotid arteriovenous anastomoses; the vascular conductance in the 
capillary fraction was increased.  In accordance with the constriction of carotid arteriovenous 
anastomoses (39, 40), S19014 produces an increase in arteriovenous oxygen saturation 
difference.  Although S19014 has only a little less affinity at the three α1-adrenoceptor 
subtypes than at the three α2-adrenoceptor subtypes, the constriction of carotid arteriovenous 
anastomoses by S19014 was antagonised by rauwolscine and not at all by prazosin.  This 
shows a possible involvement of α2-adrenoceptors in S19014 mediated effects.  Additionally, 
the vasoconstrictor responses to S19014 are variable in potency and efficacy (41), and this 
suggests that α-adrenoceptor subtypes at which S19014 is efficacious may be unevenly 
distributed. 
In this connection, it is interesting to compare the efficacy of S19014 with that of 
triptans and ergot alkaloids in the present porcine model.  As can be observed in Figure 8.1 
(42), S19014 (30 µg.kg-1) and sumatriptan (30 µg.kg-1) were equi-effective in constricting 
porcine carotid arteriovenous anastomoses, but we do not know if higher doses of S19014 
will exhibit higher efficacy with relatively little systemic haemodynamic effects.  Our 
experience with this porcine model is largely limited to 5-HT1B receptor agonists and, in view 
of the fact that porcine α-adrenoceptors have not yet been cloned and compared with the 
human receptors, we do not know how the porcine carotid vascular responses mediated via 
α-adrenoceptors would be predictive of antimigraine efficacy in humans.  Nevertheless, it 
will be worthwhile to explore this aspect with S19014, which mainly acts via 
Figure 8.1.  Comparison of the contractile effect of S19014 and some antimigraine drugs on 
carotid arteriovenous anastomoses in anaesthetised pigs. 
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α2-adrenoceptors that are less ubiquitous than α1-adrenoceptors.  It may be pointed out that 
S19014 causes mild hypotension after an initial immediate short lasting vasopressor response 
when given intravenously.  It would be interesting to observe any pressor effect after oral 
doses of S19014 in a clinical set up. 
As with the currently available antimigraine agents (43, 44), we are aware of the 
potential liability of α-adrenoceptor agonists in constricting coronary arteries.  However, 
S19014 was clearly less effective than sumatriptan in contracting human isolated coronary 
arteries and that, contrary to sumatriptan, its effect is not potentiated upon pre-contraction of 
the vessels with thromboxane A2 (Chapter 7).  This is further re-enforced in this study, where 
the distribution of cardiac output to various body organs was not effected by S19014. 
8.1.3. Calcitonin gene related peptide (CGRP) receptors 
Migraine involves dysfunction of brain stem pathways that normally modulate sensory input.  
Involvement of CGRP in migraine pathology is supported by both clinical and experimental 
evidence.  Release of CGRP and other neuropeptides from trigeminal nerves is thought to 
mediate neurogenic inflammation within the meninges that contributes to generation of the 
severe cerebral pain experienced during migraine attacks.  Although other neuropeptides, 
such as substance P and neurokinin A, are involved in regulation of the cerebral vasculature, 
their role in migraine is not clear.  Concentrations of CGRP in blood obtained from the 
external jugular vein are elevated in patients during all forms of vascular headaches, 
including migraine with and without aura and cluster headaches.  Further evidence for a role 
of CGRP in migraine comes from clinical studies in which sumatriptan was shown to 
decrease elevated CGRP levels in migraine patients, coincident with relief of headache pain 
(45, 46).  In a number of animal studies involving cats and rats (47, 48), CGRP levels have 
also been shown to be elevated in the sagittal sinus following chemical or electrical 
stimulation of the trigeminal ganglion.  Recently, chemical and electrical stimulation of dural 
afferents caused a significant increase in the amount of CGRP, but not substance P, released 
from trigeminal nerves (49).  Based on these data, CGRP is believed to play a central role in 
migraine pathophysiology, due to its ability to regulate cerebral blood flow and mediate 
neurogenic inflammation within the dura.  The key pathways of pain are the 
trigeminovascular input from the meningeal vessels, which passes through the trigeminal 
ganglion and synapses on second order neurons in the trigeminovascular complex.  This in 
turn finally synapses with the neurons in the thalamus.  This trigemino-autonomic reflex is 
present in normal persons (50) and is expressed most strongly in patients with trigeminal-
autonomic cephalgias, including migraine. Peripheral trigeminal activation in migraine is 
evident by the release of CGRP, a vasodilator (51), but the mechanism of generation of pain 
is still not clear.  Studies in animals suggest that pain may be caused by a sterile neurogenic 
inflammatory process in the dura mater (52).  The pain may be a combination of altered 
perception as a result of peripheral or central sensitisation of craniovascular input that is not 
usually painful (50) and the activation of neurovascular vasodilator mechanism that is 
specific for the first division of the trigeminal nerve (53).  To address this issue, we 
attempted to explore the role of BIBN4096BS, a novel CGRP antagonist, in the porcine 
model of migraine.  This hypothesis is based on the findings that increased concentrations of 
CGRP have been observed in migraineurs during the headache phase (54, 55).  Chapter 3 
describes the effect of BIBN4096BS in capsaicin-induced release of CGRP in porcine model 
of migraine.  Intracarotid capsaicin infusion caused an increase in mean blood pressure along 
with dose-dependent increases in total carotid, arteriovenous anastomotic and capillary blood 
flows and carotid pulsations and decreased the difference between arterial and jugular venous 
oxygen saturations (A-V SO2 difference).  BIBN4096BS significantly abolished the carotid 
haemodynamic effects.  Capsaicin infusion (10 µg kg-1 min-1, i.c.) more than doubled jugular 
 Chapter 8: General Discussion 137  
venous plasma concentration of CGRP.  This effect was not blocked, but rather increased by 
BIBN4096BS.  This is an interesting observation, based on which we hypothesise a possible 
prejunctional positive feedback regulatory mechanism of action of BIBN4096BS leading to 
CGRP release as seen with sympathetic neurotransmission involving prejunctional 
α-adrenoceptors. 
To further endorse this view that the vasodilator effects of capsaicin-induced CGRP 
release are responsible for the haemodynamic changes observed in the carotid vasculature, 
we employed intracarotid infusions of human α-CGRP, as described in Chapter 2.  A similar 
dose dependent increase in the carotid blood flow and conductance was observed which were 
blocked by BIBN4096BS.  Since we observed a decrease in the CGRP induced mean blood 
pressure, it can be concluded that CGRP does not play any important role in regulating basal 
vascular tone.  Furthermore, BIBN4096BS did not affect cardiac output, which could be an 
advantage if found effective in the clinical trials on patients of migraine.  In a recent review, 
CGRP receptor antagonist BIBN4096BS has been addressed as one of the exciting lead 
molecules presently in clinical trials for migraine patients (56). 
8.1.4. Other receptors 
Another lead molecule described is ethyl(3S,4aR,6S,8aR)-6-(4-ethoxycar-bonylimidazol-1-
ylmethyl) decahydro-isoquinoline-3-carboxylic ester.  This compound, which is a prodrug of 
a GluR5 kainate receptor antagonist, has been found active in two animal models of acute 
migraine viz. neurogenic dural plasma protein extravasation model and the nucleus caudalis 
c-fos expression model (57).  The validity of this concept was tested with LY293558, a 
non-selective AMPA/Kainate glutamate receptor antagonist, which showed similar efficacy 
to sumatriptan 6 mg in a small placebo-controlled parallel-group study (58). 
An additional avenue that may show promise in antimigraine drug development is 
regulation of Ca2+ levels.  Recently, 5-HT1 receptor activation by sumatriptan was shown to 
couple to a prolonged elevation in intracellular Ca2+ in trigeminal ganglia neurons (46).  This 
increase in Ca2+ is likely responsible for mediating the inhibitory effects of this drug on 
CGRP gene expression.  Although the signaling mechanisms of how elevated Ca2+ levels 
inhibit CGRP synthesis and release from neuronal cells are just beginning to be elucidated, it 
is highly probable that Ca2+-sensitive phosphatases are involved.  Prolonged elevations of 
intracellular Ca2+ have been reported to inhibit neuropeptide expression (59) and the activity 
of membrane-localised voltage-dependent Ca2+ channels through changes in the 
phosphorylation state of the cell.  Furthermore, α-eudesmol, a P/Q-type Ca2+-channel 
blocker, was shown to inhibit neurogenic vasodilation, plasma extravasation in the dura 
mater, and depolarisation-evoked CGRP and SP release from sensory nerves (60). 
8.2. Future prospects in migraine management 
8.2.1. Role of botulinum toxin A 
The mechanism by which botulinum toxin A (BTX-A) acts in migraine is probably unrelated 
to its effect on muscle relaxation.  BTX-A may have a distinct antinociceptive mechanism, 
either through action on the muscle spindles or through a direct effect on the                        
central nervous system.  Several trials and case reports have demonstrated the safety and 
efficacy of BTX-A in migraine headache (61). 
In the first case-report of its use, BTX-A was found effective in aborting migraine 
headache without any recurrence over two months (62), which has been supported in 
other clinical trials (63).  In a recent review, gabapentin, magnesium, lisinopril and botulinum 
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toxin A have been suggested to be effective; however, at present, there are insufficient 
rigorous and reliable controlled data on these drugs for them to be indicated for such use in 
migraine. 
8.2.2. Selective adenosine A1 receptor agonists    
In a recent study selective adenosine A1 receptor agonist, GR79236 caused a dose-dependent 
inhibition of neurogenic vasodilatation, but had no significant effect on dural vasodilation 
caused by CGRP.  This was associated with mild bradycardia and hypotension (64).  These 
data suggest that the inhibition of neurogenic vasodilatation by GR79236 is mediated via the 
activation of prejunctional adenosine A1 receptors.  In another study in cats, intravenous 
administration of the highly selective adenosine A1 receptor agonist, GR79236 had a 
dose-dependent inhibitory effect on superior sagittal sinus-evoked trigeminal activity which 
could be inhibited by the selective adenosine A1 receptor antagonist DPCPX.  Superior 
sagittal sinus stimulation increased cranial CGRP levels (65).  In this model of 
trigeminovascular nociception, adenosine A1 receptor activation leads to neuronal inhibition 
without concomitant vasoconstriction, suggesting a novel avenue for the treatment of 
migraine and cluster headache. 
8.2.3. eNOS inhibitors in migraine 
Nitric oxide (NO) can trigger a delayed migraine.  The initial headache is thought to be 
caused via a direct action of the NO-cGMP pathway that causes vasodilatation by vascular 
smooth muscle relaxation, while the delayed headache is likely to be a result of triggering 
trigeminovascular activation (66).  Nitric oxide synthase (NOS) inhibitors are effective in the 
treatment of acute migraine.  Additionally, non-specific and neuronal NOS (nNOS) inhibitors 
are able to partially inhibit neurogenic dural vasodilatation, while the non-specific and 
endothelial NOS (eNOS) inhibitors were able to partially inhibit the CGRP induced dilation.  
This suggests a role of eNOS and nNOS in the generation of initial and delayed headache 
response in migraine (66). 
8.2.4. Selective 5-HT1F receptor agonists in migraine 
Triptans (5-HT1B/1D receptor agonists) are effective drugs for acute migraine, but the side 
effect of coronary vasoconstriction restricts their use in patients who are at risk of coronary 
artery disease.  LY334370, a selective 5-HT1F receptor agonist, showed preclinical efficacy 
and no vasoconstriction, for migraine relief possibly through selective trigeminovascular 
neuronal inhibition (67). 
8.2.5. Upregulation of 5-HT2A receptor in migraine 
Recently, it has been demonstrated that activation of the 5-HT2A receptor leads to an 
enhancement of NO (nitric oxide) production in trigeminovascular pathway.  NO may trigger 
migraine attacks by inducing cerebral vasodilatation and sensitizing the perivascular 
nociceptors and central nociceptive neurons in trigeminovascular system.  Up-regulation of 
this pronociceptive receptor can increase headache attacks and contributes to the 
development of chronic daily headache (68).  An explanation for this above hypothesis stems 
from the fact that during the migraine-free period, 5-HT at its optimum concentration, will 
bind to the 5-HT1B/1D receptor.  The occupation of these receptors results in vasoconstriction 
and stabilisation of perivascular nociceptors and central nociceptive neurons.  On the other 
hand, excessive amounts of 5-HT released during migraine initiation may couple to the 
5-HT2A receptor and increase NO production.  NO will then induce vasodilatation, sensitise 
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perivascular and myofascial nociceptors, and sensitise central nociceptive neurons 
precipitating migraine (68). 
 
To conclude, one may admit that despite some exciting future prospects for migraine 
management still is wide open.  Migraine patients worldwide are not receiving adequate 
treatment and there remains a significant unmet need in migraine care.  According to a recent 
MAZE survey conducted in Europe and United States the average prevalence of migraine 
reported was 9% (69).  Less than one-third of patients reported that their current medication 
was consistently effective and only 36% were 'very satisfied' with their current therapy (69).  
Hence, the challenge for the future is to diagnose migraine early and offer patients effective 
migraine-specific therapies.  Physicians particularly need to reach patients who do not realise 
they have migraine and those who have lapsed from care. 
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9. Thesis summary 
 
9.1. Summary in English 
 
Chapter 1 describes in brief the experimental models of migraine and its drug discovery 
from the age of triptans to the exploration of novel therapeutic targets, including 
α-adrenoceptors and the calcitonin gene related peptide receptors.  Triptans, serotonin 
5-HT1B/1D receptor agonists, serve as the mainstay for migraine treatment during the latter 
part of the twentieth century.  Many migraine sufferers were relieved of their migraine in a 
way that they had not previously seen, clinical trial guidelines were redefined and revised and 
clinical studies were well organised and uniform.  Sumatriptan has now been followed by 
other triptans: zolmitriptan, naratriptan, rizatriptan, almotriptan eletriptan and frovatriptan; 
donitriptan has finished preclinical evaluation and is currently in development.  Ergotamine, 
the mainstay of specific acute treatment for most of the twentieth century after its initial 
description in the nineteenth century, now has few indications in which it is the treatment of 
choice.  Most patients do prefer triptans when asked.  However, some patients who would 
benefit from such treatment may not get them because of diagnostic or financial issues, and, 
in contrast, some patients overuse the medicines.  Furthermore, sumatriptan is has some 
limitations, for example, low oral bioavailability, short half-life, metabolic breakdown via 
monoamine oxidase and its inability to cross the blood brain barrier.  Therefore, there is 
utmost need for discovery of new molecules for migraine, which can overcome the 
limitations of the triptans. 
As propounded initially, dilatation of intracranial and extracerebral arteries and 
arteriovenous shunts is involved in the pathophysiology of migraine.  This has been 
demonstrated in the temporal arteries of migraineurs.  Later, it was proposed that neurogenic 
inflammation, involving vasodilatation and plasma protein extravasation, could also play a 
role in migraine.  A number of neuropeptides, including the calcitonin gene-related peptide 
(CGRP), are released, of which the latter plays a dominant role.  In fact, an increase in CGRP 
levels in the jugular venous blood has been demonstrated in migraine and cluster headache 
patients, and the CGRP levels are normalised after treatment with sumatriptan.  Thus, it 
appears that inhibition of CGRP release or its receptors could be beneficial in aborting 
migraine headaches.  Accordingly, specific low molecular CGRP antagonists, like 
BIBN4096BS and SB-(+)-273779, are being developed.  BIBN4096BS is the first CGRP 
antagonist under clinical trials in migraine patients.   
A possible role of α-adrenoceptors as a new avenue for migraine therapy is also 
discussed.  It has been shown that several acutely acting antimigraine agents, including the 
ergots (ergotamine and dihydroergotamine) and the triptans, produce a potent 
vasoconstriction in the canine and porcine carotid vasculature mediated by 5-HT1B/1D 
receptors.  Interestingly, the canine carotid vasoconstrictor responses of the ergot alkaloids 
are mediated by 5-HT1B/1D receptors and α2-adrenoceptors.  The above lines of evidence, 
combined with the high affinity of ergotamine and dihydroergotamine at α-adrenoceptors, 
suggests that their therapeutic efficacy may partly be explained by an action mediated via 
α-adrenoceptors. 
The experiments in the following chapters have been designed to elucidate therapeutic 
role of novel drugs like A61603, S19014, BIBN4096BS, donitriptan (F11356, F12640) and 
CGRP receptors in porcine model of migraine. 
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Chapter 2 is based on the evidence that CGRP may play an important role in the 
pathogenesis of migraine.  Increased concentrations of immunoreactive α-CGRP have been 
observed in the jugular venous blood of migraineurs during the headache phase.  We 
investigated the effects of the novel CGRP antagonist BIBN4096BS on the regional 
distribution of cardiac output and on the carotid and systemic haemodynamic changes 
induced by α-CGRP (10, 30 and 100 pmol.kg-1.min-1).  BIBN4096BS (100, 300 and 1000 
µg.kg-1, i.v.)  caused a small decrease in cardiac output, which was not significantly different 
from that in vehicle-treated animals but did not affect heart rate, mean arterial blood pressure 
or systemic vascular conductance.  The highest dose of BIBN4096BS moderately decreased 
vascular conductance in the lungs, kidneys, spleen and adrenals.  Vascular conductance in 
other tissues, including the brain, heart, gastrointestinal system, skin and skeletal muscles, 
remained unchanged. Consecutive intracarotid infusions of human α-CGRP increased total 
carotid conductance and blood flow and decreased mean arterial blood pressure as well as 
arteriovenous oxygen saturation difference (A-VSO2); the responses to CGRP were dose 
dependently blocked by BIBN4096BS.  These findings suggest that BIBN4096BS might be 
an effective drug in aborting migraine headaches with minimal side effects, but its therapeutic 
efficacy in migraine therapy will ultimately depend on its pharmacokinetic properties. The 
experiments also show that that the endogenous CGRP does not seem to play an important 
physiological role in regulating basal vascular tone. 
 
Chapter 3.  In this chapter we investigated the effects of CGRP receptor antagonist 
BIBN4096BS on capsaicin-induced porcine haemodynamic changes in a porcine model for 
migraine.  Capsaicin produces trigeminal sensory neuron stimulation, leading to the release of 
CGRP in the pigs.  Intracarotid infusions of capsaicin (0.3, 1, 3 and 10 µg.kg-1.min-1, i.c.) did 
not alter heart rate but caused an increase in the mean blood pressure, which was not 
modified by BIBN4096BS.  Capsaicin significantly increased carotid blood flow and 
conductance in both arteriovenous anastomotic and capillary fractions and decreased 
A-VSO2.  These effects were dose-dependently antagonised by BIBN4096BS.  Vascular 
conductances to the different tissues of the head, except that of salivary gland and brain, were 
also significantly increased by capsaicin and the response was antagonised by BIBN4096BS.  
As expected, capsaicin infusion more than doubled CGRP concentration in the jugular blood.  
Interestingly, the release of CGRP was potentiated by BIBN4096BS suggesting that blockade 
of prejunctional inhibitory CGRP autoreceptors by BIBN4096BS may have produced a 
positive feed back on the release of neuronal CGRP.  The above results show that 
BIBN4096BS behaves as a potent antagonist of capsaicin-induced carotid haemodynamic 
changes that are mediated via the release of CGRP.  Therefore, this compound may prove 
effective in the treatment of migraine. 
 
Chapter 4.  It has recently been shown that both α1- and α2-adrenoceptors mediate the 
constriction of porcine carotid arteriovenous anastomoses, but no attempt was made to 
identify the specific subtypes (α1A, α1B and α1D) involved.  Therefore, using the 
α1-adrenoceptor antagonists, 5-methylurapidil (α1A), L-765,314 (α1B) and BMY 7378 (α1D), 
the present study was designed to elucidate the specific subtype(s) of α1-adrenoceptors 
involved in the above response.  Intracarotid infusions of phenylephrine induced a 
dose-dependent decrease in total carotid and arteriovenous anastomotic conductance.  These 
carotid vascular effects were abolished by L-765,314, and were only attenuated by 
5-methylurapidil and BMY 7378.  Furthermore, intravenous bolus injections of 
phenylephrine produced a dose-dependent pressor response, which was only affected by 
5-methylurapidil, while the other antagonists were ineffective.  These results, coupled with 
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the binding affinities of the above antagonists at the different α1-adrenoceptor subtypes, 
suggest that both α1A- and α1B-adrenoceptors mediate constriction of carotid arteriovenous 
anastomoses in anaesthetised pigs.  In view of the less ubiquitous nature of α1B- compared to 
α1A-adrenoceptors and a minor role played α1B-receptors in the vasoconstriction of the 
peripheral blood vessels, the development of potent and selective α1B-adrenoceptor agonists 
may prove to be important for the treatment of migraine. 
 
Chapter 5.  As stated in Chapter 4, the pharmacological profile of α1-adrenoceptors 
mediating constriction of porcine carotid arteriovenous anastomoses resembles that of α1A- 
and α1B-adrenoceptor subtypes.  In an attempt to verify the involvement of 
α1A-adrenoceptors, we used a potent α1A-adrenoceptor agonist A61603 and found that 
intracarotid administration of A61603 (0.3, 1, 3 and 10 µg.kg-1) dose-dependently decreased 
porcine carotid blood flow and vascular conductance.  This decrease was exclusively due to a 
constriction of carotid arteriovenous anastomoses; the capillary blood flow and conductance 
remained unchanged.  Surprisingly, the responses to A61603 were little modified by prior 
treatment with 5-methylurapidil, prazosin or a combination of prazosin and rauwolscine.  The 
5-HT1B/1D receptor antagonist GR127935 and ketanserin also failed to modify carotid 
vascular responses to A61603, but, interestingly, methiothepin proved to be a potent 
antagonist.  Taken together, the present results show that A61603 is a relatively poor agonist 
at the α1A-adrenoceptor in pigs and that the carotid vasoconstriction produced by A61603 is 
mediated by a novel methiothepin-sensitive receptor/mechanism.  A selective agonist at this 
novel receptor, without causing major systemic haemodynamic changes could well prove its 
worth in the management of migraine. 
 
Chapter 6 assesses the antimigraine potential of a novel α-adrenoceptor agonist S19014.  
As stated above, both α1- and α2-adrenoceptors can mediate the constriction of porcine 
carotid arteriovenous anastomoses, which effectively serve as an experimental model 
predictive of antimigraine activity.  S19014  (1, 3, 10 and 30 µg.kg-1) produced an initial 
short lasting pressor response, but dose-dependently decreased total carotid and arteriovenous 
anastomotic blood flows (maximum change: 18±2% and 34±5%, respectively) and 
conductances (maximum change: 14±2% and 30±4%, respectively).  In contrast, S19014 
increased capillary blood flow and conductance (maximum change: 40±23% and 49±27%, 
respectively) and did not much affect the distribution of cardiac output to peripheral organs.  
Whereas prazosin was ineffective, rauwolscine attenuated the responses to S19014, thus 
establishing the involvement of one or more α2-adrenoceptor subtypes.  We further evaluated 
the human coronary side-effect potential of S19014 and compared it with sumatriptan.  The 
maximal contraction to S19014 was smaller than that to sumatriptan, particularly in 
precontracted coronary arteries.  The above results suggest that S19014 could be effective in 
the treatment of migraine with improved cardiovascular tolerance. 
 
Chapter 7.  Donitriptan is a new triptan that possesses a high affinity as well as efficacy at 
5-HT1B/1D receptors.  We investigated the effects of donitriptan on carotid haemodynamics 
and complete distribution of cardiac output in anaesthetised pigs.  Donitriptan 
dose-dependently decreased total carotid blood flow and vascular conductance and this effect 
was entirely due to a selective reduction in the cephalic arteriovenous anastomotic fraction.  
The dose of donitriptan that decreased arteriovenous anastomotic conductance by 50% was 
found to be 47±16 µg.kg-1 (92±31 nmol.kg-1).  Donitriptan did not decrease vascular 
conductances in or blood flows to a number of organs, including the heart and kidneys; in 
fact, vascular conductances in the skin, brain and skeletal muscles increased.  Cardiac output 
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was slightly decreased by donitriptan, but this effect was also confined to the non-nutrient 
part (peripheral arteriovenous anastomoses).  The 5-HT1B/1D receptor antagonist GR127935 
substantially reduced the haemodynamic effects of donitriptan.  These results show that 
donitriptan selectively constricts arteriovenous anastomoses via 5-HT1B receptor activation.  
The drug should be able to abort migraine headaches without affecting blood flows to 
vital organs. 
Chapter 8 discusses the findings of the present investigation in relation with the recent and 
ongoing efforts being made to further improve drug therapy in migraine.  In parallel, the 
challenge is also to diagnose migraine early and offer patients appropriate and effective 
therapy.  Physicians particularly need to reach patients who do not realise they have migraine 
and those who have lapsed from care. 
 
9.2. Samenvatting in het Nederlands 
 
Hoofdstuk 1 beschrijft kort de experimentele modellen van migraine en de ontdekking van 
medicijnen ervoor uit de tijd van triptanen tot de verkenning van nieuwe therapeutische 
doelen, waaronder α-adrenoceptors en de calcitonin gen-gerelateerde peptide (CGRP) 
receptoren.  Triptanen, serotonine 5-HT1B/1D receptor agonisten, dienen als de voornaamste 
steunpilaar voor de behandeling van migraine aan het eind van de twintigste eeuw.  Veel 
mensen met migraine werden van hun migraine verlost op een manier die nog nooit eerder 
waargenomen was, klinische richtlijnen voor proeven werden opnieuw gedefinieerd en 
aangepast en klinische studies werden goed georganiseerd en uniform gemaakt.  Sumatriptan 
is nu opgevolgd door andere triptanen: zolmitriptan, naratriptan, rizatriptan, almotriptan 
eletriptan en frovatriptan; donitriptan is door de preklinische evaluatie heen en is momenteel 
in ontwikkeling.  Ergotamine, het voornaamste middel voor de acute behandeling voor het 
grootste deel van de twintigste eeuw, is na de eerste beschrijvingen in de negentiende eeuw 
nu weinig in gebruik in de behandeling van migraine.  De meeste patiënten hebben een 
voorkeur voor triptanen.  Sommige patiënten die veel baat bij een dergelijke behandeling 
zouden hebben krijgen deze niet om diagnostieke of financiële redenen en, in contrast, 
gebruiken sommige patiënten de medicijnen te veel.  Bovendien heeft sumatriptan enkele 
beperkingen, zoals bijvoorbeeld een lage orale biologische beschikbaarheid, een korte 
halfwaardetijd, afbraak door monoamine oxidase en het feit dat het niet door de bloed-
hersenen barrière heen kan.  Daarom is het hard nodig dat er nieuwe moleculen worden 
ontdekt voor migraine, waardoor de beperkingen van triptanen wegvallen.   
Zoals in eerste instantie is geopperd, is de verwijding van intracraniale en  
extracerebrale bloedvaten betrokken bij de pathofysiologie van migraine.  Dit is aangetoond 
in de temporale arteriën van migrainepatiënten.  Later werd verondersteld dat neurogene 
onsteking met plasma-eiwitlekkage ook een rol kan spelen bij migraine.  Een aantal 
vrijgekomen neuropeptides, waaronder de CGRP, spelen later een dominante rol.  Inderdaad, 
een toename van het CGRP gehalte in het bloed in de halsaderen is aangetoond bij patiënten 
met migraine en clusterhoofdpijn, welke werd teruggebracht tot een normaal niveau na 
behandeling met sumatriptan.  Zodoende lijkt het erop dat het blokkeren van de afgifte van 
CGRP of de receptor bij kan dragen aan de verbetering van hoofdpijn bij migraine.  
Dienovereenkomstig hiermee worden specifieke lage moleculaire CGRP receptor 
antagonisten ontwikkeld, zoals  BIBN4096BS en SB-(+)-273779.  BIBN4096BS is de eerste  
CGRP antagonist dei klinisch getest wordt op migrainepatiënten. 
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Over een mogelijke rol van α-adrenoceptoren als een nieuwe manier van behandeling 
van migraine wordt ook gediscussieert.  Het is aangetoond dat een aantal middelen ter 
bestrijding van een acute migraineaanval, waaronder de ergot alkaloïden (ergotamine en 
dihydroergotamine) en de triptanen, een krachtige vaatvernauwing veroorzaken in 
halsslagaders bij honden en varkens door middel van 5-HT1B/1D receptoren.  Interessant is dat 
de respons van de ergot alkaloïden in de halsslagaders van honden door middel van 5-HT1B/1D 
receptoren en α2-adrenoceptoren tot stand komt.  De hiervoor beschreven bewijzen in 
combinatie met een hoge affiniteit van ergotamine en dihydroergotamine tot de 
α-adrenoceptoren, suggereren dat de therapeutische effectiviteit voor een deel verklaard kan 
worden door een actie via α-adrenoceptoren. 
De experimenten in volgende hoofdstukken zijn opgezet om de therapeutische rol van 
nieuwe medicijnen zoals A61603, S19014, BIBN4096BS, donitriptan (F11356, F12640) en 
CGRP receptoren in het model van migraine bij varkens op te helderen. 
 
Hoofdstuk 2 is gebaseerd op het bewijs dat CGRP een belangrijke rol kan spelen bij het 
ontstaan van migraine.  Verhoogde concentraties van immuunreactieve α-CGRP zijn 
waargenomen in de halsslagaderen van migrainepatiënten tijdens de hoofdpijnfase.  We 
onderzochten de effecten van de nieuwe CGRP antagonist BIBN4096BS op de regionale 
distributie van cardiale output en op systematische haemodynamische veranderingen 
veroorzaakt door α-CGRP bij verdoofde varkens.  BIBN4096BS veroorzaakte een kleine 
afname in hartminutenvolume, wat niet veel verschilde van dat in de controle dieren, maar dit 
had geen effect op de hartslag, bloeddruk of systemische vasculaire geleiding.  De hoogste 
dosis BIBN4096BS zorgde voor een matige afname van de bloedtoevoer naar de longen, 
nieren en bijnieren.  Infusie van humaan α-CGRP in de halsslagader verhoogde de totale 
bloeddoorstroming in de halsslagader en verlaagde de gemiddelde bloeddruk evenals 
arterieveneuze zuurstofverzadigingsverschil (A-VSO2); de reactie op CGRP werd 
doseringsafhankelijk geblokkeerd door BIBN4096BS.  Deze vondst suggereert dat 
BIBN4096BS een effectief middel kan zijn om migrainehoofdpijn tegen te gaan met 
minimale bijwerkingen.  De therapeutische effectiviteit in de behandeling van migraine zal 
echter uiteindelijk afhangen van de farmacokinetische eigenschappen van het middel. 
 
Hoofdstuk 3.  In dit hoofdstuk onderzochten we de effecten van de CGRP receptor 
antagonist BIBN4096BS op de door capsaicin veroorzaakte haemodynamische veranderingen 
in de halsslagader van een varkensmodel voor migraine.  Capsaicin prikkelt sensorische 
neuronen, hetgeen leidt tot de afgifte van CGRP in de varkens.  Infusie van capsaicin in de 
halsslagader gaf geen verandering in de hartslag maar veroorzaakte een toename van de 
gemiddelde bloeddruk, hetgeen niet beïnvloed werd door BIBN4096BS.  Capsaicin zorgde 
voor een significante stijging van de bloeddoorstroming in de halsslagader alsmede in de 
arterieveneuze ‘shunt’ en capillair fracties; er was een afname in A-VSO2.  Deze effecten 
werden tegengegaan door BIBN4096BS.  Vasculaire geleiding in de verschillende weefsels 
in het hoofd, behalve in de speekselklieren en de hersenen, nam ook significant toe door 
capsaicin en deze reactie werd tegengegaan door BIBN4096BS.  Zoals verwacht verdubbelde 
de CGRP concentratie in het bloed in de halsslagaders na infusie van capsaicin.  De afgifte 
van CGRP werd niet geremd maar zelfs versterkt door BIBN4096BS, wat zou betekenen dat 
blokkering van presynaptische CGRP autoreceptoren door BIBN4096BS een positieve 
feedback tot gevolg kan hebben op de afgifte van CGRP.  Alles bij elkaar genomen 
onderschrijven deze resultaten het idee dat BIBN4096BS een veelbelovend antimigraine 
middel zou kunnen zijn. 
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Hoofdstuk 4.  Onlangs is aangetoond dat stimulatie van zowel α1- als α2-adrenoceptoren 
leidt tot vernauwing van arterieveneuze anastomoses in het halsslagadergebied van varkens.  
Het is echter nog niet bekend welke specifieke receptor subtypen (α1A, α1B en/of α1D) hierbij 
belangrijk zijn. Daarom was deze studie opgezet om de specifieke subtypen van 
α1-adrenoceptoren die betrokken zijn bij de hiervoor beschreven reactie te definiëren, waarbij 
gebruik gemaakt is van de α1-adrenoceptor antagonisten 5-methylurapidil (α1A), L-765,314 
(α1B) en BMY 7378 (α1D).  Intra-arteriële infusie van phenylephrine veroorzaakte een afname 
van de doorstroming in de carotis arterieveneuze anastomosen.  Dit effect werd geblokkeerd 
door L-765,314, en werd alleen verminderd door 5-methylurapidil en BMY 7378.  Bovendien 
leidde de intraveneuze toediening van  fenylephrine tot een dosisafhankelijke toename van de 
arteriële bloeddruk, welke alleen werd verminderd door 5-methylurapidil, terwijl de andere 
antagonisten ineffectief waren.  Deze resultaten, gekoppeld met de binding affiniteiten van de 
bovengenoemde antagonisten tot de verschillende α1-adrenoceptor subtypen, suggereren dat 
zowel α1A- als α1B-adrenoceptoren verantwoordelijk zijn voor de vernauwing van de 
arterieveneuze anastomoses in de halsslagadergebied van verdoofde varkens.  Gezien de 
minder overheersende aard van α1B- in vergelijking met α1A-adrenoceptoren en het feit dat 
α1B-receptors geen grote rol speelt bij de regulatie van de bloeddruk, kan de ontwikkeling van 
krachtige en selectieve α1B-adrenoceptor agonisten belangrijk blijken te zijn voor de 
behandeling van migraine. 
 
Hoofdstuk 5.  Het onderzoek beschreven in hoofstuk 4 liet zien dat de α1-adrenoceptoren, 
die de vernauwing van varken carotis arterieveneuze anastomosen veroorzaken mogelijk van 
α1A en α1B subtypen zijn.  In een poging om de betrokkenheid van α1A-adrenoceptoren te 
verifiëren, gebruikten we een potente α1A-adrenoceptor agonist A61603 en hebben we 
vastgesteld dat intracarotide toediening van  A61603 dosis-afhankelijk de doorbloeding en 
vasculaire geleiding in de halsslagader deed afnemen.  Deze daling was geheel te wijten aan 
een selectieve vernauwing van de arterieveneuze anastomosen; de capillary doorbloeding en 
geleiding bleven onveranderd.  Verassend was dat de reactie op A61603 maar weinig werd 
veranderd door 5-methylurapidil, prazosine of een combinatie van prazosine en rauwolscine.  
De 5-HT1B/1D receptor antagonist GR127935 en de 5-HT2 receptor antagonist ketanserine 
slaagden er ook niet in om de vasculaire reactie op A61603 in de halsslagaders te veranderen, 
maar interessant genoeg bleek methiothepine een krachtige antagonist te zijn.  Alles bij elkaar 
genomen laten de resultaten zien dat A61603 een relatief slechte agonist is voor de 
α1A-adrenoceptor in de varkens en dat de vernauwing in de halsslagaderen dat door A61603 
veroorzaakt werd, mogelijk verloopt via een nieuw, niet-adrenerg mechanisme. 
 
Hoofdstuk 6 bestudeert de mogelijke toepassing van de nieuwe α-adrenoceptor agonist 
S19014 bij migraine.  Zoals hierboven vermeld, kunnen zowel α1- als α2-adrenoceptoren de 
vernauwing van de arterieveneuze anastomosen in de halsslagadergebied van varkens 
bewerkstellen, hetgeen kan dienen als een experimenteel model om anti-migraine activiteit te 
voorspellen.  Toediening van S19014 leidde tot een kortdurende verhoging van de bloeddruk, 
maar verlaagde de totale doorbloeding en vasculaire geleiding in de halsslagaders uitsluitend 
door een vernauwing van de arterieveneuze anastomosen.  S19014 had echter niet veel 
invloed op het hartminutenvolume en de doorbloeding  van de verschillende organen.  
Terwijl prazosine ineffectief was, verminderde rauwolscine de reactie op S19014.  Verder 
hebben we de mogelijkheid van bijwerkingen van S19014 bij humane kransslagaders 
geëvalueerd en hebben deze met sumatriptan vergeleken.  De maximale samentrekking bij 
S19014 was  minder dan die bij sumatriptan, vooral in de van tevoren gecontraheerde 
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kransslagaderen.  Bovenstaande resultaten suggereren dat S19014 effectief kan zijn bij de 
behandeling van migraine met mogelijk minder cardiovasculair risico. 
 
Hoofdstuk 7.  Donitriptan is een nieuwe triptaan, dat zowel een hoge affiniteit als 
effectiviteit heeft bij de 5-HT1B/1D receptoren.  We onderzochten de effecten van donitriptan 
op de halsslagaderdoorbloeding en de complete distributie van het hartminutenvolume  in 
verdoofde varkens.  Donitriptan liet een dosisafhankelijk afname te zien in de totale 
doorbloeding en vasculaire geleiding in de halsslagaders en dit effect was volledig te wijten 
aan een selectieve vernauwing van de arterieveneuze anastomosen.  De dosis donitriptan dat 
de vasculaire geleiding van de arterieveneuze anastomosen deed afnemen met 50% bleek 
47±16 µg.kg-1 (92±31 nmol.kg-1) te zijn.  Donitriptan-toediening leidde niet tot een 
vermindering van de vasculaire geleiding en doorbloeding van een groot aantal organen, 
waaronder het hart en de nieren; de vasculaire geleiding in de huid, hersenen en skeletspieren 
nam zelfs toe.  Het hartminutenvolume nam licht af bij het gebruik van donitriptan, maar dit 
effect was ook te wijten aan de afname van arterieveneuze anastomotische doorbloeding.  De 
5-HT1B/1D receptor antagonist GR127935 deed de haemodynamische effecten van donitriptan 
aanzienlijk afnemen.  Deze resultaten tonen aan dat donitriptan een selectieve vernauwing 
van de arterieveneuze anastomosen veroorzaakt door de activering van de 5-HT1B receptor.  
Het middel zou hoofdpijn bij migraine moeten kunnen couperen, zonder dat het invloed heeft 
op de bloedtoevoer naar vitale organen. 
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